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ABSTRACT 
 
Nordihydroguaiaretic acid (NDGA), is a naturally-occurring lignan isolated from the 
creosote bush (Larrea tridentata). The aqueous extract of this shrub, commonly referred to as 
Chaparral tea, was listed in the American pharmacopeia as an ethnobotanical used to treat 
tuberculosis, arthritis and cancer. Other documented traditional applications of creosote bush 
extract include treatment for infertility, rheumatism, arthritis, diabetes, gallbladder and kidney 
stones, pain and inflammation among many others. In spite of the numerous pharmacological 
properties, NDGA use has been associated with toxicities including hepatotoxicity in humans. 
Previous studies in our group showed that oxidative cyclization of NDGA (a di-catechol) at 
physiological pH forms a dibenzocyclooctadiene that may have therapeutic benefits whilst 
oxidation to ortho-quinone likely mediates toxicological properties.  
In order to investigate the structural features responsible for pharmacological and 
toxicological properties, a series of NDGA analogues were designed, synthesized and characterized 
for the purpose of studying their oxidative metabolism. Literature procedures were modified to 
successfully prepare seven lignan analogues via multi-step synthesis. In our effort to understand the 
mechanisms of NDGA intramolecular cyclization, the prepared analogues were incubated under 
previously established conditions where NDGA autoxidized to yield the dibenzocyclooctadiene 
derivative. We also evaluated the stability of the analogues under the conditions of this study. 
Furthermore, we evaluated bioactivation potential of the prepared analogues with a goal of 
eliminating reactive metabolite liability through rational structural modification. We incubated 
NDGA and its analogues in rat liver microsomes (RLM) in the presence of glutathione as a 
nucleophilic trapping agent. Standards for comparison were generated by performing glutathione 
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trapping experiments with chemical and enzyme oxidation systems. The potential of the 
dibenzocyclooctadiene lignan 2 derived from NDGA under physiological conditions to contribute 
to toxicological properties via reactive metabolite formation was also evaluated. Glutathione 
conjugates were detected by electrospray ionization-mass spectrometry (ESI-MS) scanning for 
neutral loss (NL) 129 Da or 307 Da in positive ion mode or precursor ion (PI) scanning for 272 Da 
in negative ion mode and further characterized by liquid chromatography–tandem mass 
spectrometry (LC–MS/MS) or in a single LC-MS run using multiple reactions monitoring (MRM) 
as a survey scan to trigger acquisition of enhanced product ion (EPI) data.  
We determined that NDGA autoxidation at pH 7.4 is dependent on substituents and/or 
substitution pattern on the two aromatic rings. In particular, spontaneous intramolecular cyclization 
to a dibenzocyclooctadiene required a di-catechol lignan, raising the possibility that o-Q formation 
may not be necessary for cyclization to occur. Cyclization was significantly inhibited in the 
presence of excess GSH which supports the involvement of free radicals as opposed to o-Q in the 
intramolecular cyclization process. The mono-catechol analogues A1 and A4 underwent oxidation 
to o-Q but no evidence of cyclization was found implying that electrophilic substitution cannot 
account for NDGA cyclization. The phenol-type analogues were oxidatively more stable in 
comparison with the catechol-type analogues at pH 7.4. The results demonstrate that electrophilic 
substitution makes no contribution to the intramolecular cyclization process and that a radical 
mediated process accurately describes the situation for NDGA. 
Oxidative metabolism and bioactivation studies on NDGA and its analogues revealed that 
reactive metabolites formation is dependent on substitution and/or substitution pattern of the 
aromatic rings. Cytochrome P450-mediated oxidation of NDGA and its catechol-type analogues 
yielded electrophilic intermediates which reacted with GSH. The GSH mono-conjugates were 
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identified as ring adducts derived from o-Q although the position at which the GSH binds to the 
aromatic rings could not be determined. We also found that NL 129 or 307 scanning in positive 
ionization mode has potential diagnostic utility in distinguishing between aromatic and benzylic 
GSH conjugates although further studies may be required for validation. We found no evidence of 
p-QM either directly or via isomerization of o-Q intermediates suggesting that o-Q is the major 
reactive toxicophore responsible for reactive metabolite mediated toxicities associated with NDGA 
use. In addition, we demonstrated that the NDGA-derived dibenzycyclooctadiene lignan (cNDGA 
2) undergoes P450-mediated oxidation to a reactive metabolite which might have toxicological 
implications. There was no evidence of P450-mediated oxidation to reactive metabolites for the 
phenol-type NDGA analogues. It is concluded that structural modification efforts should focus on 
phenol-type analogues to potentially enhance the safety profile of NDGA.  
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1 INTRODUCTION 
 
The leaves of the plant creosote bush were used commonly in traditional medicines among 
the Native Americans for diverse beneficial effects.1-3 The aqueous extract of this shrub, commonly 
referred to as Chaparral tea, was listed in the American pharmacopeia as an ethnobotanical used to 
treat tuberculosis, arthritis and cancer.3 Documented traditional applications of the plant extract 
include treatment for infertility, rheumatism, arthritis, diabetes, gallbladder and kidney stones, pain 
and inflammation among many others.1,2 Creosote bush is rich in lignans particularly 
nordihydroguaiaretic acid (NDGA, 1) (up to 15% dry weight (d.w.)).1 This natural polyphenol is 
generally accepted as responsible for both the beneficial and adverse effects associated with 
creosote bush, mainly because of its high content in the plant.1,2, 4-6 NDGA 1 has been shown to 
have promising applications in the treatment of multiple diseases, including cardiovascular 
diseases,7, 8 neurological disorders9-13 and cancers.2,14-20 It has also been reported to potently inhibit 
viruses such as human immunodeficiency virus (HIV-1), herpes simplex virus (HSV), human 
papilloma virus (HPV) and influenza virus.1,21 The radical scavenging22,23 and antioxidant effects24 
as well as anti-inflammatory25, 26 and anti-proliferative properties may be of relevance in different 
diseases. Despite its broad pharmacological activities, NDGA 1 use is associated with toxicity 
especially when ingested at higher doses.27 Reports of severe hepatic24, 27-29 and renal injuries30-32 
associated with NDGA 1 use are likely linked to bioactivation to reactive ortho-quinones (o-Qs).32-
34 
Interestingly, incubation of NDGA 1 at pH 7.4 gave a schisandrin-like 
dibenzocyclooctadiene lignan 2.35 This appears to be an intramolecular cyclization although the 
1 
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mechanism is yet unknown. The conditions of preparation of Chaparral tea2 and biological 
evaluations of NssDGA 15,36,37 favour autoxidation suggesting that any biological action by NDGA 
treatment could result from either NDGA itself or its oxidation products.37 Also, lignans with the 
dibenzocyclooctadiene structural moiety have received much research attention and are known to 
exhibit a wide variety of interesting biological activities,38,39 including antiviral,40 anticancer,41 anti-
inflammatory,42 and hepatoprotective effects.43 On the other hand, Billinsky et al.,33 reported that 
oxidative metabolism of NDGA gives rise to an o-Q but does not appear to form a para-quinone 
methide (p-QM). This is surprising given that under similar oxidative conditions 
secoisolariciresinol (SECO, 9), a structurally similar lignan, converts to lariciresinol 21 likely via a 
p-QM intermediate.33, 44 It is noteworthy that oral consumption of SECO is not reported to cause 
serious toxic effects in humans whilst use of NDGA in the food industry as an antioxidant was 
banned following reports of nephrotoxicity.31 
Research interest in NDGA continues to rise due to its encouraging treatment benefits in 
conditions such as cardiovascular diseases, neurological disorders and cancers.6 Several medicinal 
properties have been supported by in vitro and in vivo experimental studies, as well as historical 
reports. Studies suggest that NDGA derivatives such as tetramethyl-O-NDGA (M4N, 14) and tetra-
acetyl NDGA 15 exhibit similar or even higher anti-viral activities than natural compounds. It is 
worth mentioning that M4N 14 is currently under clinical evaluations for treatment of human 
cancers.45 Perhaps, the most startling observation is with 1,4-bis-(3,4-dihydroxyphenyl) butane 17, 
a simplified NDGA, which is 10 times more potent as a proliferative inhibitor of H-69 small lung 
cancer cells than NDGA.36 Given that chemical modification of NDGA may reduce toxicity, 
combined with enhancing therapeutic effects, the possibility that derivatives of NDGA may become 
important drugs in the future has been well recognized as evidenced by increasing research interest. 
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Unfortunately, the structural features that govern both pharmacological and toxicological properties 
of NDGA are poorly understood. At present, the usefulness of NDGA and its derivatives is 
hindered by the lack of understanding of the mechanisms of not only the beneficial activities but 
also toxicity. A thorough understanding of pharmacological and toxicological pathways may lead to 
rational design of NDGA analogues with improved safety profile. While a great deal of 
observational and correlative data has been reported, there have been few comprehensive 
mechanistic or structure-function studies conducted on NDGA. Therefore, the overall goal of this 
study is to synthesize analogues of NDGA to investigate the mechanisms of pharmacological and 
toxicological pathways. The study is expected to provide insight into the structural features which 
modulate biological properties of NDGA and likely lead to development of new treatments for 
human diseases in the future. The results will certainly advance our understanding of structure-
activity-relationships of NDGA and direct efforts towards discovery of new NDGA analogues with 
better safety profiles. 
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2 LITERATURE REVIEW 
 
2.1 Lignans 
Lignans constitute an important class of natural products derived from oxidative dimerization 
of two phenylpropanoid units. They are widely distributed in the plant kingdom and probably play 
important roles in plants’ defense mechanisms against various biological pathogens and pests.46 
Structurally, lignans have two C6C3 structural units linked through β and βʹ (or C8 and C8ʹ) carbons 
to form 18 carbon basic skeleton46, 47 (Figure 2-1).  
 
Figure 2-1: Structures for (a) C6C3 phenylpropane subunit and (b) basic lignan skeleton. 
 
Lignans continue to attract much research attention due largely to their significant 
pharmacological properties including antitumor, anti-inflammatory, immunosuppressive, 
cardiovascular, antioxidant and antiviral actions.48,49 In addition to their staggering biological 
activities, lignans show enormous structural diversity which partly accounts for an upsurge in 
research interest. Lignans have been classified into different families on the basis of their general 
chemical structure.49,50 
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2.2 Nordihydroguaiaretic Acid (NDGA) 
2.2.1 Source and Traditional Uses 
Nordihydroguaiaretic acid NDGA 1 is a lignan present at concentrations of up to 15% by dry 
weight of creosote bush leaves.1 Creosote bush (Larrea tridentata), is a common shrub of the arid 
regions of northern Mexico and the south-western United States. Traditionally, the shrub has been 
used by the indigenous people of these areas to treat numerous health problems.2, 51 Extracts and 
preparations of the plant were used for varied reasons including treatment for infertility, 
rheumatism, arthritis, diabetes, gallbladder and kidney stones, pain and inflammation among 
others.2, 4  
  
2.2.2 Structure and Physical Properties 
Structurally, NDGA 1 possesses two catechol moieties linked via a butane bridge with two 
methyl substitutions at C2 and C3. This polyphenol occurs naturally as a meso compound (Figure 2-
2). Its strong antioxidant properties are believed to result from the presence of four phenolic 
hydroxyl groups. NDGA 1 is classified as a dibenzylbutane lignan because the phenylpropanoid 
dimers are joined only by β-βʹ bonds47. Its molecular formula and weight are C18H22O4 and of 
302.26 g/mol respectively.  It is solid at room temperature (mp 185-186 °C).  NDGA 1 is also 
referred to as 2,3-bis(3,4-dihydroxybenzyl)butane, 4,4’-(2,3-dimethyl-1,4-butanediyl)bis[1,2-
benzenediol] and 4,4’-(2,3-dimethyltetramethylene)dipyrocatechol and trivially as masoprocol. 
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Figure 2-2: Molecular Structure of Nordihydroguaiaretic Acid (NDGA 1). 
 
2.2.3 Pharmacological Properties of NDGA 
The natural antioxidant NDGA 1 has been under study for numerous pharmacological 
activities including its anti-inflammatory and anti-cancer properties. A topical form of NDGA 
(Actinex®, Chemex Pharmaceuticals, Denver CO) was approved by the FDA for treatment of 
actinic keratosis. After a short while on the market, Actinex® was voluntarily withdrawn due to 
reports of skin hypersensitivity.4 NDGA 1 has shown benefit in cancer chemoprevention, cancer 
therapy, antimicrobial, fertility and hypoglycaemic effects in in vitro and in vivo studies as well as 
human clinical trials1. In addition, NDGA is a known potent inhibitor of lipoxygenase,4, 24 HPV,2 
HSV and HIV.1, 4 It is particularly touted for its antioxidant properties. However, its long use as 
antioxidant in the food industry52 was discontinued following reports of NDGA-induced cystic 
nephropathy in rats.31 The use of NDGA for therapeutic purposes is currently limited due largely to 
toxicity concerns. 
 
2.2.4 NDGA and Autoxidation 
A study in the 1980s reported that nordihydroguaiaretic acid underwent conversion to 
“activated NDGA” in the presence of oxygen.37 The structure of the oxidation product remained 
unstudied until a recent literature report suggesting the “activated NDGA” is a 
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dibenzocyclooctadiene.35 In this study, Billinsky et al.,35 showed that NDGA underwent rapid 
oxidative cyclization in aqueous solution at physiological pH (7.4) to a schisandrin-like 
dibenzocyclooctadiene lignan.  The structure of the oxidation product (Figure 2-3) was 
unequivocally determined from NMR and MS experiments.  
 
Figure 2-3: Structure of the NDGA-derived dibenzocyclooctadiene (cNDGA). 
 
2.2.5 Biological Implications of NDGA-derived Dibenzocyclooctadiene 
NDGA-derived dibenzocyclooctadiene lignan probably makes contribution to therapeutic 
effects attributed to NDGA.  The “activated” NDGA originally reported by Wagner et al.,37 formed 
a stable complex with duplex DNA. This suggests that any biological action by NDGA treatment 
could result from either NDGA itself or its oxidation products37 since many antimicrobial and 
antineoplastic agents are known to function by interacting with DNA and subsequently affecting 
nucleic acid metabolism.53, 54 Unlike NDGA itself, the “activated” NDGA interacted with duplex 
DNA via hydrophobic association. Further, no evidence of intercalation was seen suggesting that 
complexation might not lead to DNA structure modification. In addition, the following important 
observations lend support to potential involvement of NDGA oxidation products in therapeutic 
claims.  
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Firstly, the traditional method of preparation of products from creosote bush normally 
involves boiling the leaves in water. Under such extraction conditions, NDGA possibly converts to 
dibenzocyclooctadiene lignan.35 Secondly, reported conditions of biological activity evaluations 
involving NDGA favour its oxidation and therefore NDGA-derived dibenzocyclooctadiene lignan 
likely makes contribution to reported biological activities especially where biological studies were 
conducted under aerobic conditions for extended periods of time at pH 7.4 or higher.35  For 
example, anticancer activity reported by McDonald et al.,36 was carried out for 7 days under 
conditions that favour oxidation. NDGA autoxidation is rapid35 and therefore the observed activity 
may not result entirely from the natural polyphenol.  Lastly, lignans with dibenzocyclooctadiene 
structural moiety exhibit a wide variety of interesting biological activities,38,39,55 including 
antiviral,40 anticancer,41 anti-inflammatory,42 and hepatoprotective effects.43 For instance, gomisin J 
and derived dibenzocyclooctadiene lignans are reported to have effective anti-HIV activity56 and 
schisantherin D and kadsuranin showed similarly effective anti-HIV activity.57 A study58 involving 
a series of dibenzylbutanediols reported enhanced anti-tumor activity and benefit in breast cancer 
cell inhibition following introduction of the dibenzocyclooctadiene structural moiety. These 
findings suggest that an NDGA-derived dibenzocyclooctadiene likely makes contribution to 
therapeutic properties of NDGA. 
 
2.2.6 Proposed Mechanisms of NDGA Autoxidation 
Nordihydroguaiaretic acid autoxidation to dibenzocyclooctadiene probably occurs via a 
radical-mediated reaction.35, 59 A proposed mechanism involves sequential 2 proton 2 electron loss 
leading to a di-radical 4a which subsequently undergoes coupling via its resonance form 4b to the 
dibenzocyclooctadiene lignan 2 as shown in Scheme 2-1.35, 59 This mechanism is supported by the 
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biosynthesis of the dibenzocyclooctadiene family of lignans in plants which is known to involve 
enzymatic intramolecular biaryl oxidative coupling of phenolic precursors via radical cations, as a 
key step.38, 60 
 
Scheme 2-1: Proposed mechanism for NDGA autoxidation via radical addition. 
In addition,  the dibenzocyclooctadiene family of lignans has been successfully prepared by 
biomimetic synthetic methods.38, 59, 60 Whilst all described approaches involve oxidative aryl 
coupling, the reagents used are critical for the success of the reactions. Coupling of lignans 
containing phenol functions have been achieved using milder oxidative coupling reagents such as 
vanadium(V) oxyhalides,61 thallium(III) tris(trifluoroacetate) (TTFA),62 hypervalent iodine 
reagents,63 ruthenium oxide,60 and others.38 On the other hand, non-phenol substrates required 
oxidizing agents such VOF3.  
64 Attempts at minimizing the accompanying side reactions led to a 
variety of transition metal oxides or their salts, such as Tl(III), Mn(II), Fe(III), Co(III), and Ru(IV), 
which promote aryl-aryl couplings including intramolecular cases.38 In particular, ruthenium(IV) 
dioxide in trifluoroacetic acid-trifluoroacetic acid anhydride (TFA-TFAA) medium is a versatile 
reagent for the synthesis of bridged biaryls from non-phenolic precursors.60 Chattopadhyay et al.,65 
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demonstrated for the first  time the use a cheap, readily accessible non-transition metal based 
reagent 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) as oxidative coupling reagent for non-
phenols. This reagent has been widely used in non-phenol oxidative coupling reaction as illustrated 
with the general structure in Scheme 2-2. 
   
Scheme 2-2: Oxidative coupling of non-phenol lignans using DDQ. 
Reagents: a) TiCl4/Zn; b) CH(OEt)3, BzOH; c) (i) H2, PtO2; (ii) DDQ, TFA 
 
Notwithstanding the proposed radical mediated mechanism, autoxidation of NDGA could 
also result from electrophilic substitution66 as illustrated in Scheme 2-3. This mechanism also 
involves a 2 proton, 2 electron loss as in the case of radical-mediated addition. The sequential loss 
of 2 protons and 2 electrons is expected to occur at only one of the two equivalent rings leading to a 
di-radical 5a which possesses the resonance form o-Q 5b. A subsequent nucleophilic attack of the 
unoxidized ring on the o-Q is expected to yield the dibenzocyclooctadiene product 2. The two 
catechol moieties of NDGA are equivalent and therefore exclusive oxidation of one ring seems 
unlikely as suggested by Galano et al.22 However, only one of the two equivalent phenol rings of 
secoisolariciresinol (SECO, 9) was oxidizable with 2,2'-azobis(2-amidinopropane) dihydrochloride 
(AAPH).51 Given that SECO 9 and NGDA 1 are structurally similar and oxidation of NDGA in the 
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presence of GSH could result in a mono-conjugate derived from o-Q,33 an electrophilic substitution 
mechanism cannot be ruled out. 
 
Scheme 2-3: Autoxidation of NDGA via electrophilic substitution mechanism. 
This mechanism is further supported by observations with polyphenols present in tea.  
Oxidations have resulted in dimers such as 8 and other oligomers, whose formation is suggested to 
occur via intermolecular nucleophilic attack of an unoxidized ring of one molecule 6 on an o-Q 7 
derived from oxidation of a second molecule.66, 67 Flavonoids undergo enzymatic or non-enzymatic 
reactions known to proceed via oxidation of the 3,4-dihydroxy function of the B-ring to the 
corresponding o-Qs such as 7. The o-Qs have electrophilic properties and are able to react with 
surrounding nucleophilic molecules including unoxidized polyphenols68 such as 6 via an 
electrophilic substitution mechanism. Oxygen-dependent dimerization of dihydrochalcone  
aspalathin 6 occurred via electrophilic substitution as illustrated in Scheme 2-466. Interestingly, 
aspalathin was treated under the same conditions of incubation (phosphate buffer, pH 7.4 and 37 
ºC) as in the NDGA autoxidation study. Although, the coupling is intermolecular, the fact that an 
initially formed o-Q reacts with a nucleophilic phenolic ring suggests that NDGA o-Q 5b possibly 
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undergoes intramolecular coupling with its unoxidized catechol ring. It should be noted however 
that this mechanism was not demonstrated conclusively and a radical-mediated process remains a 
possibility for the formation of 8. 
 
Scheme 2-4: Dimerization of aspalathin via oxidative coupling.66 
The exact mechanisms of NDGA oxidative cyclization remain unknown but likely depend on 
substituents and/or substitution patterns on both aromatic rings. Understanding the mechanisms will 
be critical to designing NDGA analogues with higher propensity to undergo cyclization at 
physiologically relevant conditions. Also, NDGA analogues resistant to autoxidation can be 
designed and synthesized to investigate the contribution of cyclization product 2 to 
pharmacological activity and/or toxicity.  
 
2.3    Toxicological Properties of NDGA 
Creosote bush has been utilized in traditional healing practices for many years in a wide range 
of remedies, but its use in clinical setting is currently limited due to toxicity concerns. For instance, 
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chronic exposure to Chaparral tea, an aqueous extract of creosote bush is known to cause liver 
damage. Individuals who consumed Chaparral tea over time suffered drug-induced hepatitis.2, 24, 27 
With exception of one specific case report of total hepatic failure24, 28 and a few cases of 
progression to liver cirrhosis,24 hepatotoxicity was reversible when ingestion is discontinued.2, 24, 27, 
28 In 1968 the Canadian Food and Drug Directorate found evidence of NDGA-induced cystic 
nephrotoxicity in rats.31 Consequently, NDGA use as food preservative was banned in Canada. 
Furthermore, NDGA lost its “Generally Recognized As Safe” (GRAS) status and was removed 
from the US Food and Drug Administration’s list following several reports of toxicity.1, 31   
 
2.3.1 Secoisolariciresinol (SECO) versus Nordihydroguaiaretic acid (NDGA) 
Secoisolariciresinol (SECO, 9) belongs to the dibenzylbutanediol class of lignans. It is closely 
related to NDGA 1 in structure.  Like NDGA, is linked only by a β-βʹ bond. However, SECO 9 has 
hydroxymethyl groups at C2 and C3 of the butane bridge and methoxy substitutions at 3 and 3ʹ 
positions of the aromatic rings (Figure 2-4). Both NDGA 1 and SECO  9 have been under study for 
their diverse pharmacological properties and potential as lead drug candidates.  
 
 
Figure 2-4: Molecular structure of Secoisolariciresinol (SECO, 9) and its diglucoside (SDG, 10). 
The consumption of flaxseed has shown benefits in humans. Experimental evidence 
suggests that the lignan secoisolariciresinol diglucoside (SDG, 10) present in flaxseed and its 
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mammalian metabolites may protect against CVD and metabolic syndrome by reducing lipid and 
glucose concentrations, lowering blood pressure, and decreasing oxidative stress and 
inflammation.69 A reduction in cancer risk by preventing pre-cancerous cellular changes and by 
reducing angiogenesis and metastasis following ingestion of flax lignans has also been suggested.69 
Therefore, dietary SDG 10 has been proposed as having the potential to decrease the incidence of 
several chronic diseases. Despite its close structural similarity to NDGA 1, flaxseed lignan SECO 9 
appears to be well tolerated among adult populations69 and no known significant toxicity in humans 
has been reported.44 
 
2.3.2 Quinones and Toxicity  
Quinones represent a class of toxicological intermediates which have been implicated in a 
variety of xenobiotic toxicities in vivo, including cytotoxicity, immunotoxicity, and carcinogenesis. 
Formation of quinones from xenobiotics may be mediated by monooxygenase enzymes, 
peroxidases and in some cases molecular oxygen. Quinone-mediated toxic effects may have varied 
and often complex mechanisms.70 However, the main theories proposed over the years to explain 
quinone toxicity include alkylation or covalent binding, and oxidative stress mechanisms of 
cytotoxicity.71 
 
2.3.3 Theories of Quinones Toxicity 
2.3.3.1 Alkylation of Macromolecules 
The major non-protein sulfhydryl present in cells, glutathione (GSH, 11) is generally 
considered to protect cells from oxidative damage because its thiol function serves as “sacrificial” 
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nucleophile, preventing critical sites on cellular macromolecules from irreversible modification.70  
The physiological concentration of GSH in the liver is approximately 7mM72 of which nearly 90% 
is found in the cytosol.73    
 
Figure 2-5: Structure of glutathione (GSH, 11). 
The presence of electrophiles in the cellular environment causes a reaction with cellular 
GSH 11 leading to its depletion. Following GSH 11 depletion, nucleophilic groups on cellular 
macromolecules, such as proteins or DNA, react covalently with electrophiles (Figure 2-6) leading 
to irreversible structural and/or functional changes resulting in cell death.70,71 DNA modifications 
likely mediates cytotoxicity of rapidly dividing cells, such as tumor cells, whilst in resting or non-
dividing cells alkylation of essential protein thiol or amine groups and/or oxidation of essential 
thiols by activated oxygen species and/or GSSG is the molecular basis of quinone cytotoxicity.71  
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Figure 2-6: Covalent binding of electrophiles with (a) GSH and three possible forms of 
electrophile-protein interactions: interaction with (b) thiol group (c) amine group of protein and (d) 
reduction of semiquinone radical by sulfhydryl group and subsequent protein cross-linking in the 
presence of oxygen.74 
 
2.3.3.2 Oxidative Stress 
Quinone toxicity may result from oxidative stress. Oxidative stress arises when there is a 
disturbance in the prooxidant-antioxidant balance in favour of the former, leading to potential 
damage.75 Quinones are potent redox active compounds which can undergo enzymatic or non-
enzymatic redox cycling with their semi-quinone radicals, leading to formation of reactive oxygen 
species (ROS) such as superoxide anion radicals (Scheme 2-5). Superoxide anion radicals may 
cause damage on their own or react further with hydrogen peroxide, formed from enzymatic or 
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spontaneous dismutation of superoxide anion radical to give hydroxyl radicals. Hydroxyl radicals 
are powerful oxidizing species that may be responsible for most of the damage to essential 
macromolecules involved in oxidative cytotoxicity (Scheme 2-5)70, 71. 
 
 
Scheme 2-5: (a) Redox cycling of quinones generating reactive oxygen species (ROS) and (b) 
Oxidation of 2-deoxy-guanosine by hydroxyl radical. 
 
2.3.4 NDGA and Quinones Formation 
The mechanisms of NDGA toxicity remain unclear although quinone formation has been 
implicated in hepatotoxicity. In theory, the structure of NDGA 1 suggests possible direct oxidation 
to either o-Q 5b or p-QM 5c (Scheme 2-6). Such transformations may be cytochrome P450-
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mediated or catalysed by other oxidases.28 Formation of NDGA o-Q 5b has been reported in the 
literature.32, 33, 76 Surprisingly, NDGA does not appear to form p-QM 5c33 even though its o-Q 5b 
meets structural requirements for isomerization.77, 78 The presence of benzyl protons available for 
abstraction suggests that NDGA o-Q 5b can tautomerize to p-QM 5c.79 In addition, extended π-
conjugation at the para or 4-position of a catechol78 as well as acidity of the benzyl proton80 
enhances o-Q to p-QM isomerization rate.  On the contrary, steric hindrance at the benzyl position 
slows down tautomerization rate and may lead to non-detectable levels of p-QM. This has 
previously been cited as a possible explanation for the absence of p-QM 5c in NDGA oxidation 
experiments.33    
 
 
 
Scheme 2-6: Oxidation of meso-NDGA to o-Q and p-QM derivatives. 
2.3.5 ortho-Quinones and Reactive Oxygen Species 
In general, catechols undergo two successive 1-electron oxidations catalysed by a variety of 
oxidative enzymes, metals ions and in some situations molecular oxygen to generate reactive 
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metabolites called o-Qs (Scheme 2-5a).71  For example, tyrosinase oxidizes phenols and/or 
catechols directly to o-Qs.81, 82 o-Qs are redox active molecules with potential to undergo non-
enzymatic two-electron reduction with cellular reducing equivalents [NAD(P)H] or enzymatic one-
electron reduction. The ensuing redox cycling (Scheme 2-5a) increases production of reactive 
oxygen species (ROS), including superoxide, hydrogen peroxide and ultimately hydroxyl radical.70 
Production of ROS in the cellular environment is known to cause severe oxidative stress through 
the formation of oxidized macromolecules, including lipids, proteins, and DNA (Scheme 2-5b). The 
intermediate  semiquinone radical (Scheme 2-5a) may cause deleterious damage on its own74 or 
oxidizes further to the o-Q. Cytotoxicity of o-Qs appears to be mainly due to oxidative stress70 
although the potential to react with cellular nucleophiles can occur due to the o-Q’s ability to act as 
electrophilic Michael acceptors. NDGA o-Q 5b is therefore likely to mediate toxicological effects 
via oxidative stress resulting from redox cycling with its intermediate semiquinone radical 3 
although covalent modification of cellular macromolecules may also occur as illustrated in Scheme 
2-7. The o-Q 5b has intrinsic potential to isomerize to the more electrophilic p-QM 5c tautomer 
which may also contribute to toxicity.  
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Scheme 2-7: Proposed toxicological pathways for NDGA. The redox cycling of NDGA o-Q 5b 
with its semi-quinone radical 3 leads to ROS which may cause oxidative stress. The o-Q 5b may 
bind covalently to  cellular nucleophiles (Nu) forming aromatic adducts. 
2.3.6 p-Quinone Methide and Adduct Formation 
Quinone methides (QMs) differ structurally from quinones (Figure 2-7), as one carbonyl 
group is replaced by a methylene or substituted methylene group.77 QMs have been implicated in 
toxicity of certain exogenous compounds including food additives such as eugenol and butylated 
hydroxytoluene (BHT).79  
 
Figure 2-7: General structures of ortho-quinone and para-quinone methides.  
Oxidative metabolism generates QM by one of two major mechanisms. Firstly, phenols with 
at least one benzylic proton may be directly oxidized to the corresponding phenoxy radical as a 
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result of monooxygenase83, 84 or peroxidase activity.85, 86 The phenoxy radical is subsequently 
oxidized to a QM which is probably non-enzymatic but is likely to be enzyme-catalysed in the 
presence of cytochrome P450.87 A second pathway involves indirect conversion of a catechol to a 
QM via isomerization of the initially formed o-Q. However, this tautomerization is dependent on 
the presence of a benzylic hydrogen available for abstraction79 and steric factors around the benzyl 
position.33 
In theory, NDGA 1 should form both o-Q and p-QM. Given that the o-Q 5b has benzylic 
hydrogens it is expected to isomerize to the more electrophilic p-QM 5c as shown below (Scheme 
2-8) although there is no evidence yet for NDGA p-QM 5c. The p-QM 5c is anticipated to be 
highly electrophilic in nature and expected to exhibit higher reactivity than o-Q tautomers.88 
Therefore, NDGA p-QM, if formed, will more readily react with cellular nucleophiles than the o-Q 
tautomer implying a higher toxicity. On this basis, the molecular mechanism of toxicity for a p-QM 
will be mainly characterized by alkylation of cellular nucleophiles rather than redox chemistry.  
 
Scheme 2-8: Isomerization of NDGA o-Q 5b to p-QM 5c and subsequent reaction with cellular 
nucleophile (Nu) to form a benzylic adduct 13. 
 
 
 
22 
 
2.4   Structure Activity Relationship (SAR) Studies on NDGA 
McDonald et al.,36 examined activities of various NDGA analogues against H-69 small cell 
lung cancer cell line. The primary objective was to establish relationships between structure and 
potency as proliferative inhibitor of H-69 lung cancer cell line.  The authors report that the optimum 
carbon spacing between the two catechol moieties is four as analogues with less or greater than C4 
bridge showed decreased activity.  Findings of McDonald and co-workers  as well as those of 
others21, 89-91 also suggest that the catechol moiety has little, if any, effect on activity. A tetra-O-
methyl-nordihydroguaiaretic acid (M4N 14) is strikingly more effective,21, 92 non-toxic and 
currently in clinical trials against human cancers.91 Other hydroxyl-substituted analogues (Figure 2-
8) such as a tetraacetate of NDGA (TA 15) and the prodrug tetraglycinylated-NDGA (G4N 16) 
have also shown antiviral activity.21, 89 Lambert et al.,5 have observed a positive correlation of O-
methylation with potency for NDGA and have suggested increased lipophilicity which allows the 
compounds to traverse lipid membranes as one probable reason for the enhanced activity. Since 
NDGA binds to estrogen receptors (ERs) to elicit estrogenic response, the potent inhibition of 
MCF7 breast cancer line by methylated NDGA analogues may be related to increased affinity for 
ER which are expressed in MCF7 cells.5 
NDGA potently inhibits lipoxygenase by a  mechanism which involves reduction of ferric 
iron into inactive ferrous form,  and concomitant oxidation of the catechol moiety of NDGA to a 
semiquinone.93 Whitman et al.,94 found that “masking” of the phenolic groups of NDGA removes 
lipoxygenase inhibitory activity. It follows then that pharmacologically active analogues with 
masked phenolic groups act via a lipoxygenase independent mechanism thus suggesting NDGA 
acts at multiple targets. Although M4N 14 and other hydroxyl-substituted analogues display 
similar36 or better potency than NDGA,91 the catechol moiety is required for lipoxygenase activity 
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and also largely accounts for NDGA antioxidant activity. NDGA possibly possesses cytotoxic 
activity independent of pro-oxidant capability but its antioxidant properties have also been cited in 
many beneficial applications. For instance, NGDA is a potent in vitro scavenger of peroxynitrite, 
singlet oxygen, hydroxyl radical, superoxide anion and hypochlorous acid.23 In fact, NDGA is a 
more effective hydroxyl radical scavenger than other recognized hydroxyl radical scavengers like 
uric acid, dimethylthiourea, trolox and mannitol.23 In addition, the inhibition of cytotoxicity 
induced by t-butylhydroperoxide63 and hydrogen peroxide74 in mammalian cells is also consistent 
with the antioxidant effect of NDGA. Therefore, suggestions that the o-hydroxyl functions may not 
be critical to biological activities of NDGA are misleading and possibly simplistic. Perhaps the 
most striking SAR report is the observation that 1,4-bis(catechol-yl-)-butane 17, a double 
demethylated NDGA (Figure 2-8), is 10 times more potent than NDGA as proliferative inhibitor of 
H-69 small cell lung cancer cells.36 This raises the question of whether or not NDGA’s internal 
planes of symmetry are necessary for pharmacological activity. NGDA and its racemate showed 
similar potency as proliferative inhibitor of H-69 small cell lung cancer cells36. There are no 
systematic evaluations of stereochemical influence on biological activity for NDGA.  
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Figure 2-8: Examples of pharmalogically active o-hydroxy-substituted analogues of NDGA and a 
simplified NDGA 17. 
 
2.5    Design of NDGA Analogues 
A radical mediated mechanism (Scheme 2-9 pathway A) has been proposed to explain NDGA 
1 autoxidation to dibenzocyclooctadiene35, 59 but could also result from an electrophilic 
substitution66 mechanism (Scheme 2-9 pathway B). Although the exact mechanism of the 
intramolecular cyclization remains unknown, it likely depends on substituents and/or substitution 
patterns on both aromatic rings. Access to approapriate NDGA analogues will allow for 
investigations into the effect of aromatic rings and/or butane bidge substitutions on 
dibenzocyclooctadiene product formation. This will untimately provide insight into the structural 
features which modulate NDGA pharmacological and toxicological effects. Therefore, we proposed 
the synthesis of of eigth NDGA analogues (Figure 2-9) to primarily verify the proposed 
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mechanisms of NDGA intramolecular cyclization and whether oxidative conversion to reactive 
metabolites depends on substituents and/or substitution pattern of the aromatic rings. 
 
 
Figure 2-9: Structures of proposed NDGA analogues  for this project. 
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Scheme 2-9: Proposed mechanisms of NDGA autoxidation. Pathways A and B represent radical-
mediated and electrophilic substitution mechanisms respectively. 
 
2.6 Rationale for the Proposed NDGA Analogues 
A radical-mediated addition mechanism (Scheme 2-9, pathway A) requires initial formation 
of a di-radical 4, followed by radical coupling. This mechanism is dependent on a di-catechol 
moiety or the presence of free 3-OH and 3ʹ-OH groups, suggesting that a mono-catechol NDGA 
and other analogues lacking 3 and 3ʹ OH structural units may not undergo the intramolecular 
cyclization under similar conditions. On the other hand, an electrophilic substitution mechanism 
(Scheme 2-9, pathway B) requires at least a catechol moiety which oxidizes to an o-Q 5b via a di-
radical intermediate 5a and the potential of the other ring to act as a nucleophile. 
A mono-catechol A1 (Figure 2-9) lacks readily ionizable -OH groups on the unsubstituted 
ring and could only cyclize via an electrophilic substitution mechanism. The Hammett constants for 
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substituents σ (Table 2-1),95 suggest that the mono-catechol A1 is less nucleophilic and therefore 
expected to undergo autoxidation at a greatly reduced rate in comparison to NDGA.  A4 is 
comparable to NDGA in nucleophilicity and will be expected to autoxidize at a rate comparable to 
that reported for NDGA if the cyclization follows electrophilic substitution mechanism. However, 
the lack of free –OH functions on both aromatic rings of A4 means that the radical-mediated 
pathway cannot occur for A4. Therefore, absence of autoxidation in A4 could imply that a radical-
mediated process more accurately describes NDGA oxidative cyclization. Compounds A5 and A6 
are expected to behave like NDGA under oxidative conditions although intramolecular cyclization 
to a dibenzocyclooctadiene derivative is expected to occur at different rates. Given the potential of 
compound A6 to cyclize under oxidative conditions, we were motivated to verify whether a 
dibenzocyclooctadiene derivative possibly contributes to the remarkable anti-proliferative activity 
reported by McDonald et al.36 Compound A5 was intended to investigate the effect of butane-
bridge substitution on intramolecular cyclization rate. Lastly, if the intramolecular cyclization 
follows a radical-mediated addition mechanism, compounds A7 and A8 will be expected to form 
dibenzocyclooctadiene derivatives.  
 
 
 
 
 
 
 
 
 
 
28 
 
Table 2-1: Hammett constants for substituents95 on the prepared NDGA analogues. 
Substituents  Hammett constant (σ) 
H 
m-OH  
p-OH 
m-OCH3 
p-OCH3 
0.00 
0.12 
-0.37 
0.12 
-0.27 
 
Unlike NDGA 1, oxidation of SECO 9 did not form reactive intermediates capable of 
interacting with biological nucleophiles.33 Instead, SECO converts to lariciresinol (Scheme 2-10 ) 
which is resistant to further oxidations96. The lack of reactive metabolites likely explains the 
relative safety profile reported for SECO.33  
 
Scheme 2-10: Conversion of SECO to lariciresinol under oxidative conditions. 
The methoxy substituents of the di-phenolic lignan SECO 9 possibly prevent metabolic 
conversion to quinones (Scheme 2-11). Metabolism studies of A2 and A3 which lack the potential 
for o-Q formation are expected to aid in understanding the contribution of o-Qs and/or p-QMs to 
NDGA 1 toxicity. Oxidative metabolism studies of the analogues will help us to better appreciate 
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metabolism of lignans and possibly lead to development of some understanding of structure-activity 
relationships for lignans, an area where data is currently lacking. 
 
Scheme 2-11: Oxidation of secoisolariciresinol (SECO 9) and nordihydroguaiaretic acid (NDGA) 
analogue 3 (A3) to quinones. 
 
2.7 Synthesis of NDGA and its Analogues 
Synthesis of lignans and their analogues continues to attract attention due to their interesting 
biological properties and potential for use as medicines. One such lignan with interesting 
pharmacological properties is NDGA. In a recent review, Chen48 described various approaches to  
prepare NDGA analogues. Synthetic analogues were categorized broadly into three families (Figure 
2-10) based on the modification type as a) hydroxyl-substituted NDGA derivatives, b) butane-
bridge modified NDGA derivatives and c) phenyl-ring NDGA derivative48  
 
 
Figure 2-10: Modifications of the backbone of NDGA to (a) hydroxyl-substituted NDGA 
derivatives (b) butane-bridge modified NDGA derivatives and (c) phenyl-ring NDGA derivatives 
(shaded areas are sites of modification).48  
 
 
30 
 
Approaches to syntheses of lignans and their analogues described in the literature involve the 
use of a limited number of vital reactions to construct the basic 18-carbon skeleton which is 
subsequently modified via cyclization, reduction, oxidation or hydration among others to the 
desired target compound. The compounds of interest for this project are all hydroxyl-substituted 
NDGA derivatives. This section reviews a number of approaches with emphasis on their 
applicability to the synthesis of our anticipated NDGA analogues. Based on retrosynthetic analysis, 
hydroxyl-substituted NDGA type derivatives can be prepared via four major routes (Figure 2-11)48 
depending on synthetic objective and factors such as availability of starting materials, yield and 
stereoselectivity among others. 
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Figure 2-11: Retrosynthetic approach for synthesis of hydroxyl-substituted NDGA derivatives. 
 
2.7.1 Consecutive Stobbe Condensation 
The Stobbe condensation reaction has been used extensively in the literature for 
constructing the basic skeleton of lignans due largely to its versatility. The reaction involves 
treating an aromatic aldehyde 18 with a succinate ester 19 in the presence of a base to give a trans-
benzylidene succinate monoester 20.97 The mechanisms (Scheme 2-12) involve intramolecular 
cyclization leading to formation of a 5-membered lactone97, 98 which subsequently cleaves via β-
elimination to form the trans-benzylidene product 20. The intermediate 5-membered lactone has 
been confirmed by isolation.97 Stereochemistry of the trans-benzylidene product 20 was 
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unambiguously established through NMR studies.98 The diamagnetic anisotropic deshielding effect 
of the carbonyl group causes the olefenic proton in the E configuration to appear beyond 7.5 ppm, 
downfield from the Z proton arrangement.98  
A consecutive Stobbe condensation of the trans-benzylidene diester 21 with another 
equivalent of aromatic aldehyde 18 in refluxing alkoxide/alcohol affords the diarylbutanediene 
basic structure 22. A couple of subsequent reductive steps lead to the desired lignan.99, 100  The 
approach provides a flexible way for preparing lignans in good yield with individual steps ranging 
from 73-99% in the literature. The major drawback, however, is lack of stereo-control for the 
forming stereogenic centers. This has led to various modifications aimed at controlling 
stereochemistry as reviewed in the subsequent sections.  
 
Scheme 2-12: General mechanism of Stobbe condensation reaction. 
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The analogues of interest for this project can all be synthesized by using a double Stobbe 
condensation approach as illustrated below for A1 (Scheme 2-13). In the case of A2, A3, A4, A7 
and A8 protection of the active phenol group in the starting aromatic aldehyde may be necessary to 
prevent side reactions.  
 
Scheme 2-13: Consecutive Stobbe condensation approach for synthesis of A1. 
Reagents and Conditions: i) EtONa/EtOH, reflux; ii or iv) MeI, K2CO3/DMSO, rt; iii) BnCHO, 
EtONa/EtOH, reflux; v) H2, Pd-C, vacuum; vi or viii) LiAlH4/THF, rt; vii) TsCl/py, 0°C; ix) 
BBr3/DCM, -78°C.  
 
Following hydrogenation, the resulting four stereoisomers in the case of A1, A2 and A4 for 
example are expected to exist as two pairs of enantiomers which should be separable 
chromatographically.101 A3, A7 and A8 will exist as a meso-compound and a pair of enantiomers 
which are separable chromatographically.101 Figure 2-12 shows the possible stereoisomers of A1, 
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A2, A3 and A4 following hydrogenation. It is not known whether any preference for the formation 
of any specific stereoisomers will occur, but it remains a possibility. 
 
 
Figure 2-12: Stereoisomers of analogues A1, A2, A3 and A4. 
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2.7.1.1 Approach to controlling stereochemistry of the Stobbe Condensation  
2.7.1.1.1 Stobbe Condensation-Alkylation 
Xia et al.,58, 102 described an approach for enantioselective synthesis of NDGA, (–)-saururenin 
and their analogues using a Stobbe condensation followed by alkylation as key synthetic steps 
(Scheme 2-14). The Stobbe condensation product, a benzylidene half-ester was esterified and 
treated with appropriate alkylating agent in the presence of LDA to give the basic lignan structure. 
After basic hydrolysis, the resulting diacids were resolved via their quinine salts. Hydrogenation of 
esterified (+) or (-) acid followed by LiAlH4 reduction gave diols which were readily separable by 
chromatography. Further reductive steps gave the desired stereospecific lignans with individual 
yields varying from 38-92%.  
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Scheme 2-14: Enantioselective synthesis of NDGA analogues by Stobbe Condensation-alkylation 
approach. 
Reagents and conditions: i) substituted BnBr, LDA/THF, -78°C; ii) NaOH/H2O, reflux; iii) (-)-
quinine resolution; iv) EtOH/C6H6, H
+; v) H2, Pd-C; vi) LiAlH4/THF, rt. 
 
This approach will allow access to A1 and A2 needed for this project as illustrated in Scheme 
2-15 for A2. The key advantage of this approach is stereo-control leading to analogues with defined 
stereochemistry. The major drawback is the lack of general applicability as appropriate alkylating 
agents needed may not be readily available.  
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Scheme 2-15: Synthesis of A2 via Stobbe condensation-alkylation method. 
Reagents and Conditions: i) BnBr, K2CO3/DMF; ii) EtONa/EtOH, reflux; iii, v or viii) MeI, 
K2CO3/DMSO, rt; iv) BnBr, LDA/THF, -78°C; vi) NaOH/H2O, reflux; vi) (-)-quinine resolution; 
ix) H2, Pd-C; x or xii) LiAlH4/THF, rt; xi) TsCl, Pyridine, 0 °C; xii) KOH/EtOH-H2O (1:1), reflux.  
  
2.7.1.1.2 Stobbe Condensation-Lactonization 
The backbone conformation of NDGA analogues can be established by catalytic 
hydrogenation of a racemic lactone.101, 103 The Stobbe condensation product, benzylidene half-ester 
is hydrogenated over Pd/C to give the corresponding saturated hemiester which is chemoselectively 
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reduced and lactonized with Ca(BH4)2 in ethanol to give the racemic lactone in good yield (Scheme 
2-16). Stobbe condensation of the lactone with another equivalent of substituted benzyladehyde 
followed by catalytic hydrogenation with Pd/C yields the cis-lactone exclusively, which was 
reduced to the diol with Ca(BH4)2.
48
 The approach is useful for stereoselective synthesis of 
dibenzylbutane type lignans.   
  
 
Scheme 2-16: Synthesis of NDGA analogues via Stobbe condensation-lactonization approach. 
Reagents and Conditions: i) : (i) H2, Pd-C; (ii) KOH, Ca(BH4)2; (iii) NaH, THF, ArCHO, reflux; 
(iv) H2, Pd-C; (v) Ca(BH4)2, THF, H2O. 
 
2.7.2 Grignard Reaction 
Lieberman et al.,104 used the coupling of 1-piperonyl-1-bromoethane and its Grignard 
derivative as a key step to make the skeleton of NDGA. This approach has been modified without 
success to improve yield and stereo-control in the literature.105 Son et al.,106 developed a modified 
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procedure via 1,4-di(substituted-phenyl)-2,3-dimethyl- butan-2-ol as a key intermediate for the 
synthesis of NDGA and related lignans (Scheme 2-17).  
 
Scheme 2-17: Synthesis of NDGA analogues via Grignard synthesis approach. 
Reagents and Conditions: i) (a) Mg/ether, (b) then H3O
+; ii) H2SO4; iii) H2/PtO2. 
 
Following dehydration, the resulting (E) and (Z) stereoisomers were readily separable since 
the (E) and (Z) forms were crystalline and oily respectively at room temperature.106 The effect of 
various ring substitutions on these physical states is unknown and likely not general. However, this 
approach has a wider applicability because it allows access to both symmetrical and unsymmetrical 
NDGA analogues. In addition, the method uses ketones which are readily available and cheap as 
electrophilic coupling reagents. The overall yields range from 45-54%. The attractiveness of this 
approach may, however, be limited by lack of stereoselectivity although isomers following 
hydrogenation may be separable by chromatography.101 In principle, this approach is expected to 
allow synthesis of all four analogues of interest. Following hydrogenation, the two pairs of 
enantiomers in the case of A1, A2, A4 and the meso-compound and a pair of enantiomer of A3 
(Figure 2-12) should be separable by chromatography.101 
 
 
40 
 
 
2.7.3 McMurry Coupling Reaction 
Ti-induced carbonyl-coupling reactions of substituted phenylacetones, surprisingly, resulted 
in 1,4- disubstituted-butane-2,3-diols instead of expected McMurry type butenes. This finding 
provides an attractive alternative route to NDGA and its non-meso isomer using (3,4-
dimethoxyphenyl)-acetone as starting material as shown in Scheme 1-18.107 The method is simple 
and stereoselective although yields were not fully reported.  Also, the approach offers many 
possibilities to produce a wide variety of NDGA derivatives, since carbonyl containing compounds 
are easily accessible. 
However, applicability is limited to symmetrical NDGA analogues since McMurry coupling 
reactions between two different ketones are rarely successful.108 Therefore, A3, A6, A7 and A8 
may be obtainable via this approach as illustrated in Scheme 2-19 for A3. We have also observed 
that an electron-withdrawing substituent on the OH para to the benzyl carbon prevents the coupling 
reaction, resulting only in reduction of starting material to the alcohol (unpublished work). Hence 
the need for an electron-donating group such as trimethylsilyl (TMS) group shown in Scheme 2-19. 
Dehydroxylation of the resulting butanediol is expected to give both Z and E-butenes. As reported 
previously for NDGA,108 the Z and E-isomers may be separable by crystallization. Subsequent 
hydrogenations should either form the meso-compound or a racemic mixture of A3.  
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Scheme 2-18: Synthetic route to NDGA and its stereoisomer using Ti-induced carbonyl-coupling 
reaction. 
Reagents and Conditions: i) TiCl4/Zn, THF; ii) CH(OEt3), BzOH; iii) H2/PtO2; iv) BBr3. 
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Scheme 2-19: Synthesis of A3 via McMurry coupling reaction. 
Reagents and Conditions: i) TiCl4/Zn, THF; ii) CH(OEt3), BzOH; iii) H2/PtO2; iv) H2O/H
+. 
 
2.7.4 Oxidative Coupling Approach 
Matairesinol has been synthesized through oxidative coupling of ferulic acid as a key step.109 
The poor control of regiochemistry in the oxidative coupling step led to low yield of the desired 
coupling product.  Oxidized ferulic acid exists in three mesomeric forms (Figure 2-13) which 
allows for six different coupling patterns leading to a mixture of coupling products.101, 110 The 
major coupling pathway seems to be β-5 linked compound.111 
 
Figure 2-13: Mesomeric forms of oxidized ferulic acid. 
This strategy has been modified over the years to improve regioselectivity of the coupling 
reaction. Notably, the use of tert-butyl protection at C5 of the phenyl ring enhances the desired β-β 
coupling by blocking the major β-5 pathway.101, 110 The attractiveness of this approach, however, is 
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limited by its applicability. It does not allow access to unsymmetrical lignan skeletons and therefore 
applicable only to A3 as shown in Scheme 2-20.  
 
Scheme 2-20: Synthesis of A3 via oxidative coupling approach. 
Reagents and Conditions: i) t-BuOH, 85% H3PO4, 75°C; ii) Br2, t-BuOH, r.t.; iii) Ph3PCHCOOEt, 
CH3OCH2CH2OCH3, reflux; vi) K3[Fe(CN)6], KOH, C6H6-H2O, rt; v) H2, Pd/C(10%); vi) AlCl3, 
C6H6, 50°C; vii) LiAlH4/THF, rt.; viii) TsCl, Pyridine, 0°C; ix) LiAlH4/THF, rt;  x) KOH/EtOH-
H2O (1:1), reflux.   
 
2.8 Oxidative Metabolism 
In order to facilitate elimination from the body, xenobiotics are metabolized by various 
oxidation and conjugation enzymes to more electrophilic metabolites. However, this generally 
accepted detoxification process may lead to chemically reactive metabolites in vivo, a process 
known as bioactivation. Most reactive metabolites are electrophilic in nature and can react with 
nucleophiles. Due to a possible link between reactive metabolites and drug toxicity, screening for 
metabolic activation has become integral part of the drug development process.112, 113  
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2.8.1 Metabolism of Nordihydroguaiaretic Acid 
The low bioavailability of NDGA is attributed to efficient first-pass metabolism as opposed 
to low absorption given that NDGA readily forms glucuronides, and liver function test (LFT) 
abnormalities have been detected in multiple patients indicating delivery of NDGA to the 
hepatocyte.114 Lambert et al.,4 detected mono- and diglucuronides of NDGA within minutes in the 
plasma of mice following intravenous treatment.  When incubated with human hepatic microsomes, 
however, NDGA formed only the monoglucuronide. While this finding suggests that 
glucuronidation may be a major detoxification pathway for NDGA, it remains to be determined 
whether differences in mouse and human glucuronosyltransferases accounted for this observation or 
it simply reflects in vitro versus in vivo situations.4 Rats fed 0.5-1.0 % NDGA in the diet developed 
cystic reticuloendotheliosis of the paracaecal lymph nodes and vacuolation of kidney epithelium. 
Subsequent isolation of o-Q intermediate of NDGA from kidney extracts suggests that the observed 
kidney lesions are mediated by the o-Q reactive metabolite.32  In another study, Woodrats which 
had adapted to a creosote bush diet had elevated levels of cytochrome P450s (CYP2B, CYP1A)  
and glutathione conjugation liver enzymes compared to Woodrats on a traditional juniper diet,  
indicating the importance of these enzymes in the metabolism and elimination of NDGA 
metabolites.115   
 
2.8.2 Assessment of Bioactivation Potential 
Catechols and phenols form quinones and/or quinone methides via oxidative metabolism 
which may be enzyme-catalyzed.33, 34, 70, 71, 84, 86, 87  Like other reactive metabolites, the high 
reactivity of quinones and quinone methides preclude their detection by traditional analytical 
methods. However, reactive metabolites are generally analyzed by LC-MS/MS after chemical 
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trapping with nucleophilic agents such as GSH 11.113,116-119 This approach traps the otherwise 
highly unstable electrophilic intermediates as GSH adducts to allow structural elucidation of the 
stable conjugates by LC-MS/MS and/or NMR methods. The data obtained provide indirect 
information about the structure of the electrophilic species, and hence the bioactivation 
mechanism.113 GSH 11 as nucleophilic trapping agent is known to work well with ‘soft’ 
electrophiles but does not trap effectively some ‘hard’ electrophiles.119 Therefore, other 
nucleophilic trapping agents, such as  semicarbazide or methoxylamine120, 121 and potassium 
cyanide122, 123 that are capable of trapping ‘hard’ electrophiles have been employed for 
comprehensive screening protocols for reactive metabolite. A few other trapping agents have also 
been suggested in the literature for simultaneously trapping both ‘soft’ and ‘hard’ electrophiles.124, 
125 
 
2.8.3 Methods for Studying GSH Adducts  
2.8.3.1 Nuclear Magnetic Resonance (NMR) Approach 
Glutathione conjugates of NDGA o-Q 5b have previously been studied by NMR and LC-MS 
methods.33 The GSH conjugate of p-QM 5c of NDGA will be distinguishable by NMR as it forms 
exocyclic GSH adduct 13 whilst the o-Q generally yields ring conjugates 12.33, 78 (Scheme 2-21). 
 
Scheme 2-21: Glutathione conjugates derived from NDGA o-Q 12 and p-QM 13. 
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2.8.3.2 Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) Approach 
LC-MS/MS techniques have been routinely utilized in in vitro evaluations of new chemotypes for 
reactive metabolites via GSH trapping experiments. Dieckhaus et al.,116 demonstrated that precursor 
ion (PI) scanning of m/z 272 (deprotonated γ-glutamyl-dehydroalanyl-glycine) in the negative ion 
mode (Scheme 2-22 ) provides a general survey scan applicable for the detection of a wide variety 
of GSH conjugates.116  
 
Scheme 2-22: Detection of GSH conjugates via precursor ion (PI) scan of m/z 272 in the negative 
ion mode. 
Previously, a triple quadrupole MS technique employing neutral loss (NL) of  m/z 129 
(pyroglutamic acid moiety) in the positive ion mode (Scheme 2-23) was largely used for screening 
GSH-trapped reactive metabolites.126 Neutral loss 307 (glutathione) has also been employed as a 
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detection technique.116, 126 The structure of a suspected glutathione conjugate is elucidated 
following a product ion scanning of the parent ion (MH+).116, 126 However, general applicability of 
NL 129 as a detection technique suffers from low sensitivity and limited selectivity resulting from 
the interference of endogenous compounds and background noise.116 
 
 
Scheme 2-23: Detection of GSH conjugates via neutral loss scan (NL) of m/z 129 or 307 in the 
positive ion mode. 
More recently, a complementary technique utilizing multiple reaction monitoring (MRM) as 
a survey scan to trigger the acquisition of enhanced product ion (EPI) spectra has been reported.127 
Although this MRM-based approach seems to provide superior sensitivity and selectivity for GSH 
adducts, it only detects the GSH adducts pre-set on an MRM transition protocol. Therefore MRM-
EPI approach must be used in conjunction with PI or NL when comprehensive analysis of predicted 
and unpredicted GSH conjugates is desired.127 Recent developments in mass spectrometry have 
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revolutionized reactive metabolites analysis in the drug discovery process. For example, the 
quadrupole-linear ion trap mass spectrometry (Q-trap) retains the MS/MS scan functions of both 
the triple quadrupole and the ion trap.128 In addition to speeding the data acquisition process, the Q-
trap allows information dependent acquisitions which provide the advantages of combining the 
selectivity of PI, NL and MRM scans by the triple quadrupole and the sensitivity of MS/MS 
spectral acquisition by the ion trap.129 The Q-trap allows detection and MS/MS acquisition of 
analytes to be accomplished in a single LC-MS run.       
 
2.9 Perspective 
The structural features that govern both pharmacological and toxicological properties of 
NDGA are poorly understood. In the drug discovery process, chemical modification is commonly 
used to reduce toxicity and/or enhance pharmacological effects of potential drug candidates or new 
chemotypes.  It is likely that NDGA 1 toxicity is related to its catechol moieties.32-34 The 
structurally similar lignan secoisolariciresinol (SECO 9) which exists as a di-phenol has limited 
toxicity suggesting that the o-dihydroxy function in the case of NDGA 1 is possibly culpable.  Also, 
the rapid intramolecular cyclization to a dibenzocyclooctadiene derivative reported35 for NDGA 1 
at physiological conditions did not seem to occur when SECO 9 was treated under similar 
conditions. Instead, SECO 9 yields lariciresinol 2344 which likely occurs via a para-quinone 
methide intermediate as shown in Scheme 2-24.  
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Scheme 2-24: Proposed mechanism of SECO oxidation to Lariciresinol. 
In theory, a p-QM 5c derived from NDGA is expected to be formed directly or via 
isomerization of the o-Q  5b as depicted by Scheme 2-6. The p-QM 5c, if formed, will be expected 
to contribute to toxicity (Scheme 2-25) as has been confirmed for the o-Q.32 It is unclear why 
NDGA does not seem to form the p-QM 5c and will be investigated in these studies.  The structural 
features which govern the pathways to reactive metabolites and intramolecular cyclization which 
likely have toxicological and pharmacological implications respectively (Scheme 2-25) were of 
interest in this study.  
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Scheme 2-25: Autoxidation of NDGA 1 at physiological conditions to a dibenzocyclooctadiene 
lignan (cNDGA 2) and ortho-quinone (o-Q 5b). There is no evidence yet for a para-quinone 
methide (p-QM 5c).  
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2.10 Purpose of this Project 
2.10.1 Rationale 
Nordihydroguaiaretic acid has a broad spectrum of important biological activities but its 
usefulness is hindered by toxicity concerns. Rational modifications of the structure of NDGA will 
allow for identification of its pharmacophore and toxicophore and likely lead to design and 
synthesis of analogues with better safety profiles in the future. The pathways mediating 
pharmacological and toxicological effects of NDGA are presently unclear. Therefore, 
understanding the mechanistic pathways is the way forward to develop NDGA analogues with 
better safety profiles. To this end, there is the need to design and synthesize appropriate NDGA 
analogues (Figure 2-9) that will provide vital information to unravel the mechanisms of its 
oxidative conversion to a dibenzocyclooctadiene derivative which likely has pharmacological 
implications. The conditions of formation35 and the known biological properties of the 
dibenzocyclooctadiene family of lignans55 suggest that this oxidation product likely contributes to 
the pharmacological effects of NDGA.  Autoxidation studies on appropriate analogues will aid in 
understanding the mechanisms of NDGA-derived dibenzocyclooctadiene formation and the design 
of analogues with higher propensity to convert to a dibenzocyclooctadiene under physiologically 
relevant conditions. Also, oxidation studies on the prepared analogues will provide vital 
information about structural features which influence reactive metabolite formations. This is 
expected to help in design strategies to metabolically block reactive intermediates formation with 
potential implication for ameliorating the safety profile of NDGA analogues. The overall outcome 
of this study is expected to advance our understanding of structural features that influence 
biological activities of NDGA and likely lead to discovery of analogues with improved 
pharmacological effects and safety profile. 
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2.10.2 Hypotheses 
The following hypotheses were tested in this study: 
1. Nordihydroguaiaretic acid intramolecular cyclization to dibenzocyclooctadiene involves a 
radical mediated addition mechanism. 
2. Formation and type of quinoid species is dependent on substitution and/or substitution pattern 
of the aromatic rings 
3. A p-QM of nordihydroguaiaretic acid contributes to its toxicity 
 
2.10.3 Objectives and Aims 
In order to verify our hypotheses, the following objectives and aims were outlined. 
2.10.3.1 Objective 1 
Synthesis and characterization of NDGA analogues for the purpose of understanding 
structural features that influence pharmacological and toxicological properties of NDGA. The two  
specific aims of this objective are: 
1.  To develop synthetic protocols for the preparation of the NDGA analogues 
2.  To purify and characterize prepared analogues using various chromatographic, mass 
spectroscopy (MS) and nuclear magnetic resonance (NMR) methods  
2.10.3.2 Objective 2 
Evaluate the synthesized NDGA analogues for their potential to undergo autoxidative 
cyclization under physiologically relevant conditions. This study is expected to help explain the 
mechanisms of NDGA oxidative cyclization in a phosphate buffer (pH 7.4) at 37°C and provide 
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information about structural features that influence pharmacological properties of NDGA. The two 
specific aim of objective 2 are: 
1. To develop an HPLC method for detection and quantification of the autoxidation products 
and subsequently quantify the rates of autoxidation 
2. To isolate and elucidate the structures of the autoxidation products. 
2.10.3.3  Objective 3 
Study the oxidative metabolism and bioactivation of the NDGA analogues. This will provide 
understanding of the effect of aromatic rings substitution and/or substitution pattern on quinoid 
species formed under oxidative conditions and also help determine the major toxicophore 
responsible for NDGA’s toxicity.  The two specific objective are: 
1. Perform enzymatic and chemical oxidation on the prepared analogues and trap reactive 
quinones as glutathione conjugates for HPLC and LC-MS analyses. 
2. Perform in vitro microsomal incubations and identify glutathione-trapped conjugates by 
MS and/or NMR techniques 
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2 MATERIALS AND METHODS 
 
3.1 Materials/Chemicals  
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO): 
Benzaldehyde, 3,4-dimethoxybenzaldehyde, vanillin, 3-hydroxy-4-methoxybenzaldehyde, 4-
hydroxy-3-methoxybenzaldehyde, 3,4- dihydroxybenzaldehyde,  3-hydroxybenzaldehyde, diethyl 
succinate, benzyl bromide, lithium diisopropylamide, CH3I, eugenol, BBr3 (1 M in DCM), p-
toluenesulfonyl chloride, methanesulfonyl chloride, Pd/C (10%), anhydrous DMSO, anhydrous 
pyridine, AgNO3, LiAlH4, anhydrous THF, anhydrous DCM, molecular sieves 3Å, MgSO4, 
trifluoroacetic acid (TFA), nordihydroguaiaretic acid (NDGA), reduced glutathione (GSH), 
mushroom tyrosinase, reduced nicotinamide adenine dinucleotide phosphate (NADPH) tetrasodium 
salt, 3,4-dimethoxyphenyl acetone (DMPA), K2HPO4, MgCl2, salicylamide. NaOH and silica gel 
60 (0.040-0.063 mm) used in flash columns were obtained from EMD. K2CO3, NaHCO3, H2SO4, 
Na2HPO4, KOH, formic acid and perchloric acid were obtained from BDH Chemicals (Toronto). 
Celite® 545, H3PO4, HCl, NaCl, citric acid and sea sand used in the flash columns were obtained 
from Fisher Scientific (Fairlawn, NJ); ethanol (it was distilled and stored over sieve under N2(g) 
prior to use) was obtained from Commercial Alcohols Inc. (Brampton, ON); CDCl3, CD3OD, and 
DMSO-d6 were obtained from Cambridge Isotope Laboratories Inc. (Andover, MA). Silver oxide 
(Ag2O) was freshly prepared from AgNO3 and KOH according to literature procedure.
130 NaOEt 
solution in ethanol was prepared by addition of Na(s) to dry ethanol. Hydrogenation of eugenol gave 
PC2; PC1 was obtained from PC2 by demethylation with BBr3 solution in DCM; NDGA analogues 
were prepared according to literature procedures with modifications where appropriate as described 
in Section 3.3. All other solvents were of the highest grade purity obtained from EMD (Gibbstown, 
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NJ).  HPLC runs were done with HPLC grade water and acetonitrile. LC/MS grade water, methanol 
and acetonitrile were used for all LC-MS analyses.  
 
3.2 Equipment/Instrumentation 
TLC aluminium sheets were coated with silica gel 60 F254 purchased from EMD Chemicals 
Inc. (Gibbstown, NJ). Rotary evaporator systems consisted of Büchi Rotavapor R-200, and Büchi 
v700 vacuum pump with attached v850 vacuum controller. Samples in test tubes were concentrated 
using Eppendorf Concentrator 4301 with Büchi Vac V-500 with attached v850 vacuum controllers. 
Incubates were centrifuged using an Eppendorf Centrifuge 5417C. Trace amounts of solvent and 
moisture were removed using an Edwards High Vacuum Pump. Vortexed reactions utilized a Janke 
& Kunkel IKA-Vibrax VXR with VX2 attachment. Incubations were done in a VWR incubating 
orbital shaker. Water was purified with a Millipore Milli-Q system with a Quantum EX Cartridge 
(Mississauga, ON). HPLC system consisted of Waters Alliance 2695 connected to Waters 2996 
photodiode array detector. The HPLC system was controlled by, and data interpreted with the 
Waters Empower software. NMR experiments were performed on a Bruker AVANCE DPX-500 
spectrometer, and data processed by X-WIN NMR 3.5 software or TopSpin 3.2. All compounds 
were named using ACD/ChemSketch. MS experiments were conducted using AB SCIEX 4000 
QTRAP (AB SCIEX instruments) quadrupole linear ion trap mass spectrometer coupled to an 
Agilent 1100 system consisting of an Agilent 1100 G1311A pump and an Agilent 1100 G1329A 
autosampler (Agilent Technologies, Mississauga, ON). Data acquisition and analysis was 
performed using Analyst 1.5.1 software from AB SCIEX.  
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3.3 Experimental 1: Synthesis and Characterization of NDGA Analogues 
3.3.1 Synthesis of (3E)-4-(3,4-dimethoxyphenyl)-3-(ethoxycarbonyl)but-3-enoic acid (25)100, 
102  
 
Sodium ethoxide (28%) solution (44.5 ml, 180.54 mmol), dried ethanol (180.5 ml) were 
transferred into the reaction flask under nitrogen gas. 3,4-dimethoxybenzyladehyde (15 g, 90.27 
mmol) was added to the stirring mixture. Diethyl succinate (22.6 ml, 135.40 mmol) was added via 
syringe in drops and the mixture refluxed for 4 h. Ethanol was removed and the resulting orange 
solid was acidified (5 M HCl) and extracted with ethyl acetate (70 ml × 3). The combined organic 
layer was extracted with satd. NaHCO3 (80 ml). The NaHCO3 extract was acidified to pH 2, and the 
resulting oily solution re-extracted with EtOAc (20 ml × 3). The combined organic extract was 
dried over MgSO4, filtered and evaporated in vacuo to give yellowish brown oil. On further drying 
under vacuum, yellowish solid form which was recrystallized form ethyl acetate/petroleum ether 
(26 g, 98 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.35 (t, J = 7.1Hz, 3H), 3.63 (s, 2H), 3.89 (s, 
3H), 3.91 (s, 3H), 4.31 (q, J = 7.1Hz, 2H), 6.91 (d, 1H), 7.00 (d, 2H), 7.87 (s, 1H), 11.60 (bs, 1H). 
13C NMR (500 MHz, CDCl3): δ (ppm) 14.4, 34.2, 56.1, 61.7, 111.3, 112.4, 122.9, 123.4, 127.5, 
142.69, 149.1, 150.2, 168.3, 176.8. ESI-MS (m/z) = 293.0 [M-H]-. 
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3.3.2 Synthesis of 1-ethyl 4-methyl (2E)-2-(3,4-dimethoxybenzylidene)butanedioate (26)102 
 
 
DMSO (176 ml) and K2CO3 (24.80 g, 179.46 mmol) were stirred for 5 min in the reaction 
flask at RT. The half-ester 25 (35.21 g, 119.64 mmol) was added followed by iodomethane (11.2 
ml, 179.46 mmol). After stirring 2 h at RT, water (1000 ml) was added and extracted with DCM 
(100 ml × 4).  The combined DCM layer was washed with water (1000 ml), and the aqueous layer 
re-extracted with DCM (50ml). The combined DCM extract was dried over MgSO4, filtered and 
evaporated in vacuo. Flash chromatography over silica (2:1 PE/EtOAc) gave the product as 
yellowish oil (34.4 g, 93 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.30 (t, J = 7.1Hz, 3H), 3.56 (s, 
2H), 3.69 (s, 3H), 3.84 (s, 3H), 3.86 (s, 3H), 4.24 (q, J = 7.1Hz, 2H), 6.85 (d, 1H), 6.93 (m, 2H), 
7.81 (s, 1H). 13C NMR (500 MHz, CDCl3): δ (ppm) 14.2, 33.5, 51.9, 55.7, 60.9, 110.6, 112.3, 
122.5, 124.2, 127.3, 141.7, 148.7, 149.7, 167.37, 171.7. ESI-MS (m/z) = 309.1 [M+H]+. 
3.3.3 Synthesis of compound 27102  
 
A well-stirred solution of the diester 26 (11.15 g, 36.16 mmol) in THF (45 ml) was added 
dropwise to a solution of LDA (39.78 mmol, 2 M in THF) in THF at -78°C under nitrogen 
atmosphere. After stirring at -78°C for 20 min, benzyl bromide (6.80 g, 39.78 mmol) in THF (22.6 
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ml) was added in drops. The mixture was stirred at -78°C for 2h, then allowed to warm up to room 
temperature. THF solvent was evaporated in vacuo after which excess saturated aqueous NH4Cl 
solution was added. The mixture was extracted with DCM (40 ml × 3), washed with brine (50 ml), 
dried over MgSO4 and evaporated in vacuo. Flash chromatography over silica (3:2 Pet. 
Ether/EtOAc) gave orange oil (10.5 g, 73%).  1H NMR (500 MHz, CDCl3): δ (ppm) 1.33 (t, J = 
7.1Hz, 3H), 3.00 (dd, 1H), 3.44 (dd, 1H), 3.72 (s, 6H), 3.86 (s, 3H), 4.13 (dd 1H), 4.28 (q, 1H), 
6.44 (s, 1H), 6.58 (d, 1H), 6.74 (d, 1H), 6.92 (d, 2H), 7.12 (m, 3H), 7.69(s, 1H). 13C NMR (500 
MHz, CDCl3): δ (ppm) 14.2, 36.1, 45.5, 52.0, 55.8, 60.8, 110.6, 111.4, 121.3, 126.0, 127.9, 128.1, 
129.2, 129.7, 139.1, 142.4, 148.6, 149.3, 166.7, 173.3. ESI-MS (m/z) = 399.2 [M+H]+. 
3.3.4 Synthesis of compound 2899-101  
 
The reaction flask was evacuated and Pd/C (10%, 2.0g) added under N2 gas. The flask was 
sealed, then ethanol (700 ml) and TFA (100 µl) were added. The diester 27 (10 g, 25.09 mmol) in 
ethanol (100 ml) was added. The flask was evacuated until the solvent just begun to bubble, then 
flushed with N2 gas several times. The N2 gas was replaced with H2 gas. After flushing three times 
the mixture was left to stir under H2
 for 132 hours. The reaction was filtered through a pad of celite 
and washed with ethanol. The solvent was evaporated and after flash chromatography over silica 
gave yellow oil (8.8g, 88 %).  1H NMR (500 MHz, CDCl3): δ (ppm) 1.20 (t, 3H), 3.01 (m, 4H), 
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3.62 (s, 3H), 3.79 (s, 3H), 3.85 (s, 3H), 4.09 (m, 4H), 6.57 (d, 1H), 6.75 (m, 2H), 7.09 (m, 2H), 
7.21(m, 3H). ESI-MS (m/z) = 401.2 [M+H]+. 
3.3.5 Synthesis of compound 29100, 102  
 
A suspension of LiAlH4 (3.0 g, 79 mmol) in THF (90 ml) was stirred under N2 and cooled to 
0°C. The diester 28 (7.6 g, 18.97 mmol) in THF (150 ml) was slowly added. The mixture was 
allowed to come to RT and stirred 2h. The mixture was diluted with ether (50 ml) and cooled to 
0°C. Water (3 ml) was carefully added via syringe, followed with 15% NaOH (3 ml) after stirring 5 
min. Water (15 ml) was added after allowing the mixture to come to RT. EtOAc (50ml) and anhy. 
MgSO4 were added and stirred overnight.  The mixture was filtered, evaporated in vacuo and the 
resulting crude product chromatographed via flash column over silica gel (1:1 Pet 
ether/ethylacetate) to give white solid (4.1 g, 65 %) 1H NMR (500 MHz, CDCl3): δ (ppm) 1.92 (m, 
2H), 2.78 (m, 4H), 3.54 (m, 4H), 3.83 (s, 3H), 3.87 (s, 3H), 6.66 (s, 1H), 6.71 (m, 1H), 6.78 (d, J = 
8.1, 1H), 7.16 (d, J = 7.1, 2H), 7.21 (t, J = 5.1, 7.2, 1H), 7.28 (t, J = 7.2, 7.5, 2H). 13C NMR (500 
MHz, CDCl3): δ (ppm) 35.9, 36.4, 43.1, 55.9, 56.1, 60.6, 111.0, 112.3, 121.2, 126.3, 128.5, 129.4, 
133.2, 140.6, 147.4, 148.9. ESI-MS (m/z) = 329.1 [M-H]-. 
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3.3.6 Synthesis of compound 30100, 102, 144  
 
Pyridine (7.8 ml) was added via syringe to the diol 29 (2.0 g, 6.053 mmol) in the reaction 
flask under nitrogen. The mixture was stirred at 0°C for 20 min. Toluenesulfonyl chloride (2.77 g, 
14.53 mmol) was added to the mixture and stirred 2 h at 0°C. HCl (60ml, 2M) was added and 
filtered by suction. The filtrate was extracted with EtOAc (30ml×3). The combined organic layer 
was washed with water (30 ml), brine (30ml) and dried over MgSO4. After evaporation in vacuo, 
the crude product was purified by flash chromatography over silica gel to give white solid (1.0 g, 
26 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 2.10 (m, 2H), 2.47 (s, 6H), 2.52 (m, 2H), 2.69 (m, 
2H), 3.81 (s, 3H), 3.87 (s, 3H), 3.96 (m, 4H), 6.48 (d, J = 8.1, 1H), 6.55 (s, 1H), 6.69 (d, J = 8.1, 
1H), 7.17 (m, 3H), 7.34 (d, J = 8.7, 4H), 7.72 (m, 4H). ESI-MS (m/z) = 639.4 [M+H]+. 
3.3.7 Synthesis of compound 31100, 102  
 
To a stirred suspension of LiAlH4 (0.26, 6.85 mmol) in THF (12 ml) at 0°C under nitrogen 
was added the substrate 30 (0.99 g, 1.56 mmol) in THF (12 ml) slowly via syringe. The mixture 
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was stirred 2 h at RT. Diethyl ether (20ml) was added to the mixture and cooled to 0°C. Water 
(0.26 ml) was carefully added via syringe, followed with 15% NaOH (0.26 ml) after stirring 5 min. 
Water (0.81 ml) was added after allowing the mixture to come to RT and stirring continued for 15 
min. EtOAc (20 ml) and anhy. MgSO4 were added and stirred overnight.  The mixture was filtered 
and evaporated in vacuo. Flash chromatography over silica gel (hexane-EtOAc 9:1) gave yellowish 
oil (0.4 g, 82 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 0.88 (d×2, 6H), 1.82 (m, 2H), 2.40 (m, 1H), 
2.43 (m, 1H), 2.65 (m, 1H), 2.83 (m, 1H), 3.84 (s, 3H), 3.89 (s, 3H), 6.61 (s, 1H), 6.67 (d, J = 8.1, 
1H), 6.79 (m, 1H), 7.12 (d, J = 7.1, 1H), 7.20 (d, J = 7.2, 2H), 7.28 (m, 2H) 13C NMR (500 MHz, 
CDCl3) 14.1, 16.3, 37.9, 41.1, 41.7, 55.9, 56.0, 111.0, 112.1, 121.0, 125.8, 125.8, 128.3, 128.3, 
129.2, 129.3, 134.3, 141.8, 147.1, 148.8.  ESI-MS (m/z) = 299.2 [M+H]+. 
3.3.8 Synthesis of 4-(2,3-dimethyl-4-phenylbutyl)benzene-1,2-diol (A1)100, 106  
 
To a stirred solution of the substrate 31 (0.20g, 0.67 mmol) in DCM (6.67 ml) at -78 °C under 
nitrogen was added 1M BBr3 in DCM (3.35ml, 3.35 mmol) carefully via syringe. The mixture was 
stirred 2 h at -78 °C. After warming to RT, the reaction was quenched with water (6.67 ml) and 
extracted with EtOAc (15ml, 7ml×3).  The combined organic layer was washed with 10 ml each of 
NaHCO3 (10%), HCl (1 M), water, and brine. It was dried over MgSO4, filtered and the solvent 
evaporate in vacuo to give purplish dark oil (180 mg, > 99 %). 1H NMR (500 MHz, CDCl3): δ 
(ppm) 0.84-0.87 (6H, 2×d, J = 4.3, H9, 9'), 1.74-1.84 (2H,  m, H8, 8'), 2.32-2.36 (1H, dd, J = 8.5, 
13.4, H7α), 2.43-2.48 (1H, dd, J = 8.6, 13.4, H7α'), 2.55-2.59 (1H, dd, J = 6.4, 13.6, H7β), 2.66-
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2.70 (1H, dd, J = 6.2, 13.6, H7β'), 5.78 (2H, bs, o, p-ArOH), 6.55-6.57 (1H, dd, J = 1.9, 8.1, H6), 
6.64 (1H, d, J = 1.9, H2), 6.79 (1H, d, J = 7.9, H5), 7.14 (2H, d, J = 7.2, H2', 6'), 7.21 (1H, t, J = 
7.4, H4'), 7.30 (2H, t, H3', 5'). 13C NMR (500 MHz, CDCl3): δ (ppm) 13.9, 16.2, 38.1, 39.3, 40.8, 
41.5, 115.2, 116.1, 121.6, 125.6, 128.2, 128.2, 129.1, 129.2, 134.9, 141.3, 141.8, 143.3. ESI-MS 
(m/z) = 269.1 [M-H]-. 
3.3.9 Synthesis of 4-(benzyloxy)-3-methoxybenzaldehyde (32)46  
 
Vanillin (10 g, 65.72 mmol) and K2CO3 (13.7g, 98.58 mmol) were stirred in DMF (60 ml) 
under nitrogen atmosphere at room temperature. Benzyl bromide (9.4 ml, 78.86 mmol) was slowly 
added via syringe with agitation. The mixture was stirred at RT for 1 h. The reaction mixture was 
diluted with water (27 ml), neutralized with 50% HCl (20 ml) and extracted with EtOAC (67 ml, 20 
ml ×2). The combined EtOAc extract was wash with water, brine (67 ml each) and dried with 
MgSO4. The solvent was evaporated in vacuo to give orange solid which after recrystallization 
from heptane-EtOAc (9:1) gave white crystals (84 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 3.95 
(s, 3H), 5.25 (s, 2H), 6.99 (d, J = 8.2, 1H), 7.33 (t, J = 7.3, 1H), 7.39 (m, 3H), 7.44 (d, J = 7.3), 9.84 
(s, 1H). 13C NMR (500 MHz, CDCl3): δ (ppm) 56.1, 70.9, 109.3, 112.4, 126.6, 127.2, 128.2, 129.0, 
130.3, 136.0, 150.1, 153.6. ESI-MS (m/z) = 243.1 [M+H]+ obs; 243.1016 Da calc. 
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3.3.10 Synthesis of (3E)-4-[4-(benzyloxy)-3-methoxyphenyl]-3-(ethoxycarbonyl)but-3-enoic 
acid (33)100, 102  
  
The procedure described for 25 but starting with 32 (9.6 g, 39.63 mmol) gave compound 33 as 
yellow oil (98 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.25 (t, J = 7.1, 3H), 3.61 (s, 2H), 3.87 (s, 
3H), 4.14 (q, J = 7.1, 2H), 5.16 (s, 2H), 6.89 (m, 2H), 6.97 (s, 1H), 7.30 (m, 1H), 7.35 (t, J = 7.3, 
7.6, 2H), 7.42 (d, J = 7.3, 2H), 7.84 (s, 1H), 11.39 (s, 1H). ESI-MS (m/z) = 369.0 [M-H]- obs; 
269.1332 Da calc. 
3.3.11 Synthesis of compound 34102 
 
Following the procedure described for 26 but starting with 33 (20.9 g, 54.24 mmol), 
compound 34 was obtained as yellow oil (92 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.33 (t, J = 
7.1, 3H), 3.58 (s, 2H), 3.72 (s, 3H), 3.88 (s, 3H), 4.27 (q, J = 7.1, 2H), 5.18 (s, 2H), 6.87 (s, 2H), 
6.96 (s, 1H), 7.30 (t, J = 7.3, 5.1, 1H), 7.37 (t, J = 7.2, 7.7, 2H), 7.42 (d, J= 7.3, 2H), 7.83 (s, 1H). 
13C NMR (500 MHz, CDCl3): δ (ppm) 14.3, 33.7, 52.2, 56.0, 60.9,  70.9, 112.7, 113.5, 122.4, 
124.4, 127.2, 127.9, 128.7, 136.9, 141.8, 148.9, 149.4, 167.5, 171.8. ESI-MS (m/z) = 385.2 [M+H]+ 
obs; 285.1645 Da calc. 
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3.3.12 Synthesis of compound 35102 
 
Following the procedure described for 27 but starting with 34 (10.22 g, 26.57 mmol), compound 35 
was obtained as orange oil (92 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.37 (t, J = 7.1, 3H), 3.04 
(dd, 1H), 3.47 (dd, 1H), 3.76 (s, 3H), 3.77 (s, 3H),  4.16 (m, 1H), 4.31 (q, J = 7.1, 2H), 5.18 (s, 2H), 
6.49 (s, 1H), 6.56 (d, J = 8.2, 1H), 6.78 (d, J = 8.2, 1H), 6.92-6.94 (m, 2H), 7.11-7.14 (m, 3H), 7.39-
7.42 (m, 3H), 7.46 (d, J = 7.2, 2H), 7.72 (s, 1H). ESI-MS (m/z) = 475.2 [M+H]+obs; 475.2115 Da 
calc. 
3.3.13 Synthesis of compound 36102  
 
A 20% sodium hydroxide solution (2.44 ml, 12.2 mmol) was added to the diester 35 (0.29 g, 
0.61mmol) and refluxed for 6 h. After cooling to room temperature, the mixture was washed with 
ethyl acetate (5 ml×3) and acidified until pH ≤ 2. The mixture was extracted with ethyl acetate (10 
ml×4), dried over anhy. MgSO4 and solvent evaporated in vacuo. Recrystallization from acetic acid 
gave the product as white crystals (57 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 3.13 (dd, 1H), 
3.48 (dd, 1H), 3.82 (s, 3H), 4.20 (dd, J = 4.7, 4.5, 1H), 5.26 (s, 2H), 6.79 (s, 2H), 7.11-7.15 (m, 3H), 
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7.28-7.31 (m, 3H), 7.56-7.63 (m, 5H), 7.72 (s, 1H), 12.63 (s, 2H). ESI-MS (m/z) = 431.1 [M-H]- 
obs; 431.1489 Da calc. 
3.3.14 Synthesis of compound 3758 
 
To a stirred suspension of LiAlH4 (1.93 g, 50.83 mmol) in THF (100 ml) was added AlCl3 
(2.04 g, 15.26 mmol) under N2. After stirring 20 min, the mixture was cooled to 0 °C. The substrate 
13 (5.86 g, 12.35 mmol) in THF (40 ml) was slowly added via syringe. The mixture was allowed to 
come to RT and stirred 2.5 h. The mixture was diluted with ether (50 ml) and cooled to 0°C. Water 
(2 ml) was carefully added via syringe, followed with 15% NaOH (2 ml) after stirring 5 min. Water 
(6 ml) was added after allowing the mixture to come to RT. EtOAc (50ml) and anhy. MgSO4 were 
added and stirred overnight.  The mixture was filtered, evaporated in vacuo and the resulting crude 
product chromatographed via flash column over silica gel eluting with ethyl acetate to give white 
solid (3.67g, 73.5%) 1H NMR (500 MHz, CDCl3): δ (ppm) 2.73-2.84 (m, 2H), 3.05 (bs, 2H), 3.38-
3.44 (m, 1H), 3.69-3.76 (m, 2H), 3.82 (s, 3H), 4.10 (d, J = 11.8, 1H), 4.43 (d, J = 11.8, 1H), 5.16 (s, 
2H), 6.57-6.61 (m, 2H), 6.63 (s, 1H), 6.81 (d, J = 7.1, 1H), 7.00 (d, J = 7.0, 2H), 7.14-7.21 (m, 3H), 
7.32 (t, J = 7.2, 1H), 7.39 (t, J = 7.4, 2H ), 7.45 (d, J = 7.4, 2H). 13C NMR (500 MHz, CDCl3): δ 
(ppm) 36.0, 43.1, 56.1, 64.9, 65.2, 71.2, 112.7, 113.8, 121.2, 126.2, 127.5, 128.1, 128.41, 128.8, 
129.1, 130.4, 133.3, 137.3, 139.8, 140.8, 147.3, 149.4.  ESI-MS (m/z) = 403.2 [M-H]-. 
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3.3.15 Synthesis of 2-benzyl-3-(4-hydroxy-3-methoxybenzyl)butane-1,4-diol (39)99 
 
The diol 37 (0.812 g, 2.0 mmol) in ethanol (150 ml) and catalytic amount of TFA (50 µl) is 
stirred under hydrogen atmosphere for 24 h in the presence of 10 % Pd/C (162 mg). The reaction 
mixture was filtered through a pad of celite and solvent removed in vacuo. Flash chromatography 
over silica gel (3:1 EtOAc/Pet. ether) gave the desired product as two pairs of enantiomers. 1H 
NMR (500 MHz, MeOD): δ (ppm) 1.91 (m, 1H), 1.96 (m, 1H), 2.62 (m, 2H), 2.68 (m, 2H), 3.56 
(m, 4H), 3.73 (s, 3H), 6.54 (d, J=7.9Hz, 1H), 6.65 (m, 2H), 7.11 (m, 3H), 7.19 (m, 2H). 13C NMR 
(500 MHz, MeOD): δ (ppm) 35.6, 36.4, 44.4, 44.5, 56.4, 62.0, 62.1, 113.7, 115.9, 122.8, 126.9, 
129.4, 130.3, 133.9, 142.9, 145.7, 148.9. ESI-MS (m/z) = 315.1 [M-H]-. 
3.3.16 Synthesis of compound 40101 
 
Pyridine (0.98 ml) was added via syringe to the diol 39 (308 mg, 0.76 mmol) in the reaction 
flask under nitrogen. The mixture was stirred at 0°C for 20 min. Toluenesulfonyl chloride (1.16 g, 
6.06 mmol) was added to the mixture and stirred 4 h at 0°C. HCl (4 ml, 2M) was added and the oil 
mixture extracted with ethyl acetate. The combined organic layer was washed with water, brine and 
dried over MgSO4. After evaporation in vacuo, the crude product was purified by flash 
chromatography over silica (363.6 mg, 62%). 1H NMR (500 MHz, CDCl3): δ (ppm) 2.10 (m, 2H), 
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2.47 (s, 6H), 2.52 (m, 2H), 2.69 (m, 2H), 3.81 (s, 3H), 3.87 (s, 3H), 3.96 (m, 4H), 6.48 (d, J = 8.1, 
1H), 6.55 (s, 1H), 6.69 (d, J = 8.1, 1H), 7.17 (m, 3H), 7.34 (d, J = 8.7, 4H), 7.72 (m, 4H). ESI-MS 
(m/z) = 639.4 [M+H]+. 
3.3.17 Synthesis of compound 42100 
 
Following the procedure described for 25 but starting with substrate 34 (7.65g, 19.90 mmol) 
and benzaldehyde 41 (2.32 g, 21.89 mmol), the resulting half-ester was esterified according the the 
procedure described for 26 to give compound 42 as yellow oil (> 90 %). 1H NMR (500 MHz, 
CDCl3): δ (ppm) 1.11 (t, J = 7.1, 3H), 3.56 (s, 3H), 3.74 (s, 3H), 4.14 (q, J = 7.1, 2H), 5.12 (s, 2H), 
6.75 (s, 1H), 6.77(s, 1H), 7.01 (t, J = 6.6, 8.2, 2H), 7.11 (d, J = 8.5, 1H), 7.16 (d, J = 8.4,  1H), 7.20 
(s, 1H), 7.25 (s, 2H), 7.44-7.46 (m, 3H), 7.89 (m, 1H), 8.05 (s, 1H), 8.08 (s, 1H).  
3.3.18 Synthesis of 4-(2,3-dimethyl-4-phenylbutyl)-2-methoxyphenol (A2)101 
 
To a stirred suspension of LiAlH4 (88.57 mg, 2.33 mmol) in THF (7 ml) at 0 °C under 
nitrogen was added the substrate 40 (363.6 mg, 0.47 mmol) in THF (4 ml) slowly via syringe. The 
mixture was stirred 2 h at RT. The reaction mixture is diluted with ether and cooled to 0 °C. The 
reaction is quenched with saturated sodium sulfate solution and H2SO4 (10%) solution. The mixture 
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is extracted with EtOAc, washed with brine and dried over anhy. MgSO4.  The solvent is removed 
in vacuo. The resulting residue in 3% KOH in ethanol-water (1:1) solution is refluxed overnight (12 
h). On cooling to rt, the mixture is neutralized with acetic acid and extracted with ether. Combined 
ether is washed brine, dried over MgSO4 and solvent removed in vacuo. Flash chromatography over 
silica (4:1 hexane/EtOAc) gave pale yellow oil (54.4 mg, 41 % in 2 steps) 1H NMR (500 MHz, 
CDCl3): δ (ppm) 0.86-0.88 (6H, overlapping d, H9, 9'), 1.77-1.85 (2H, m, H8, 8'), 2.38-2.49 (2H, 
m, H7α, 7α'), 2.57-2.68 (2H, m, H7β, H7β'), 3.84 (3H, s, OCH3), 5.51 (1H, bs, p-ArOH), 6.58 (s, 
1H), 6.62-6.65 (1H, m,), 6.84-6.88 (1H, m,), 7.13 (d, J = 7.2, 1H), 7.18-7.23 (m, 2H), 7.23-7.33 (m, 
2H). 13C NMR (500 MHz, CDCl3): δ (ppm) 13.95, 16.11, 37.81, 38.94, 41.09, 41.45, 55.84, 111.34, 
113.97, 121.67, 125.64, 128.15, 129.08, 133.57, 141.73, 143.55, 146.29. ESI-MS (m/z) = 283.18 
[M-H]- obs; 283.17 Da calc. 
3.3.19 Synthesis of compound 44100  
 
Following the procedure described for 25 but starting with substrates 32 (7.83, 32.31) and 34 
(11.29 g, 29.37 mmol), compound 44 was obtained as yellow powder (72 %). 1H NMR (500 MHz, 
CDCl3): δ (ppm) 1.07 (t, J = 7.1, 3H), 3.56 (s, 6H), 3.64 (s, 3H), 3.65 (s, 3H), 4.12 (q, J = 7.1, 2H), 
5.07 (s, 4H), 7.01 (t, J = 6.6, 8.2, 2H), 7.11 (d, J = 8.5, 1H), 7.16 (d, J = 8.4,  1H), 7.20 (s, 1H), 7.25 
(s, 2H), 7.30-7.33 (m, 2H), 7.35-7.40 (m, 8H), 7.79 (s, 2H), 12.53 (bs, 1H).  
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3.3.20 Synthesis of compound 45100 
 
The esterification procedure described for 26 but starting with 44 (10.79 g, 18.59 mmol) was 
employed to obtain 45 as sparkling yellow crystals (87 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 
1.11 (t, J = 7.1, 3H), 3.69 (s, 3H), 3.76 (s, 6H), 4.16 (q, J = 7.1, 2H), 6.80 (d, J = 7.5, 2H), 7.03 (d, J 
= 8.3, 2H), 7.16 (s, 2H), 7.30 (m, 2H), 7.36 (m, 4H), 7.39 (m, 4H), 7.86 (s, 2H). 13C NMR (500 
MHz, CDCl3): δ (ppm) 14.3, 52.6, 56.1, 61.2, 70.9, 112.5, 112.9, 124.7, 124.9, 125.1, 127.1, 128.2, 
128.8, 136.7, 142.3, 142.5, 149.4, 149.7, 167.3, 167.9. 
3.3.21 Synthesis of compound 4658 
 
The reduction method described for 37 but starting with 45 (9.42 g, 15.83 mmol) afforded 46 
as yellow powder (6.2 g, 74%). 1H NMR (500 MHz, CDCl3): δ (ppm) 2.51 (bs, 2H), 3.76 (s, 6H), 
4.16 (s, 4H), 5.14 (s, 4H), 6.65 (s, 2H), 6.79 (d, J = 8.3, 2H), 6.97 (d, J = 8.3, 2H), 7.14 (s, 2H), 7.30 
(m, 2H), 7.36 (m, 4H), 7.42 (m, 4H). 13C NMR (500 MHz, CDCl3): δ (ppm) 56.0, 66.9, 70.9, 111.5, 
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113.6, 121.1, 127.2, 127.9, 128.6, 129.2, 129.5, 136.9, 137.4, 147.9, 149.4. ESI-MS (m/z) = 537.20 
[M-H]- obs; 537.22 Da calc. 
3.3.22 Synthesis of meso-secoisolariciresinol (47a) and racemic (±)-secoisolariciresinol (47b)99, 
101 
               
 meso-Secoisolariciresinol 47a        (±) Secoisolariciresinol 47b 
Hydrogenation procedure described for 28 but starting with 46 (2.38 g, 4.43 mmol) afforded 
meso- and rac(±)-secoisolaricirenol as pale yellow oil (747.4 mg, 47 %)  and as pale orange solid 
(771.7 mg, 48 %) respectively after flash chromatography over silica (3:1 EtOAc/hexanes). 47a, 
off-white solid, 1H NMR (500 MHz, CDCl3), δ (ppm): 1.91 (m, 1H), 1.96 (m, 1H), 2.62 (m, 2H), 
2.68 (m, 2H), 3.56 (m, 4H), 3.73 (s, 3H), 6.54 (d, J=7.9Hz, 1H), 6.65 (m, 2H), 7.11 (m, 3H), 7.19 
(m, 2H). 13C NMR (500 MHz, MeOD): δ (ppm) 35.6, 36.41, 44.4, 44.5, 56.4, 62.0, 62,1, 113.7, 
115.9, 122.8, 126.9, 129.4, 130.3, 133.9, 142.9, 145.7, 148.9. ESI-MS (m/z) = 315.1 [M-H]-. 
3.3.23 Synthesis of 4,4'-[(2S,3S)-2,3-dimethylbutane-1,4-diyl]bis(2-methoxyphenol) (A3)101 
 
To meso-secoisolariciresol 47a (443.2 mg, 1.22 mmol) in pyridine (1.6 ml) was added tosyl 
chloride (1.86 g) at 0ᴼC and stirred 4h. The reaction was quenched with HCl (2M) solution and 
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extracted with ethyl acetate. After drying over MgSO4, the solvent is removed in vacuo. The crude 
product was added to a suspension of LiAlH4 (270 mg, 7 mmol) in THF (25 ml) at 0ᴼC under 
nitrogen and stirred at room temperature overnight (12 h). The reaction was quenched with 
saturated NA2SO4 solution and 10% H2SO4 solution.  The clear mixture was extracted with ethyl 
acetate, washed with brine, dried over MgSO4 and solvent removed in vacuo to give colourless oil 
(983 mg). KOH (3%, 25 ml) solution in ethanol-water (1:1) of was added to the oil and refluxed 
overnight (12h). On cooling to RT, the mixture was neutralized with acetic acid and extracted with 
ether. Combined ether layer was washed with brine, dried over MgSO4 and solvent removed in 
vacuo. Flash chromatography over silica (3:1 pet. ether/EtOAc) gave A3a as off white solid (296.9 
mg, 73.47% in 3 steps). The procedure was repeated with (±)-secoisolariciresol 47b (476.3 mg, 
1.31 mmol) to afford A3b as white solid (276.1 mg, 64 % in 3 steps). A3a, off-white solid, mp 79-
80°C; 1H NMR (500 MHz, CDCl3): δ (ppm) 0.83-0.86 (6H, overlapping d, J = 6.4, H9, 9'), 1.72-
1.76 (2H, m, H8, 8'), 2.26-2.32 (1H, dd, J = ,H7α), 2.37-2.41 (1H, dd, J = 7.4, 13.4, H7α'), 2.51-
2.55 (1H, dd, J = 7.4, 13.7, H7β), 2.72-2.76 (1H, dd, J = 4.1, 12.9,  H7β'), 3.82 (3H, s, p-OCH3), 
3.87 (3H, s, o-OCH3), 5.58 (2H, bs, p-ArOH), 6.55 (1H, s, H2), 6.60 (1H d, J = 7.8, H6), 6.64 (1H, 
s, H2'), 6.68 (1H, d, J = 7.8, H6'), 6.83 (1H, d, J = 8.0, H5), 6.85 (1H, d, J = 8.0, H5'). 13C NMR 
(500 MHz, CDCl3) δ (ppm) 14.0, 16.4, 21.3, 37.6, 39.1, 39.4, 41.3, 55.9, 56.0, 60.6, 111.5, 111.6, 
114.0, 114.2, 121.8, 121.9, 133.8, 133.9, 143.7, 143.7, 146.4, 146.5. ESI-MS m/z: 329.1 [M-H]- 
obs; 329. 18 Da calc. 
A3b, δ (ppm) 0.83-0.86 (6H, overlapping d, J = 6.8, H9, 9'), 1.72-1.76 (2H, m, H8, 8'), 2.28-2.32 
(1H, dd, J = 9.3, 13.3 ,H7α), 2.37-2.42 (1H, dd, J = 7.7, 13.7, H7α'),  2.51-2.55 (1H, dd, J = 7.3, 
13.7, H7β), 2.72-2.76 (1H, dd, J = 5.2, 13.7,  H7β'), 3.82 (s, 3H, p-OCH3), 3.87 (s, 3H, o-OCH3), 
5.50 (bs, 2H, p-ArOH), 6.53 (1H, s, H2 ), 6.60 (1H, d, J = 7.7, H6), 6.63 (1H, s, H2'), 6.68 (1H, d, J 
 
 
72 
 
= 8.0, H6'), 6.81 (1H, d, J = 7.7, H5), 6.84 (1H, d, J = 7.7, H5'). 13C NMR (500 MHz, CDCl3) δ 
(ppm) 13.9, 16.3, 37.5, 38.9, 39.2, 41.1, 55.8, 55.9, 111.3, 111.5, 113.9, 114.0, 121.7, 121.7, 133.6, 
133.8, 143.5, 143.6, 146.3, 146.3. ESI-MS m/z: 329.13 [M-H]- obs; 329. 18 Da calc. 
3.3.24 Synthesis of compound 4946 
 
Benzylation procedure described for 32 but starting with 3,4-dihydroxybenzaldehyde 48 
(15.06 g, 109.04 mmol) gave 49 as white crystals (84%). 1H NMR (500 MHz, CDCl3): δ (ppm) 
5.23 (s, 2H), 5.27 (s, 2H), 7.03 (d, J = 8.2, 1H), 7.34 (m, 2H), 7.39 (m, 5H), 7.47 (m, 5H), 9.82 (s, 
1H). 13C NMR (500 MHz, CDCl3): δ (ppm) 31.1, 70.9, 71.1, 112.5, 113.2, 126.9, 127.2, 127.5, 
128.2, 128.3, 128.8, 128.8, 130.5, 136.4, 136.7, 149.3, 154.4, 191.0. ESI-MS m/z: 319.10 [M+H]+ 
obs; 319.13 Da calc. 
3.3.25 Synthesis of compound 50100, 102 
 
Stobbe condensation procedure described for 25 but starting with 49 (24.95 g, 78.23 mmol) 
gave 50 as yellow solid (98 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.33 (t, J = 7.1 Hz, 3H), 3.51 
(s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 5.21 (s, 2H), 5.22 (s, 2H), 6.96 (s, 2H), 7.03 (s, 1H), 7.38 (m, 5H), 
7.46 (m, 5H), 7.82 (s, 1H), 11.48 (bs, 1H). ESI-MS m/z: 445.10 [M-H]- obs; 445.16 Da calc. 
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3.3.26 Synthesis of compound 51102 
 
Esterification procedure described for 26 but starting with 50 (35.05 g, 78.56 mmol) gave 51 
as yellow oil (98 %).1H NMR (500 MHz, CDCl3): δ (ppm) 1.34 (t, J = 7.1 Hz, 3H), 3.51 (s, 2H), 
3.74 (s, 3H), 4.28 (q, J = 7.1 Hz, 2H), 5.19 (s, 2H), 5.20 (s, 2H), 6.96 (s, 2H), 7.04 (s, 1H), 7.36-
7.40 (m, 5H), 7.45-7.46 (m, 5H), 7.82 (s, 1H). ESI-MS m/z: 461.20 [M+H]+ obs; 461.19 Da calc. 
3.3.27 Synthesis of compound 5299 
 
Following the procedure described for 25 but starting with 51 (10 g, 21.71 mmol) and 3,4-
dimethylbenzylaldehyde 24 (3.97g, 23.89 mmol), compound 52 was obtained as yellow solid (> 
90%). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.07 (t, J = 7.1, 3H), 3.56 (s, 6H), 3.64 (s, 3H), 3.65 (s, 
3H), 4.12 (q, 2H), 5.07 (s, 4H), 7.01 (t, J = 6.6, 8.2, 2H), 7.11 (d, J = 8.5, 1H), 7.16 (d, J = 8.4,  1H), 
7.20 (s, 1H), 7.25 (s, 2H), 7.31 (m, 2H), 7.37 (m, 8H), 7.79 (s, 2H), 12.53 (bs, 1H).  
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3.3.28 Synthesis of compound 53100, 102 
 
Esterification procedure described for 26 but starting with compound 52 (12.6 g, 21.71 mmol) 
gave the desired product as orange oil (98 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.09 (t, J = 7.0 
Hz, 3H), 3.67 (s, 3H), 3.71 (s, 3H), 3.87 (s, 3H), 4.13 (q, J = 7.0 Hz, 2H), 5.16 (s, 2H), 5.19 (s, 2H), 
6.78 (d, 1H), 6.83 (d, 1H), 7.01-7.01 (m, 3H), 7.33-7.38 (m, 5H), 7.39-7.43 (m, 3H), 7.81 (s, 1H), 
7.82 (s, 1H).  
3.3.29 Synthesis of compound 5499 
 
Hydrogenation procedure described for 28 but starting with 53 (8.42 g, 13.84 mmol) afforded 
the desired product 54 in > 99% yield. 1H NMR (500 MHz, CDCl3): δ (ppm) 1.09 (t, J = 7.0 Hz, 
3H), 3.67 (s, 3H), 3.71 (s, 3H), 3.87 (s, 3H), 4.13 (q, J = 7.0 Hz, 2H), 6.78 (d, 1H), 6.83 (d, 1H), 
7.01-7.01 (m, 2H),  7.81 (s, 1H), 7.82 (s, 1H).  
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3.3.30 Synthesis of compound 5546 
 
Benzylation procedure described for 32 but starting with compound 54 (5.8 g, 13.41 mmol) 
gave 55 as white solid (63 %) after flash chromatography over silica (2:1 pet. Ether/EtOAc).  1H 
NMR (500 MHz, CDCl3): δ (ppm) 5.23 (s, 2H), 5.27 (s, 2H), 7.03 (d, J = 8.2, 1H), 7.34 (m, 2H), 
7.39 (m, 5H), 7.47 (m, 6H), 9.82 (s, 1H). 13C NMR (500 MHz, CDCl3): δ (ppm) 31.1, 70.9, 71.1, 
112.5, 113.2, 126.9, 127.2, 127.5, 128.2, 128.3, 128.8, 128.8, 130.5, 136.4, 136.7, 149.4, 154.4, 
191.0.  
3.3.31 Synthesis of compound 56100 
 
To a stirred suspension of LiAlH4 (1.45 g, 38 mmol) in THF (80 ml) at 0°C under nitrogen 
was added the substrate 55 (3.9 g, 6.36 mmol) in THF (45 ml) slowly via syringe. The mixture was 
stirred 4 h at RT. The reaction mixture was diluted with ether and cooled to 0°C, then quenched 
with saturated sodium sulfate solution and H2SO4 (10%) solution. The mixture was extracted with 
EtOAc, washed with brine and dried over anhy. MgSO4.  The solvent is removed in vacuo to give 
compound 56 as colourless oil. 1H NMR (500 MHz, CDCl3): δ (ppm) 2.43-2.49 (m, 4H), 2.59-2.66 
(m, 2H), 3.32-3.38 (m, 4H), 3.79 (s, 3H), 3.83 (s, 3H), 5.07 (s, 2H), 5.12 (s, 2H), 6.40 (d, J = 7.8 , 
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1H), 6.44 (d, J = 7.8, 1H), 6.55 (s, 1H), 6.64-6.68 (m, 2H), 6.74 (d, J = 8.0, 1H), 7.30-7.32 (m, 6H), 
7.36-7.38 (m, 4H), 7.44-7.46 (m, 4), 7.70-7.72 (m, 4H). 
3.3.32 Synthesis of compound 57101 
 
Pyridine (8.22 ml) was added via syringe to the substrate 56 (3.45 g, 6.36 mmol) in the 
reaction flask under nitrogen. The mixture was stirred at 0°C for 20 min. Toluenesulfonyl chloride 
(4.85 g, 25.44 mmol) was added to the mixture and stirred 4 h at 0°C. Addition of HCl (20 ml, 2M) 
gave a mixture of white solid and pale yellow oil. The oil was extracted into ethyl acetate and the 
white solid into DCM.  The two organic extracts were washed separately with water, brine and 
dried over MgSO4. The white solid obtained by DCM extraction 57a was pure by NMR and was 
used without further purification (1.60g, 30 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 2.10 (s, 6H), 
2.43-2.49 (m, 4H), 2.59-2.66 (m, 2H), 3.79 (s, 3H), 3.83 (s, 3H), 3.86-3.94 (m, 4H), 5.07 (s, 2H), 
5.12 (s, 2H), 6.40 (d, J = 7.8 , 1H), 6.44 (d, J = 7.8, 1H), 6.55 (s, 1H), 6.64-6.68 (m, 2H), 6.74 (d, J 
= 8.0, 1H), 7.30-7.32 (m, 6H), 7.36-7.38 (m, 4H), 7.44-7.46 (m, 4), 7.70-7.72 (m, 4H). 13C NMR 
(500 MHz, MeOD): δ (ppm) 35.6, 36.4, 44.4, 44.5, 56.4, 62.0, 62,1, 113.7, 115.9, 122.8, 126.9, 
129.4, 130.3, 133.9, 142.9, 145.7, 148.9. ESI-MS (m/z) = 851.20 [M-H+]. After evaporation, the 
ethyl acetate extract was purified by flash chromatography over silica to yield 57 57b (2.97g, 55 
%). 
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3.3.33 Synthesis of compound 58101 
 
LiAlH4 reduction described for compound 56 but starting with 57a (1.6 g, 1.85 mmol) 
resulted in 58a. Flash chromatography over silica gel (2:1 Pet. Ether/EtOAc) gave 58a as colorless 
oil (632.6 mg, 67%). 1H NMR (500 MHz, CDCl3): δ (ppm) 0.79-0.81 (2 d, 6H), 1.71-1.74 (m, 2H), 
2.34-2.40 (m, 2H), 2.51-2.57 (m, 2H), 3.82 (s, 3H), 3.85 (s, 3H), 5.11 (s, 2H), 5.14 (s, 2H), 6.58 (s, 
1H), 6.60-6.63 (m, 2H), 6.70 (s, 1H), 6.76 (d, J = 8.9, 1H), 6.84 (d, J = 8.1 , 1H), 7.29-7.32 (m, 2H), 
7.34-7.38 (m, 4H), 7.45-7.47 (m, 4H). 13C NMR (500 MHz, MeOD): δ (ppm) 35.6, 36.4, 44.4, 44.5, 
56.4, 62.0, 62,1, 113.7, 115.9, 122.8, 126.9, 129.4, 130.3, 133.9, 142.9, 145.7, 148.9. ESI-MS (m/z) 
= 511.2 [M+H+] obs; 511.28 Da calc. The procedure was repeated with 57b to obtain 58b. 
3.3.34 Synthesis of 4-[4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol (A4)99 
 
Treatment of 58a (0.812 g, 2.0 mmol) or 58b with excess H2 in the presence of Pd-C(10%) as 
described for compound 28 gave compound A4a as dark purple solid (323.7 mg, 98%) or 
compound A4b. A4a, dark purple solid, mp 105-108 °C, 1H NMR (500 MHz, CDCl3): δ (ppm) 
0.81-0.83 (6H, overlapping d, J = 4.5, H9, 9'), 1.69-1.76 (2H, m, H8, 8'), 2.31- 2.33 (2H, dd, J = 
7.8, 13.4, H7α), 2.38-2.42 (1H, dd, J = 7.7, 13.4, 7α'), 2.46-2.51 (1H, dd, J = 7.0, 13.3, H7β), 2.51-
2.55 (1H, dd, J = 7.3, 13.5, 7β'), 3.82 (3H, s, p-OCH3), 3.86 (3H, s, o-OCH3), 6.50 (1H, d, J = 6.2), 
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6.56 (1H, s), 6.58 (1H, s), 6.77-6.78 (m, 2H). 13C NMR (500 MHz, MeOD): δ (ppm) 13.8, 13.9, 
37.3, 37.4, 40.7, 40.9, 55.9, 55.99, 111.0, 112.3, 115.0, 115.9, 121.2, 121.5, 134.4, 134.7, 141.5, 
143.3, 146.9, 148.6. ESI-MS (m/z) = 329.13 [M-H+]- obs; 329. 18 Da calc.  
3.3.35 Synthesis of compound 59 
 
Stobbe condensation procedure described for 25 but starting with substrates 26 (7.50g, 
24.32 mmol) and 24 (4.45g, 24.33 mmol), gave a yellow oil which was esterified with MeI in 
K2CO3/ DMSO as describe for 26 to afford compound 59. 
1H NMR (500 MHz, CDCl3): δ (ppm) 
1.12 (t, J = 7.1 Hz, 3H), 3.59 (s, 3H), 3.73 (s, 3H), 3.74 (s, 3H), 3.84 (s, 3H), 3.85 (s, 3H), 4.12 (q, J 
= 3.4, 7.1, 2H), 6.77-6.80 (m, 2H), 7.11-7.17 (m, 4H), 7.90 (s, 1H), 7.94(s, 1H).  
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3.3.36 Synthesis of compound 60 
  
Compound 59 (12.85, 29.04 mmol) was hydrogenated in excess H2 atmosphere in the 
presence of Pd-C(10%) as described for 28 to afford compound 60. 1H NMR (500 MHz, CDCl3): δ 
(ppm) 1.12 (t, J = 7.1 Hz, 3H), 2.87-2.90 (m, 2H), 2.93-2.98(m, 2H), 3.54 (s, 3H), 3.78 (s, 6H), 3.83 
(s, 6H), 4.12 (q, J = 3.4, 7.1, 2H), 6.55 (s, 2H), 6.60-6.62 (m, 2H), 6.63-6.74 (m, 2H). 
3.3.37 Synthesis of compound 64 
  
LiAlH4 reduction described for compound 56 but starting with 60 (6.5 g, 14.11 mmol) 
resulted in 64 as a white solid (91 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 0.86-0.88 (m, 2H), 
2.66-2.70 (dd, 2H, J = 5.8, 13.7 Hz), 2.76-2.80 (dd, 2H, J = 8.4, 13.7 Hz), 3.19 (s, 2H), 3.52-3.55 
(dd, 3H, J = 4.4, 11.1 Hz), 3.60-3.63 (dd, 1H, J = 7.1, 11.1 Hz), 3.83 (s, 4H), 3.86 (s, 8H), 6.66 (s, 
2H), 6.69 (d, 2H, J = 7.7 Hz), 6.77 (d, 2H, J = 7.7). 
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3.3.38 Synthesis of tetra-O-methyl NDGA (14) 
 
Compound 64 (3.5, 8.96 mmol) was tosylated as described for compound 57 to yield white 
solid which was reduced with LiAlH4 in THF as described for 56 to afford compound 14 as white 
solid (93 %) 1H NMR (500 MHz, CDCl3): δ (ppm) 0.84-0.86 (overlapping d, 6H), 1.75-1.80 (m, 
2H), 2.29-2.34 (dd, 1H, J = 5.3, 13.3 Hz), 2.39-2.43 (dd, 1H, J = 6.5, 13.6 Hz), 2.55-2.59 (dd, 1H, J 
= 7.7, 13.6 Hz), 2.75-2.78 (dd, 1H, J = 9.3, 13.3 Hz), 3.83 (s, 4H), 3.86 (s, 8H), 6.59 (s, 1H), 6.62 – 
6.66 (m, 2H), 6.70-6.72 (m, 1H), 6.76-6.80 (m, 2H). 
3.3.39 Synthesis of 4-(3,4-dimethoxyphenyl)butan-1-ol (66) 
 
A 4-(3,4-dimethoxyphenyl)butyric acid (3.0 g, 13.4 mmol) was reduced with LiAlH4 as 
described for compound 56 to obtain 66 (86 %). 1H NMR (500 MHz, CDCl3): δ (ppm) 1.26 (s, 2H), 
1.60-1.65 (m, 2H), 1.66-1.72 (m, 2H,), 2.60 (t, J = 7.2 Hz, 2H), 3.68 (bs, 1H), 3.86 (s, 3H), 3.88 (s, 
3H), 6.72 (d, J = 8.0, 2H), 6.79 (d, 1H, J = 7.8 Hz). 
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3.3.40 Synthesis of 4-(3,4-dimethoxyphenyl)butanal (67)  
 
A solution of 66 (2.0 g, 9.5 mmol) in dried CH2Cl2 (10 ml) was treated with pyridinium 
chlorochromate (PCC) (4.10 g, 19.0 mmol) in dried CH2Cl2 (20 ml). The mixture was allowed to 
stir for 2.5 h and filtered through a pad of silica gel. The residue was washed thoroughly with 
CH2Cl2 and solvent removed in vacuo to afford 67 (84%). 
1H NMR (500 MHz, CDCl3): δ (ppm) 
1.94 (m, 2H), 2.46 (t, J = 7.2 Hz, 2H), 2.61 (t, J = 7.6 Hz, 2H,), 3.86 (s, 3H), 3.87 (s, 3H), 6.70 (d, J 
= 8.7 Hz, 2H), 6.79 (d, J = 7.8 Hz, 1H), 9.76 (s 1H). 
3.3.41 Synthesis of compound 70 
 
The Grignard reagent 3,4-dimethoxyphenylmagnesium bromide  generated in situ refluxing 
a mixture of magnesium turning (0.46 g), 3,4-dimethoxyphenyl bromide (2.69 ml), iodine (1 
crystal) in THF under N2. The reagent was cooled to -78 
oC under N2 and treated with a solution of 
67 (2.6 g, 12.5 mmol) in anhydrous THF (10 ml).  The mixture was warmed to RT, and after 2 h the 
reaction was judged complete by TLC.  Et2O (35 ml) was added and the product mixture was 
washed with 20 ml NH4Cl (5 % aq) followed by NaCl (satd aq).  The crude product mixture was 
dried over MgSO4, concentrated, and purified by flash column chromatography to afford 70 (71%).  
1H NMR (500 MHz, CDCl3): δ (ppm) 1.52-1.60 (m, 1H), 1.68-1.75 (m, 2H), 1.80-1.86 (m, 1H) 
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3.57 (t, J = 7.0, 2H), 3.84 (s, 6H), 3.86 (s, 3H), 3.87 (s, 3H), 4.61 (t, J = 7.0, 1H), 6.67 (m, 2H), 6.76 
(d, J = 7.8 Hz, 1H), 6.82 (m, 2H), 6.87 (s, 1H). 
3.3.42 Synthesis of compund 72 
 
Compound 70 (2.3 g, 6.64 mmol) was treated with excess hydrogen gas as described for 28 
to afford 71 in 91% yield.  1H NMR (500 MHz, CDCl3): δ (ppm) 1.65 (s, 4H), 2.58 (s, 4H), 3.85 (s, 
12H) 6.70 (m, 4H), 6.79 (m, 2H). 
3.3.43 Synthesis of 4,4'-butane-1,4-diyldibenzene-1,2-diol (A6) 
 
Compound 71 (0.61 g, 1.83 mmol) was demethylated with BBr3 in DCM as described for A1 
to afford A6 as brown solid (> 99%).1H NMR (500 MHz, CD3OD): δ (ppm) 1.52 (4H, s, H8, 8'), 
2.43 (4H, s, H7, 7'), 6.44 (2H, d, J = 8.0, H6, 6'), 6.56 (2H, s, H2, 2'), 6.63 (2H, d, J = 8.0, H5, 5'). 
13C NMR (500 MHz, CD3OD): δ (ppm) 32.58 (C8, 8'), 36.26 (C7, 7'), 116.31 (C6, 6'), 116.64 (C5, 
5'), 120.78 (C2, 2'), 135.75 (C1, 1'), 144.20 (C4, 4'), 146.13 (C3, 3'). 
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3.4 Characterization of NDGA Analogues 
3.4.1 High Performance Liquid Chromatography (HPLC) Analyses 
A reverse phase, high performance liquid chromatography (RP-HPLC) method was 
developed to determine purity of the prepared analogues. Standard NDGA was run alongside for 
comparison. The RP-HPLC method employed a 150 × 2.1 mm Hypersil GOLD, ODS 3µ, 
microbore column at a flow rate of 200 µL/min using gradient elution.  Solvent A consisted of 
water with 0.1% formic acid and Solvent B was acetonitrile containing 0.1% formic acid. A 
gradient of 90% A for 2 min, decreased to 60% A over 10 min, then 10% A over 5 min, held 
isocratic for 10 min, returned to 90% A in 5min and held isocratic for 2 min. All eluates were 
monitored by UV diode array detection.  
 
3.4.2 Nuclear Magnetic Resonance (NMR) Spectroscopy Experiments  
The prepared analogues were characterized by 1H-NMR, 2-D COSY and 13C-NMR 
experiments. 
 
3.4.3 Mass Spectroscopy Experiments 
The molecular masses of the prepared analogues were confirmed by ESI-MS analyses. The 
molecular ions and isotopic masses were determined by Enhanced Resolution (ER) scanning in 
negative ionization mode. Fragmentation patterns were studied by tandem ESI-MS/MS in negative 
ion mode. Tandem ESI-MS/MS data for NDGA was obtained for comparison. Instrument 
parameters  were set as follows: Cur = 0, Temp = 200, GS1 = 14, GS2 = 40, ihe = on, IS = -4500, 
CAD = high, DP = 50, EP = -10, CE = -40 and CXP = -15. 
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3.4.4 Characterization of NDGA 
 
Figure 2-1: Molecular structure of NDGA (C18H22O4, 302.36 g/mol) 
 
Figure 2-2: HPLC chromatogram (Panel A) and UV absorption maxima (Panel B) for NDGA. 
A retention time of 19.1 min by the method described in section 3.4.1 was observed with a 
characteristic absorption at 282.8 nm obtained by UV-PDA detection. 
 
Summary of NMR data for NDGA 
[1H] NMR (500 MHz, DMSO-d6) δ(ppm): 0.74 (6H, d, J=6.6 Hz, H9,9’), 1.60 (2H, m, H8,8’), 
2.09 (2H, dd, J=4.8, 13.3 Hz, H7α,7’α), 2.56 (2H, dd, J=9.3, 13.2 Hz, H7β,7’β), 6.38 (2H, dd, 
J=1.8, 7.8 Hz, H6,6’), 6.52 (2H, d, J=1.8 Hz, H2,2’), 6.61 (2H, d, J=7.8 Hz, H5,5’), 8.58b (2H, s, 
o,p Ar-OH), 8.65b (2H, s, o,p Ar-OH) 
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Figure 2-3: ER-ESI-MS in negative ionization mode for NDGA  
 
Figure 2-4: Tandem ESI-MS/MS in negative ionization mode for NDGA. 
A m/z 301.1 was observed consistent with calculated mass of NDGA 1 (302.36 g) based on 
molecular formula (C18H22O4). Product ions observed were consistent with predicted fragmentation 
patterns NDGA with a base peak at m/z 122.1 Da. 
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3.4.5 Characterization of A1 
 
Figure 2-5: Molecular structure of A1 (C18H22O2, 270.36 g/mol). 
 
Figure 2-6: HPLC chromatogram (Panel A) and UV absorption maximum (Panel B) for A1. 
A retention time of 24.2 min by the method described in section 3.4.1 was observed with a 
characteristic absorption at 282.8 nm obtained by UV-PDA detection.  
 
Summary of NMR data for A1 
[1H] NMR (500 MHz, CDCl3): δ (ppm) 0.84-0.87 (6H, 2×d, J = 4.3, H9, 9'), 1.74-1.84 (2H,  m, H8, 
8'), 2.32-2.36 (1H, dd, J = 8.5, 13.4, H7α), 2.43-2.48 (1H, dd, J = 8.6, 13.4, H7α'), 2.55-2.59 (1H, 
dd, J = 6.4, 13.6, H7β), 2.66-2.70 (1H, dd, J = 6.2, 13.6, H7β'), 5.78 (2H, bs, o, p-ArOH), 6.55-6.57 
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(1H, dd, J = 1.9, 8.1, H6), 6.64 (1H, d, J = 1.9, H2), 6.79 (1H, d, J = 7.9, H5), 7.14 (2H, d, J = 7.2, 
H2', 6'), 7.21 (1H, t, J = 7.4, H4'), 7.30 (2H, t, H3', 5'). 
[13C] NMR (500 MHz, CDCl3): δ (ppm) 13.97, 16.24, 38.10, 39.33, 40.67, 41.45, 115.18, 116.08, 
121.55, 125.64, 128.17, 128.23, 129.13, 129.17, 134.89, 141.28, 141.78, 143.25. 
 
 
Figure 2-7: ER-ESI-MS in negative ionization mode for A1.  
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Figure 2-8: Tandem ESI-MS/MS in negative ionization mode for A1. 
A m/z 269.1 was observed consistent with calculated mass of A1 (270.36 g) based on 
molecular formula (C18H22O2). Product ions observed were consistent with fragmentation patterns 
observed for standard NDGA with a base peak at m/z 122.0 Da.  
 
3.4.6 Characterization of A2 
 
Figure 2-9: Molecular structure of A2 (C19H24O2, 284.39 g/mol). 
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Figure 2-10: HPLC chromatogram (Panel A) and UV absorption maximum (Panel B) for A2. 
A retention time of 26.3 min by the method described in section 3.4.1 was observed with a 
characteristic absorption at 281.6 nm obtained by UV-PDA detection.  
 
Summary of NMR data for A2 
1H NMR (500 MHz, CDCl3): δ (ppm) 0.86-0.88 (6H, d×2, H9, 9'), 1.77-1.85 (2H, m, H8, 8'), 2.38-
2.49 (2H, m, H7α, 7α'), 2.57-2.68 (2H, m, H7β, H7β'), 3.84 (3H, s, OCH3), 5.51 (1H, bs, p-ArOH), 
6.58 (s, 1H), 6.62-6.65 (1H, m,), 6.84-6.88 (1H, m,), 7.13 (d, J = 7.2, 1H), 7.18-7.23 (m, 2H), 7.23-
7.33 (m, 2H).  
13C NMR (500 MHz, CDCl3): δ (ppm) 13.95, 16.11, 37.81, 38.94, 41.09, 41.45, 55.84, 111.34, 
113.97, 121.67, 125.64, 128.15, 129.08, 133.57, 141.73, 143.55, 146.29.  
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Figure 2-11: ER-ESI-MS in negative ionization mode for A2.  
 
Figure 2-12: Tandem ESI-MS/MS in negative ionization mode for A2. 
A m/z 283.2 was observed consistent with calculated mass of A2 (284.39 g) based on 
molecular formula (C19H24O2). Product ions observed were consistent with fragmentation patterns 
observed for standard NDGA with a base peak at m/z 121.0 Da. 
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3.4.7 Characterization of A3 
 
Figure 2-13: Molecular structure of A3 (C20H26O4, 330.42 g/mol). 
 
Figure 2-14: HPLC chromatogram (Panel A) and UV absorption (Panel B) for A3. 
A retention time of 22.7 min by the method described in section 3.4.1 was observed with a 
characteristic absorption at 281.6 nm obtained by UV-PDA detection. 
 
Summary of NMR data for A3 
A3a, 1H NMR (500 MHz, CDCl3): δ (ppm) 0.83-0.86 (6H, 2×d, J = 6.4, H9, 9'), 1.72-1.76 (2H, m, 
H8, 8'), 2.26-2.32 (1H, dd, J = ,H7α), 2.37-2.41 (1H, dd, J = 7.4, 13.4, H7α'), 2.51-2.55 (1H, dd, J = 
7.4, 13.7, H7β), 2.72-2.76 (1H, dd, J = 4.1, 12.9,  H7β'), 3.82 (3H, s, p-OCH3), 3.87 (3H, s, o-
OCH3), 5.58 (2H, bs, p-ArOH), 6.55 (1H, s, H2), 6.60 (1H d, J = 7.8, H6), 6.64 (1H, s, H2'), 6.68 
(1H, d, J = 7.8, H6'), 6.83 (1H, d, J = 8.0, H5), 6.85 (1H, d, J = 8.0, H5') 
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13C NMR (500 MHz, CDCl3) δ (ppm) 14.04, 16.40, 21.25, 37.62, 39.07, 39.36, 41.26, 55.95, 56.03, 
60.62, 111.46, 111.61, 114.04, 114.15, 121.81, 121.89, 133.77, 133.97, 143.67, 143.73, 146.42, 
146.50.  
A3b, δ (ppm) 0.83-0.86 (6H, 2×d, J = 6.8, H9, 9'), 1.72-1.76 (2H, m, H8, 8'), 2.28-2.32 (1H, dd, J = 
9.3, 13.3 ,H7α), 2.37-2.42 (1H, dd, J = 7.7, 13.7, H7α'),  2.51-2.55 (1H, dd, J = 7.3, 13.7, H7β), 
2.72-2.76 (1H, dd, J = 5.2, 13.7,  H7β'), 3.82 (s, 3H, p-OCH3), 3.87 (s, 3H, o-OCH3), 5.50 (bs, 2H, 
p-ArOH), 6.53 (1H, s, H2 ), 6.60 (1H, d, J = 7.7, H6), 6.63 (1H, s, H2'), 6.68 (1H, d, J = 8.0, H6'), 
6.81 (1H, d, J = 7.7, H5), 6.84 (1H, d, J = 7.7, H5')  
13C NMR (500 MHz, CDCl3) δ (ppm) 13.89, 16.25, 37.45, 38.91, 39.21, 41.10, 55.79, 55.87, 
111.31, 111.47, 113.89, 114.00, 121.66, 121.74, 133.62, 133.82, 143.51, 143.57, 146.27, 146.34. 
 
 
Figure 2-15: ER-ESI-MS in negative ionization mode for A3.  
 -ER: 205 MCA scans from Sample 1 (IA-3-146-01 ERMS) of IA-3-146-01 ERMS.wiff (Turbo Spray), Ce... Max. 1.5e10 cps.
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Figure 2-16: Tandem ESI-MS/MS in negative ionization mode for A3. 
A m/z 329.1 was observed consistent with calculated mass of A3 (330.42 g) based on 
molecular formula (C20H26O4). Product ions observed were consistent with fragmentation patterns 
observed for standard NDGA with a base peak at m/z 122.3 Da. 
 
3.4.8 Characterization of A4 
 
Figure 2-17: Molecular structure of A4 (C20H26O4, 330.42 g/mol). 
 
 -MS2 (329.13) CE (-40): 478 MCA scans from Sample 1 (IA-3-146-01 MSMS) of IA-3-146-01 MSMS.wif... Max. 8.1e8 cps.
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Figure 2-18: HPLC chromatogram (Panel A) and UV absorption maximum (Panel B) for A4. 
A retention time of 22.2 min by the method described in section 3.4.1 was observed with a 
characteristic absorption at 280.4 nm obtained by UV-PDA detection.  
 
Summary of NMR data for A4 
A4a, 1H NMR (500 MHz, CDCl3): δ (ppm) 0.81-0.83 (6H, overlapping d, J = 4.5, H9, 9'), 1.69-
1.76 (2H, m, H8, 8'), 2.31- 2.33 (2H, dd, J = 7.8, 13.4, H7α), 2.38-2.42 (1H, dd, J = 7.7, 13.4, 7α'), 
2.46-2.51 (1H, dd, J = 7.0, 13.3, H7β), 2.51-2.55 (1H, dd, J = 7.3, 13.5, 7β'), 3.82 (3H, s, p-OCH3), 
3.86 (3H, s, o-OCH3), 6.50 (1H, d, J = 6.2), 6.56 (1H, s), 6.58 (1H, s), 6.77-6.78 (m, 2H),  
13C NMR (500 MHz, MeOD): δ (ppm) 13.82, 13.89, 37.31, 37.44, 40.69, 40.98, 55.89, 55.92, 
110.99, 112.28, 115.04, 115.96, 121.16, 121.49, 134.40, 134.69, 141.52, 143.29, 146.96, 148.55.  
A4b, 1H NMR (500 MHz, CDCl3): δ (ppm) 0.81-0.85 (6H, overlapping d, J = 6.3, H9, 9'), 1.69-
1.76 (2H, m, H8, 8'), 2.24-2-29 (m, 1H), 2.31-2.42 (m, 1H), 2.46-2.56 (m, 1H), 2.67-2.75 (2H, m), 
3.82 (3H, s), 3.86 (3H, s), 6.55 (2H, m), 6.67 (2H, m), 6.79 (2H,  m)  
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Figure 2-19: ER-ESI-MS in negative ionization mode for A4.  
 
Figure 2-20: Tandem ESI-MS/MS in negative ionization mode for A4. 
A m/z 329.1 was observed consistent with calculated mass of A4 (330.42) based on 
molecular formula (C20H26O4). Product ions observed were consistent with fragmentation patterns 
observed for standard NDGA with a base peak at m/z 122.2 Da 
 -ER: 229 MCA scans from Sample 1 (IA-3-141 ERMS) of IA-3-141 ERMS.wiff (Turbo Spray), Centroid... Max. 4.0e10 cps.
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3.4.9 Characterization of A6 
 
Figure 2-21: Molecular structure of A6 (C16H18O4, 274.31 g/mol). 
 
Figure 2-22: HPLC chromatogram (Panel A) and UV absorption for A6. 
A retention time of 17.5 min by the method described in section 3.4.1 was observed with a 
characteristic absorption at 281.6 nm obtained by UV-PDA detection 
 
Summary of NMR data for A6 
1H NMR (500 MHz, CD3OD): δ (ppm) 1.52 (4H, s, H8, 8'), 2.43 (4H, s, H7, 7'), 6.44 (2H, d, J = 
8.0, H6, 6'), 6.56 (2H, s, H2, 2'), 6.63 (2H, d, J = 8.0, H5, 5') 
13C NMR (500 MHz, CD3OD): δ (ppm) 32.58 (C8, 8'), 36.26 (C7, 7'), 116.31 (C6, 6'), 116.64 (C5, 
5'), 120.78 (C2, 2'), 135.75 (C1, 1'), 144.20 (C4, 4'), 146.13 (C3, 3') 
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Figure 2-23: ER-ESI-MS in negative ionization mode for A6.  
 
Figure 2-24: Tandem ESI-MS/MS in negative ionization mode for A6. 
A m/z 273.1 was observed consistent with calculated mass of A6 (274.31 g) based on 
molecular formula (C16H18O4). Product ions observed were consistent with fragmentation patterns 
observed for standard NDGA with a base peak at m/z 122.2 Da. 
 -ER: 146 MCA scans from Sample 1 (HLH-1-171 ERMS) of HLH-1-171 ERMS.wiff (Turbo Spray), Cent... Max. 1.7e10 cps.
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3.4.10 Characterization of A7 
 
Figure 2-25: Molecular structure of A7 (C18H22O2, 270.36 g/mol). 
 
Figure 2-26: HPLC chromatogram (Panel A) and UV absorption for A7. 
A retention time of 22.5 min by the method described in section 3.4.1 was observed with a 
absorption at 273.3 nm obtained by UV-PDA detection 
 
Summary of NMR data for A7 
1H NMR (500 MHz, CDCl3): δ (ppm) 0.87-0.89 (6H, 2×d, J = 6.5, H9, 9'), 1.61-1.69 (2H, m, H8, 
8'), 2.32-2.36 (2H, dd, J = 8.3, 13.3, H7α, H7α'), 2.59-2.63 (2H, dd, J = 6.3, 13.4, H7β, H7β'), 5.56 
(2H, bs, ArOH), 6.68-6.60 (2H, s), 6.70 (1H, d, J = 1.6), 6.76 (2H, d, J = 7.3), 6.83-6.86 (1H, m), 
7.14-7.17 (2H, m) 
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Figure 2-27: ER-ESI-MS in negative ionization mode for A7.  
 
Figure 2-28: Tandem ESI-MS/MS in negative ionization mode for A7. 
A m/z 269.1 was observed consistent with calculated mass of A7 (270.36 g) based on 
molecular formula (C18H22O2). Product ions observed were consistent with fragmentation patterns 
observed for standard NDGA with a base peak at m/z 106.0 Da.  
 -ER: 4 MCA scans from Sample 1 (IA-2-281 ERMS) of IA-2-281 ERMS.wiff (Turbo Spray), Centroided Max. 1.1e9 cps.
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3.4.11 Characterization of A8 
 
Figure 2-29: Molecular structure of A8 (C20H26O4, 330.42 g/mol). 
 
Figure 2-30: HPLC chromatogram (Panel A) and UV absorption maximum (Panel B) for A8. 
A retention time of 22.9 min by the method described in section 3.4.1 was observed with a 
characteristic absorption at 281.6 nm obtained by UV-PDA detection. 
 
Summary of NMR data for A8 
A8a, 1H NMR (500 MHz, CDCl3): δ (ppm) 0.80-0.84 (6H, 2×d, J = 6.7, H9, 9'), 1.74-1.78 (2H, m, 
H8, 8'), 2.22-2.27 (1H, dd, J = 9.6, 13.3, H7α), 2.31-2.35 (1H, dd, J = 7.9, 12.8, H7α'), 2.54-2.58 
(1H, dd, J = 5.8, 13.5, H7β), 2.70-2.74 (1H, dd, J = 4.5, 13.4, H7β'), 3.89 (6H, s, 3,3' OCH3), 5.58 
(2H, bs, ArOH), 6.58-6.60 (1H, dd, J = 1.6, 8.1), 6.63-6.65 (1H, dd, J = 1.6, 8.1), 6.71 (1H, d, J = 
1.6), 6.75-6.79 (3H, m) 
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A8b, 1H NMR (500 MHz, CDCl3): δ (ppm) 0.81-0.84 (6H, 2×d, H9, 9'), 1.73-1.79 (2H, m, H8, 8'), 
2.23-2.28 (1H, dd, J = 9.5, 13.3, H7α), 2.32-2.36 (1H, dd, J = 8.5, 13.5, H7α'), 2.55-2.59 (1H, dd, J 
= 5.8, 13.5, H7β), 2.71-2.74 (1H, dd, J = 4.6, 13.4, H7β'), 3.87 (6H, s, 3,3' OCH3), 5.68 (2H, bs, 
ArOH), 6.59-6.61 (1H, dd, J = 1.7, 7.9), 6.64-6.66 (1H, dd, J = 1.7, 7.9), 6.71 (1H, d, J = 1.7), 6.75-
6. 79 (3H, m) 
 
 
Figure 2-31: ER-ESI-MS in negative ionization mode for A8.  
 
 -ER: 112 MCA scans from Sample 1 (IA-4-13-02) of IA-4-13-02.wiff (Turbo Spray), Centroided Max. 9.7e10 cps.
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Figure 2-32: Tandem ESI-MS/MS in negative ionization mode for A8. 
A m/z 329.2 was observed consistent with calculated mass of A8 (330.42 g) based on 
molecular formula (C20H26O4). Product ions observed were consistent with fragmentation patterns 
observed for standard NDGA with a base peak at m/z 121 Da.  
  
 -MS2 (329.20) CE (-40): 464 MCA scans from Sample 4 (IA-4-A8b MSMS) of August 2 2014.wiff (Turbo... Max. 1.6e9 cps.
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Table 2-1: Summary of ESI-MS analyses data for NDGA and its analogues. 
Compound 
(M) 
a[M-H]- 
found 
b[M-H]- 
calcd 
cProduct ion following CID aIsotopic Peaks 
NDGA (302) 301.1 301.1 177, 149, 135, 122, 109  301.1, 302.1, 303.1 
A1 (270) 269.1 269.2 149, 135, 122, 108 269.1, 270.1, 271.1 
A2 (284) 283.2 283.2 268, 121 283.2, 284.2. 285.2 
A3 (330) 329.1 329.2 314, 177, 149, 136, 122, 109 329.1, 330.1, 331.1 
A4 (330) 329.1 329.2 314, 177, 149, 136, 122, 109 329.1, 330.1, 331.1 
A6 (274) 
A7 (270) 
273.1 
269.1 
273.1 
269.1 
245, 217, 149, 135, 122, 109 
147, 133, 119, 106 
273.1, 274.1, 275.1 
269.1, 270.1, 271.2 
A8 (330) 329.1 239.2 314, 177, 149, 135, 121, 109 329.1, 330.1, 331.1 
aThe parent ion and isotopic peaks were determined by ER scanning in negative ion mode. bThe calculated parent ions 
were obtained from ACD/ChemSketch software.  cThe product ion determine by MS-MS scannind using the following 
instrument parameters: CUR = 10, Temp = 200ºC, GS1 = 14, GS2 = 40, ihe = on, IS = 4500, CAD = high, DP = -50, 
EP = -10, CE = -30 to -55, CXP = -15. The boldface type denotes base peak. 
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3.5 Experimental 2: Autoxidative Cyclization Potential of NDGA Analogues 
3.5.1 General HPLC Method 
An HPLC method was developed to monitor autoxidation and glutathione trapping 
experiments. The RP-HPLC method employed a 150 × 2.1 mm Hypersil GOLD, ODS 3µ, 
microbore column at a flow rate of 200 µL/min using gradient elution.  Solvent A consisted of 
water with 0.1% formic acid and Solvent B was acetonitrile containing 0.1% formic acid. An initial 
isocratic phase of 90% A for 2 min, decreased to 60% A over 8 min, then 10% A over 12 min, held 
isocratic for 10 min, and finally increased to 90% A over 1 min and held isocratic at 90% A  for 6 
min to equilibrate the column. All eluates were monitored by UV diode array detection.  
 
3.5.2 Autoxidative Cyclization Studies 
The potential of the prepared analogues to autoxidize to their corresponding 
dibenzocyclooctadiene lignans was examined using a method developed by Billinsky et al.35 
Briefly, the substrate in CH3CN (20 mM) is added to phosphate-citric acid buffer (0.5 M, pH 8.5) 
pre-equilibrated to 37 °C to give a final substrate concentration of 0.1 mM. The reaction mixture 
was stirred at the same temperature for 90 min and monitored by HPLC. The reaction was stopped 
by acidification to pH 1.5 with HCl. The mixture was extracted with ethyl acetate, dried over 
MgSO4 and solvent evaporated in vacuo. The oxidation product was purified over a C-18 column 
(RedSep®Rf GOLD, Teledyne Isco) on a Tris Pump connected to UA-6 UV/Vis Detector 
(Teledyne Isco) separation system using 70:30 H2O/CH3CN (v/v) containing 0.1% formic acid. The 
product was analyzed by HPLC, MS and NMR techniques. Standard NDGA was used as positive 
control.  
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3.5.2.1 Chemical Stability Determination 
The test compound in CH3CN (20 mM)  and internal standard (DMPA) were added to a 
phosphate-citric acid buffer (0.5 M, pH 7.4) pre-equilibrated to 37 °C to give final concentrations of 
0.5 mM each. The mixture was incubated at 37 ºC in incubating Orbital Shaker (VWR). Aliquots 
were taken at various time intervals and the reactions quenched by acidification to pH 1.5 with HCl. 
Samples were analyzed directly by HPLC. Test analogues were verified by the elution time of 
standards and quantitated by their corresponding standard curves (R2 = 0.97-1.0). All calibration 
curves were developed by plotting peak area ratios of substrate versus internal standard as a 
function of concentration   
 
3.5.2.2 Dibenzocyclooctadiene Formation via o-Q intermediate 
The experiment as described in section 3.5.2.1 was repeated in the absence and presence of 
GSH (added at time t = 0 h) and also with GSH added in aliquots over time. All samples were 
treated as in section 3.5.2.1 and analyzed by HPLC. A separate experiment was conducted without 
and with 20 fold excess of GSH at 37 ºC for 6 h to further investigate the involvement of o-Q 
intermediate in the intramolecular cyclization process.  
 
3.5.2.3 Reaction Kinetics 
The concentrations of the test analogues that remained in solution over time were used to 
establish the kinetics of the loss of each analogue in phosphate buffer at pH 7.4. The loss of NDGA 
in phosphate buffer at pH 7.4 follows apparent first-order kinetics.33 Thus, the disappearance rate of 
the analogues can be described by: 
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   𝑙𝑛
𝐶
𝐶𝑜
=  −𝑘𝑡  
where Co and C are initial concentration and concentration at different time points respectively; k is 
the reaction rate constant and t is time. A plot of ln C against time is expected to give a straight line 
with intercept ln C0 and a gradient -k for a first order degradation reaction. 
 
3.6 Experimental 3: Reactive Metabolites Formation Potential of NDGA Analogues 
3.6.1 Enzymatic Oxidation Studies 
Each test compound (1 mM), glutathione (5.0 mM) and mushroom tyrosinase (47.25 units) 
in 500 µl NA2HPO4 buffer (50 mM, pH 6.0) was vortexed for 60 min at room temperature (25 °C). 
The reaction was stopped by addition of perchloric acid (20 µl). After centrifugation (14,000 for 10 
min), aliquots of the supernatant were analyzed directly by HPLC and further by MS. Control 
experiments were performed in the absence of GSH, in the absence of mushroom tyrosinase, and 
with the addition of GSH after the 60 min vortex. Each reaction was performed in triplicate. 
 
3.6.1.1 Pilot Enzymatic Oxidation Study 
4-Propylbenzene-1,2-diol (PC1) and 2-methoxy-4-propylphenol (PC2) were synthesized 
from eugenol. The PC1 and PC2 were used as mimics of the catechol analogues (A1, A4 and A6)  
and phenol analogues (A2, A3, A7 and A8) respectively. HPLC and MS conditions for oxidative 
metabolism studies were validated using PC1, PC2 and standard NDGA. The compounds were 
oxidized as described in section 3.6.1 
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3.6.1.2 Mushroom Tyrosinase-catalysed Oxidation of the prepared Analogues 
The analogues prepared for this study were oxidized with mushroom tyrosinase as described 
in section 3.6.1 and the oxidation products analyzed by HPLC and MS technique 
 
3.6.1.3 Isomerization of o-Q to p-QM Studies 
Analogues A1 or A4 was oxidized with mushroom tyrosinase in the presence and absence 
of GSH for 60 min. For the incubations containing GSH, salicylamide (internal standard) was 
added at 60 min and quenched with perchloric acid. For the experiments conducted in the absence 
of GSH, an aliquot was stirred in a phosphate buffer after 60 min incubation and sampled at various 
time points. To each 1 hour interval aliquot, GSH was added and treated similarly as incubations 
with GSH. Samples were taken for 8 hours. Samples were analysed by HPLC and LS-MS. 
 
3.6.2 Chemical Oxidation Studies 
Freshly prepared silver oxide (300 mg) was added to the test sample in dried acetonitrile 
(2.5 mM) pre-equibilirated to 60ºC. 1 ml aliquots were taken at 30 s or 30 min and centrifuged at 
14,000 for 10 min. The resulting supernatant was added to a potassium phosphate buffer (pH 7.4) 
containing GSH to a final concentration ratio of 1:5 substrate-GSH. Control experiments contained 
no GSH and were all performed in duplicates. The samples were analyzed directly by HPLC. For 
MS analysis, samples were loaded on C-18 extraction cartridges (Bond Elut, Varian) and eluted 
with methanol. 
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3.6.2.1 Pilot Chemical Oxidation Studies 
The two pilot compounds (PC1 and PC2) and standard NDGA were oxidized as described 
in section 3.6.2 to validate the oxidation, HPLC and MS method. 
3.6.2.2 Silver oxide-catalysed Oxidation of prepared Analogues 
The analogues prepared for this study were oxidized with Ag2O as described in section 3.6.2 
and the oxidation products analyzed by HPLC and MS techniques 
 
3.6.3 Cytochrome P450 Oxidation Studies 
Test compounds in DMSO (0.5 mM) were incubated in NA2HPO4 buffer (50 mM, pH 7.4) 
containing GSH (5 mM), rat liver microsomes (0.5 mg/ml) and MgCl2 at 37 °C for 60 min. The 
final reaction volume (500 µl) contained 0.5% DMSO solvent. The reaction was initiated with 
NADPH after 5 min pre-incubation and terminated by chilling in ice bath followed by addition of 
ice cold acetonitrile (200 µl). After centrifugation at 14,000 rpm for 10 min, the supernatant was 
analyzed by HPLC and LC-MS. Samples for LC-MS were loaded on C-18 extraction cartridges 
(Bond Elut, Varian) and eluted with methanol. Control experiments contained no NADPH. All 
experiments were run in duplicates. 
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4 RESULTS 
 
4.1 Syntheses of NDGA Analogues 
4.1.1 Syntheses of A1: 4-(2,3-dimethyl-4-phenylbutyl)benzene-1,2-diol 
 
Figure 4-1: Molecular structure of NDGA analogue 1 (A1). 
The basic lignan skeleton was constructed using a Stobbe condensation followed by 
alkylation.58, 102 Reaction of the aromatic aldehyde 24 with succinate ester 19 gave a trans-
benzylidene succinate monoester 25 in 98% yield (Scheme 4-1). The monoester 25 was esterified to 
26 using CH3I/K2CO3 in DMSO in 93% yield. Alkylation with benzyl bromide and LDA in THF at 
-78 °C afforded the basic lignan skeleton 27 as orange oil (73%). Compound 27 was hydrolyzed to 
a diacid to allow resolution via quinine salts. However, this theoretically possible step proved 
practically challenging as the expected fractional crystallization did not occur. This separation step 
was not pursued further. Instead, compound 27 was hydrogenated under H2 atmosphere using Pd-
C(10%) catalyst to give 28 as yellowish oil (87% ) which was reduced with LiAlH4 in THF to the 
diol 29, a white solid in 65% yield. Tosylation of compound 29 in pyridine gave the resulting 
tosylate 30 as white crystals in low yield (26%). Contrary to our expectation, this step does not 
seem to provide separation into two pairs of enantiomers for A1. The 1H NMR and ESI-MS data of 
only one of the two isolated products was consistent with the expected product. A further reduction 
of 30 with LiAlH4 in THF gave 31 as yellowish oil (82 %). Demethylation of compound 31 with 
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BBr3 in DCM at -78 °C afforded the final NDGA mono-catechol A1 as a purple oil in quantitative 
yield. 
 
Scheme 4-1: Synthetic pathway to NDGA analogue 1 (A1). 
Reagents and Conditions: i) EtONa/EtOH, reflux, 98%; ii) MeI, K2CO3/DMSO, rt, 93%; iii) BnBr, 
LDA/THF, -78 °C, 73%; iv) H2, Pd-C, 88%; v) LiAlH4/THF, rt, 65%; vi) TsCl, Pyridine, 0 °C 
26%; vii) LiAlH4/THF, rt, 82%;  viii) BBr3/DCM, -78 °C, > 99%. 
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4.1.2 Synthesis of A2: 4-(2,3-dimethyl-4-phenylbutyl)-2-methoxyphenol  
 
Figure 4-2: Molecular Structure of NDGA analogue 2 (A2). 
Benzylation of vanillin gave compound 32 which was treated with diethyl succinate 19 via a 
Stobbe condensation reaction to give the trans-benzylidene succinate monoester 33 (Scheme 4-2). 
After methylation, the resulting diester 34 was alkylated with BnBr/LDA in THF to give the basic 
lignan structure 35. Compound 35 was hydrolyzed to diacid 36 to allow resolution of the 
enantiomeric pair via diastereomeric quinine salts. As observed in the case of A1, the desired 
fractional crystallization of diastereomeric quinine salts did not occur even though ESI-MS data 
showed successful reaction. Compound 35 was subsequently reduced with LiAlH4/AlCl3 mixture in 
THF to the diol 37. Compound 35 required a more vigorous condition obtained by using LiAlH4 in 
the presence of a Lewis acid, AlCl3to undergo reduction. Reduction with LiAlH4 in the absence of a 
Lewis acid was unsuccessful. It is noteworthy that this reduction step does not cleave the benzyl 
protecting group and therefore offers synthetic advantage as it shortens the synthetic steps by one. 
Attempts to tosylate diol 37 led to undesired lactone 38a and 38b possibly through tosylation of one 
OH group followed by elimination. When compound 37 was hydrogenated to 39, subsequent 
tosylation easily gave the desired tosylate 40 in good yield (62%). This step however tosylates the 
de-protected aromatic OH group as well.   LiAlH4 reduction followed by aromatic detosylation with 
refluxing KOH (3%) in ethanol-water (1:1) mixture afforded A2 as a yellow oil. Compound A2 was 
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also prepared via consecutive Stobbe condensation reaction on 34 using benzylaldehyde 41 
followed with methylation to give the diester 42. Compound 42 was hydrogenated and the resulting 
mixture reduced with LiAlH4 to give 43. Compound 43 was treated with mesyl chloride and the 
resulting mesylate reduced with LiAlH4 and further with refluxing KOH (3%) in ethanol-water 
(1:1) mixture afforded A2 as yellow oil. 
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Scheme 4-2: Synthetic pathway to NDGA analogues 2 (A2). 
Reagents and Conditions: i) EtONa/EtOH, reflux, 98%; ii) MeI, K2CO3/DMSO, rt, 92%; iii) BnBr, 
LDA/THF, -78 ºC, 92%; iv) NaOH/H2O, reflux, H3O
+, 57%; v) LiAlH4/AlCl3, THF, rt, 74%, vi) 
63%; vii) H2, Pd/C (10%), EtOH, 99% viii) TsCl, Pyridine, 0 ºC 62%; ix) (a) LiAlH4, THF, rt; (b) 
KOH/EtOH-H2O (1:1), reflux, 41%; x) (a) H2, Pd/C (10%), EtOH; (b) LiAlH4, THF, rt; xi (a) 
MsCl, Pyridine, 0 ºC; (b) LiAlH4, THF, rt; (c) KOH/EtOH-H2O (1:1), reflux. 
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4.1.3 Synthesis of A3: 4,4ʹ-(2,3-dimethylbutane-1,4-diyl)bis(2-methoxyphenol) 
  
Figure 4-3: Molecular Structure of NDGA analogue 3 (A3). 
A second Stobbe condensation reaction on 34 using benzylated vanillin 32 in EtONa/EtOH 
gave the basic lignan skeleton 44 (Scheme 4-3). Compound 44 was esterified to 45 and reduced 
under similar conditions as 35 to give the diol 46. Flash chromatography over silica on the 
hydrogenation product of 46 led to meso-secoisolariciresinol 47a and racemic (±)-
secoisolariciresinol 47b. Treatment of 47a or 47b with toluenesulfonyl chloride in pyridine at 0 ºC, 
followed by LiAlH4 reduction and refluxing the resulting crude product in KOH (3%) in ethanol-
water (1:1) mixture afforded A3 as the meso-compound A3a or rac (±)-compound A3b.  
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Scheme 4-3: Synthetic pathway to NDGA analogues 3 (A3). 
Reagents and Conditions: i) EtONa/EtOH, reflux, 72%; ii) MeI, K2CO3/DMSO, rt, 87%; iii) 
LiAlH4/AlC3, THF, rt., 74%, iv) H2, Pd-C, EtOH, 47% 23a, 48% 23b; v) (a) TsCl, Pyridine, 0 ºC;  
(b) LiAlH4, THF, rt.; (c) KOH/EtOH-H2O (1:1), reflux, 74% 24a, 64% 24b. 
 
4.1.4 Synthesis of A4: 4[4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol  
     
Figure 4-4: Molecular Structure of NDGA analogue 4 (A4). 
Benzylation of  3,4-dihydroxybenzyladehyde 48 gave 49 as white crystals in 84% yield 
(Scheme 4-4). Treatment of 49 with a succinate ester 19 via Stobbe condensation followed by 
esterification gave 50 and 51 respectively. A second Stobbe condensation reaction on 51 using 24 
in EtONa/EtOH afforded the half-ester 52 which on esterification gave 53, the basic lignan skeleton 
for A4. After hydrogenation of 53 under H2 atmosphere, the de-protected OH groups of the 
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resulting compound 54 were protected again via benzylation to give 55. Compound 55 was reduced 
with LiAlH4 in THF. Treatment of the resulting diol 56 with tosyl chloride in pyridine at 0 ºC and a 
flash chromatography over silica gel resulted in 57a and 57b. Reduction of 57a or 57b with LiAlH4 
in THF gave 58a or 58b which were separately hydrogenated under H2 atmosphere to afford A4 as 
two enantiomeric pairs A4a or A4b.  
 
Scheme 4-4: Synthetic pathway to NDGA analogue 4 (A4). 
Reagents and Conditions: i) BnBr, K2CO3/DMF, rt., 84%; ii) EtONa/EtOH, reflux; 98%, iii) MeI, 
K2CO3/DMSO, r.t., 98%; iv) EtONa/EtOH, reflux; > 90 % v) MeI, K2CO3/DMSO, rt., 98%;  vi) H2, 
Pd-C, vacuum; > 99%; vii) BnBr, K2CO3/DMF, rt., 63 %; viii) LiAlH4/THF, rt; ix) TsCl, pyridine, 
0 °C; x) LiAlH4/THF, rt; 67 %;  xi) H2, Pd-C, vacuum; > 98%. 
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4.1.5 Attempted synthesis of A5: 4,4'-(2,2,3,3-tetramethylbutane-1,4-diyl)dibenzene-1,2-diol 
 
Figure 4-5: Molecular structure of NDGA analogue 5 (A5). 
Treatment of compound 26 with 24 in a refluxing EtONa/EtOH followed by esterification 
afforded the basic lignan structure 59 which on hydrogenation gave 60 (Scheme 4-6). We have 
previously observed that base-catalyzed esterification of a dicarboxylic acid 61 with iodomethane 
(Scheme 4-5) resulted in additional methylation at the α-position to produce 62 as the major 
product. Although 62 was a side-product not useful for the synthesis of the intended target 
compound A2, we thought this reaction could be exploited to make A5. However, treatment of 60 
with powdered KOH in anhydrous DMSO in the presence of iodomethane surprisingly failed to 
form the expected di-methylated product 63. After a number of unsuccessful attempts, compound 
60 was reduced with LiAlH4 to 64 followed by tosylation and a further reduction with LiAlH4 to 
obtain tetra-O-methyl NDGA (M4N 14)  
 
 
Scheme 4-5: Base-catalysed esterification of a di-carboxylic acid using KOH in DMSO. 
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Scheme 4-6: Attempted synthesis of NDGA analogue 5 (A5) led to tetra-O-methyl NDGA 14. 
Reagents and Conditions: i) (a) EtONa/EtOH, reflux, 98%; (b), MeI, K2CO3/DMSO, 92%; ii) H2, 
Pd/C (10 %), EtOH, 99%;  iii) MeI, KOH/DMSO, rt.;  iv) LiAlH4, THF, rt., v) (a) TsCl, Pyridine, 0 
ºC; (b) LiAlH4, THF, rt. 
 
4.1.6 Synthesis of A6: 4,4'-butane-1,4-diyldibenzene-1,2-diol 
 
Figure 4-6: Molecular structure of NDGA analogue 6 (A6). 
Compound A6 was prepared according to previously reported literature method131 with 
minor modification as shown in Scheme 4-7.  Reduction  of carboxylic acid 65 with LiAlH4 gave 
the alcohol 66 which was oxidized with pyridinium chlorochromate (PCC) to the intermediate 
aldehyde 67. Treatment of 67 with the Grignard reagent 68 which was generated in-situ gave 70 
which upon hydrogenolysis resulted in compound 71. Compound 71 was treated with BBr3 in DCM 
to afford the target compound A6. 
 
 
119 
 
 
Scheme 4-7: Synthetic pathway to NDGA analogue 6 (A6). 
Reagents and conditions: i) LiAlH4, THF, rt. 86%; ii) PCC, DCM, rt 84%; iii) THF, -78 ºC, then rt 
71%; iv) H2, Pd-C, EtOH 91%;  v) BBr3, DCM, -78 ºC, then rt > 99%.  
 
4.1.7 Synthesis of A7: 3,3'-(2,3-dimethylbutane-1,4-diyl)diphenol 
 
Figure 4-7: Molecular structure of NDGA analogue 7 (A7). 
Benzylation of  3-hydroxybenzyladehyde 72 followed by treatment with succinate ester 19 
in refluxing EtONa/EtOH and esterification of the resulting half-ester gave 73 (Scheme 4-8). 
Compound 73 was subsequently treated with benzylated 72 in refluxing EtONa/EtOH and esterified 
to generate the basic lignan skeleton 74. Following hydrogenation of 74 and reduction of the 
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resulting mixture with LiAlH4, compound 75 was isolated. Tosylation of 75 with TsCl in pyridine 
followed by reduction with LiAlH4 gave 76 which upon refluxing in KOH (3%) in ethanol-water 
(1:1) mixture afforded A7 as yellowish brown oil. 
 
Scheme 4-8: Synthetic pathway to NDGA analogue 7 (A7). 
Reagents and conditions: i) BnBr, K2CO3/DMF, rt; ii) diethyl succinate, EtONa/EtOH, reflux; iii or 
v) MeI, K2CO3/DMSO, rt; iv) 3-(benzyloxy)benzaldehyde, EtONa/EtOH, reflux; vi) H2, Pd-C, 
EtOH, vii) LiAlH4, THF, rt., viii) TsCl, Pyridine, 0 ºC;  ix) LiAlH4, THF, rt.; (x) KOH/EtOH-H2O 
(1:1), reflux.  
 
4.1.8 Synthesis of A8: 3,3'-(2,3-dimethylbutane-1,4-diyl)bis(6-methoxyphenol)  
 
Figure 4-8: Molecular structure of NDGA analogue 8 (A8). 
Benzylation of 4-methoxy-3-hydroxybenzaldehyde 77 followed by Stobbe condensation 
reaction with succinate ester 19 and esterification of the resulting half-ester gave the di-ester 78 
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(Scheme 4-9).  Compound 78 was treated with benzylated 77 and the resulting acid esterified to 
give 79. Reduction of 79 with a mixture of LiAlH4 and AlCl3 in THF gave the unsaturated diol 80 
which upon hydrogenation and purification via flash column chromatography resulted in easily 
separable 81a and 81b. Compound 81a or 81b was tosylated to 82a or 82b and reduced with 
LiAlH4 to 83a or 83b. Refluxing of 83a or 83b in KOH (3%) in ethanol-water (1:1) mixture 
afforded the target compound as A8a or A8b. 
 
Scheme 4-9: Synthetic pathway to NDGA analogue 8 (A8). 
Reagents and conditions: i) BnBr, K2CO3/DMF, rt.; ii) diethyl succinate, EtONa/EtOH, reflux; iii 
or v) MeI, K2CO3/DMSO, rt.; iv) 3-(benzyloxy)-4-methoxybenzaldehyde, EtONa/EtOH, reflux; vi) 
LiAlH4/AlCl3, THF, rt.; vii) H2, Pd-C, EtOH; viii) TsCl, Pyridine, 0 ºC;  ix) LiAlH4, THF, rt.; (x) 
KOH/EtOH-H2O (1:1), reflux. 
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4.2 Autoxidation Cyclization Potential of NDGA Analogues 
4.2.1 Autoxidation Studies 
Two possible mechanisms were proposed (Schemes 2-1 and 2-3) for NDGA autoxidation 
based on literature reports.35, 59, 66 We hypothesized that NDGA autoxidation is a radical-mediated 
process in which the slightly lower pKa of the meta hydroxyl group resulted in preferential 
oxidation and cyclization of the carbon-centered resonance form. The NDGA analogues prepared 
for this study were examined for their potential to undergo autoxidative cyclization under 
previously described conditions.35 Compound A6 cyclized into its corresponding 
dibenzocyclooctadiene derivative as shown below in Scheme 4-10. 
 
Scheme 4-10: Intramolecular cyclization of A6 to its dibenzocyclooctadiene derivative 84. 
 
A decrease in retention time and the 3.5 nm shift to a higher absorbance observed by HPLC 
(Figure 4-9) is consistent with previous35 and current results obtained for NDGA under the same 
condition. The λmax for NDGA and A6 changed from 282.8 to 286.3 and 281.6 to 285.1 respectively 
(Figure 4-10). ESI-MS in negative ion mode (Figure 4-11) was consistent with predicted m/z 299.1 
and 271.1 Da for NDGA and A6 dibenzocyclooctadiene derivatives respectively. Both were two 
mass units less than their respective m/z 301.1 and 273.2 prior to oxidative cyclization. 
Fragmentation patterns following collision induced dissociation (CID) in Tandem MS/MS 
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experiments were consistent for dibenzocyclooctadiene derivatives for NDGA and A6 as shown in 
Figure 4-12.  
1H and 13C NMR data as summarized below confirmed intramolecular cyclization of A6 
under oxidative conditions to dibenzocyclooctadiene derivative 84. 1H NMR (500 MHz, CD3OD): 
δ (ppm) 1.37 (2H, m), 1.94 (2H, m), 2.00 (2H, m), 2.47 (2H, m'), 6.54 (2H, s,  H2, 2'), 6.60 (2H, s,  
H5, 5'). 13C NMR (500 MHz, CD3OD): δ (ppm) 31.3 (C8, 8'), 33.4 (C7, 7'), 117.0 (C2, 5, 2', 5'), 
133.8 (C1, 1'), 135.6 (C6, 6'), 143.9 (C4, 4'), 145.7 (C3, 3'). The loss of C6, 6' proton, coupling of 
C7, 7' and well as C8, 8' protons are all consistent with cyclization. 
       
      
Figure 4-9: HPLC Chromatogram for incubation in phosphate-citrate buffer pH 7.4 at 37 °C for 90 
min for NDGA (panel A) before and (panel B) after incubation; A6 (panel C) before and (panel D) 
after incubation. 
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Figure 4-10: UV absorption of dibenzocyclooctadiene derivatives for NDGA (panel A) and A6 
(panel B). 
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Figure 4-11: ER-ESI-MS scanning in negative ionization mode for dibenzocyclooctadiene 
derivative of NDGA (panel A) and A6 (panel B).  
The m/z 299.1 and 271.1 Da observed were consistent with calculated monoisotopic masses 
of dibenzocyclooctadiene derivatives for NDGA (300.13 g) and A6 (272.10 g) respectively. The 
observed masses were two mass units less than their respective m/z 301.1 and 273.2 prior to 
oxidative cyclization. 
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Figure 4-12: ESI-MS/MS of dibenzocyclooctadiene derivative for NDGA (panel A) and A6 (panel 
B). 
A consistent fragmentation pattern was observed generating product ions which were 
different than those observed for standard NDGA (Figure 3-4) and A6 (Figure 3-24).  
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When the other catechol (A1 or A4) and phenol (A2 or A3) analogues were subjected to the 
same oxidative conditions as describe in section 3.5.2, no evidence of intramolecular cyclization 
was observed. Unlike NDGA or A6, no changes in retention time and UV absorption characteristics 
were seen by HPLC (Figure 4-13) although concentration of the starting materials appeared to 
decrease over time. This prompted us to determine the chemical stability of these compounds and 
also establish their rates of disappearance in the phosphate buffer (pH 7.4).  
 
 
             
Figure 4-13: HPLC chromatograph for A1 before (panel A) and after (panel B) reaction; A4 before 
(panel C) and after (panel D) reaction; A2 before (panel E) and after (panel F) reaction. Reactions 
were performed by incubating substrates in phosphate-citrate buffer (7.4) at 37ºC for 90 min.  
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We predicted that A4 will cyclize at a comparable rate to NDGA if the intramolecular 
cyclization follows electrophilic substitution mechanism and that absence of cyclization could 
imply that the radical-mediated pathway more accurately describes NDGA autoxidation. Based on 
our observations with A1 and A4, an electrophilic substitution mechanism (Scheme 2-9, pathway 
B) was ruled out. We synthesized and evaluated A7 to advance more support for the radical-
mediated pathway. Contrary to our expectations, A7 did not cyclize although it meets the minimum 
structural requirements for di-radical ion formation.77, 78 We thought stability of a possible radical 
or di-radical intermediate might be important for cyclization60 although this does not appear to be 
the case. We predicted that methoxy substituents of compound A8 should stabilize the di-radical 
intermediate via a positive inductive effect to allow for cyclization. Surprisingly, we found no 
evidence of intramolecular cyclization for A8. We could detect the starting material quantitatively 
even after 48 h incubation at 37 °C in a phosphate buffer (pH 7.4) by HPLC (Figure 4-14). A 
further analysis of the reaction mixture by MS techniques gave no evidence of cyclization for A8. 
The predicted mass at m/z 327.16 Da in negative ionization mode was not detected.  
 
Figure 4-14: HPLC Chromatogram for A8 incubation in phosphate-citrate buffer (pH 7.4) at 37°C 
for 90 min: Before (panel A) and after (panel B) incubation. The UV absorption of the 21.5 min 
peak was inconsistent with dibenzocyclooctadiene product.  
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4.2.2 Chemical Stability and Reaction Kinetics  
Autoxidation experiments revealed a decrease in concentration of the analogues over time 
although no product peaks were seen by HPLC. This prompted us to determine the chemical 
stability of these compounds and also establish their rates of disappearance in the phosphate-citric 
acid buffer (pH 7.4) at 37ºC.  
     
 
 
Figure 4-15 : Chemical degradation profiles (panel A) and first-order degradation regression lines 
(panel B) for NDGA (●) and A6 (▲) in 0.5 M phosphate-citric acid buffer (pH 7.4) at 37ºC. 
Changes in concentration of substrates were determined from the peak area ratios and plotted as a 
function of time. 
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Figure 4-16: The disappearance of substrates (●) and appearance of corresponding 
dibenzocyclooctadiene derivatives (▲) for NDGA (panel A) and A6 (panel B) in 0.5 M phosphate-
citric acid buffer (pH 7.4) at 37ºC. The decrease and increase in concentrations of substrates and 
dibenzocyclooctadiene derivatives respectively were determined from the peak area ratios and 
plotted as a function of time.  
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Figure 4-17: Chemical degradation profiles (panel A) and first-order regression lines (panel B) for 
the catechol analogues A1 (♦), A4 (●) and A6 (▲) in 0.5 M phosphate-citric acid buffer (pH 7.4) at 
37ºC. Changes in concentration of substrates were determined from peak area ratios and plotted as 
a function of time. 
0.00
20.00
40.00
60.00
80.00
100.00
0 1 2 3 4 5 6 7 8 9
P
er
ce
n
t 
re
m
a
in
in
g
Time/h
A1
A4
A6
R² = 0.8424
R² = 0.7991R² = 0.9915
-1.80
-1.60
-1.40
-1.20
-1.00
-0.80
-0.60
-0.40
-0.20
0.00
0 2 4 6 8
ln
 C
/C
o
Time/h
A1
A4
A6
(A) 
(B) 
 
 
132 
 
 
 
 
 
Figure 4-18: Chemical degradation profiles (panel A) and first-order regression lines (panel B) for 
the phenol analogues A2 (♦), A3 (●) and A8 (▲) in 0.5 M phosphate-citric acid buffer (pH 7.4) at 
37ºC. Changes in concentration of substrates were determined from peak area ratios and plotted as 
a function  of time. 
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Table 4-1: Rate of autoxidative degradation of NDGA and its analogues in 0.5 M phosphate-citric 
acid buffer (pH 7.4) at 37ºC. 
Compound Rate constant k (s-1) Half-life t1/2 (h) Coefficient of determination R
2 
NDGA 4.8778 × 10-5 3.94 0.9936 
A6 13.1111 × 10-5 1.47 0.9598 
A1 4.5611 × 10-5 4.22 0.9116 
A2 3.5027 × 10-5 5.49 0.9473 
A3 2.8722 × 10-5 6.70 0.9512 
A4 4.1583 × 10-5 4.62 0.9413 
A8 4.1138 × 10-5 4.68 0.888 
A plot of lnC as a function of time t gave the rate constant k as the gradient. Half-life t1/2 was determined from t1/2 = 
0.693/k(h). 
 
4.2.3 Dibenzocyclooctadiene Formation via o-Q intermediate 
We monitored the rate of formation of dibenzocyclooctadiene derivatives for NDGA and A6 
in the presence (i.e. added to the incubation mixture at time t = 0 min) and absence of GSH as well 
as addition of GSH at different time intervals. The results show a significant decrease in the 
formation of the dibenzocyclooctadiene derivatives for NDGA and A6 in the presence of GSH 
(Figure 4-19). The detection of GSH conjugates and significant reduction in the amount of 
dibenzocyclooctadiene derivatives when GSH was added to the incubation mixture suggested that 
an o-quinone intermediate is possibly involved in the intramolecular cyclization process. It is 
possible that competition exists between intramolecular cyclization and an intermolecular reaction 
with GSH and that after 3h for NDGA or 2 h for A6, the intramolecular cyclization pathway is 
favoured leading to a rise in the amount of dibenzocyclooctadiene derivatives as observed by 
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HPLC. Given the apparent suppression of intramolecular cyclization in the presence of GSH, the 
effect of GSH on the formation of dibenzocyclooctadiene derivatives was further investigated with 
the aim of establishing whether the observed inhibition is concentration dependent. The substrate-
GSH ratio in the incubation mixture was increased from a 1:2 ratio to a 20 fold excess of GSH 
(1:20). Incubations were done with and without GSH at 37ºC for 6 h and the percent compositions 
estimated by comparison of peak area ratios with time zero samples. The results (Figure 4-20, Table 
4-2) indicate that excess GSH significantly inhibits intramolecular conversion of A6 or NDGA to 
dibenzocyclooctadiene derivatives. Over 91% conversion was observed in the absence of GSH 
compared to barely 5% in the presence of 20 fold excess GSH for A6. NDGA formed no 
dibenzocyclooctadiene derivative in the presence of a 20 fold excess GSH compared to 33% 
conversion in the absence of GSH.  
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Figure 4-19: Formation of dibenzocyclooctadiene derivatives for NDGA (panel A) and A6 (panel 
B) over time in the absence of GSH (♦), GSH added at time points (●) and GSH added at time t = 0 
h (▲). The graphs show that the presence of GSH in the incubation mixture significantly affected 
the amount of dibenzocyclooctadiene formed over time.  
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Figure 4-20: HPLC Chromatogram for A6 (panel A) and NDGA (panel B) incubation in 
phosphate-citrate buffer (pH 7.4) at 37°C for 6 hr in the presence (i) and absence (ii) of glutathione. 
The 17.2 or 19.1 min peaks represent A6 or NDGA while the corresponding 
dibenzocyclooctadienes derivatives gave 15.6 or 17.9 min peaks respectively. Peak at 13.4 min 
represent internal standard.  
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Table 4-2: Relative composition of A6 or NDGA and their dibenzocyclooctadiene derivatives 
following 6 h incubation in phosphate-citrate buffer (pH 7.4) at 37°C in the absence or presence of 
20 fold excess glutathione. Concentrations were calculated from peak area ratios.  
Compound Incubation for 6h at 37 °C in the 
presence of GSH, (%) 
Incubation for 6h at 37 °C in the 
absence of GSH, (%) 
SM  CycloL  Adduct SM CycloL Adduct 
A6 95.46 4.54 - 8.52 91.47 - 
NDGA 87.08 - 12.91 66.90 33.09 - 
      SM = starting material; CycloL = dibenzocyclooctadiene derivative 
 
We determined that the dibenzocyclooctadiene derivatives 2 and 84 are unstable in the 
phosphate buffer over time. Compound 84 degraded at a rate of 1.75×10-5 s-1 in comparison with 
0.470×10-5 s-1 for compound 2. 
 
Table 4-3: The rate of formationa and degradationb of dibenzocyclooctadiene derivatives 2 and 84 
in a phosphate buffer (pH 7.4) at 37°C. 
Compound ak × 10-5 s-1 aRel rate bk× 10-5 s-1 bRel rate 
2 2.78 1 0.47 1 
84 8.70 3.1 1.75 3.7 
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4.3 Assessment of Reactive Metabolites Formation of NDGA analogues 
4.3.1 Synthesis of Pilot Compounds PC1 and PC2 
Two pilot compounds PC1 and PC2 were prepared from eugenol according to Scheme 4-11 
below. PC1 and PC2 were used to mimic the catechol and phenol NDGA analogues respectively 
under oxidative conditions. 
 
Scheme 4-11: Synthesis of pilot compounds from eugenol. 
 
4.3.2 Enzymatic Oxidation Studies 
Enzymatic oxidation experiments were performed using mushroom tyrosinase and the 
resulting quinoid species trapped as GSH conjugates. Tyrosinase-catalyzed oxidization of catechol 
is a common method for producing an o-Q moiety.77, 78, 87 Pilot studies were done using PC1, PC2 
and standard NDGA. The experiments were repeated using A1, A2, A3, A4 or A6. All glutathione 
conjugates were analyzed by HPLC and further by MS techniques. 
 
4.3.2.1  Neutral Loss (NL) ESI-MS Analysis 
Glutathione conjugates were detected by NL scanning for protonated ions that fragment to 
give m/z 129 Da corresponding to the pyroglutamic acid moiety. This MS technique has been 
extensively utilized in the literature for detecting GSH adducts although it lacks general 
applicability.116 As exemplified by PC1, NDGA, A1 and A4 in Figure 4-21, a NL 129 scanning in 
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positive ion mode gave the masses m/z 458.2, 608.3, 576.2 and 636.3 Da consistent with mono-
GSH conjugates of PC1, NDGA, A1 and A4 respectively. In addition, GSH is capable of losing m/z 
129 Da as indicated by the presence of m/z 308.1 Da for excess GSH.   
 
          
 
Figure 4-21: Positive ion ESI-MS in NL scan mode (129 Da) for detection of GSH conjugates for 
PC1 (panel A), NDGA (panel B), A1 (panel C) and A4 (panel D). The masses m/z 458.2, 608.3, 
576.2 and 636.3 Da detected by NL 129 scanning in positive ion mode are consistent with mono-
GSH conjugates of PC1, NDGA, A1 and A4 respectively. The ion at m/z 308 Da is due to a NL 129 
from excess GSH present in all the samples. 
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4.3.2.2 Enhanced Resolution ESI-MS Analysis 
To further confirm the presence of GSH conjugates, parent ions (MH+)  were determined by ESI-
MS in enhanced resolution (ER) positive ionization scanning mode. This gave isotopic peaks 
separated by one mass unit indicating singly charged adducts (Figure 4-22). Doubly charged 
adducts will be expected to have one-half mass unit difference between isotopic peaks. The ratio of 
substrate to GSH (1:5) was optimized to favour addition of one GSH molecule33 although trace 
amounts of di-conjugate were observed in the case of NDGA and A4 which is consistent with 
results of  Billinsky et al.33 
                                                                             
       
Figure 4-22: Positive ion ESI-MS in ER scan mode for detection of GSH conjugates for PC1 
(panel A), NDGA (panel B), A1 (panel C) and A4 (panel D). The isotopic peaks obtained following 
ER scanning for the parent ions [M+H+]+ differed by one mass unit for all observed masses. This is 
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consistent with addition of one GSH molecules as di-conjugates will be expected to have one-half 
mass unit difference. 
4.3.2.3 Tandem ESI-MS-MS Analysis 
In order to obtain further information for structural elucidation, tandem ESI-MS/MS 
analyses were performed on all suspected GSH conjugates. This was preceded by MS/MS analysis 
of standard GSH. The product ions generated by MS/MS analyses (Figure 4-23, Table 4-4) were 
consistent with fragmentation patterns reported for glutathione adducts116, 126, 132 and mirrored those 
obtained for standard GSH (Figure 4-23A). The fragmentation pathways were consistent for all 
GSH conjugates examined including standard NDGA-GSH conjugate (Figure 4-23B). The mass 
loss patterns and the resulting product ions suggest that fragmentation mainly occurred in the GSH 
moiety consistent with previous reports.116, 132  
The common neutral losses of glycine (75 Da), pyroglutamic acid (129 Da) and 146 Da 
mass units observed for standard GSH were also seen for GSH conjugates of PC1, NDGA and the 
cateccol analogues (A1, A4, A6). In addition, other typical losses from the parent ion MH+  
including 232, 249 and 275 Da mass units were consistently observed for all GSH conjugates 
analyzed. 
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Figure 4-23: Tandem ESI-MS/MS in positive ion mode for standard GSH (Panel A); NDGA-GSH 
(Panel B), A1-GSH (Panel C) and A4-GSH (Panel D) conjugates. 
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Table 4-4: Summary of Tandem MS/MS data for GSH conjugates following mushroom tyrosinase-
catalysed oxidation. 
Compound  
    (M) 
MH+ and (Major fragments) of GSH 
adductb 
    Adduct 
composition 
Isotopic peaksc 
PC1 (152) a458 (383, 329, 312, 237, 266, 183, 
130) 
 P + GSH – 2H   458.1, 459.1, 460.1 
PC2 (166) - - - 
NDGA (302) a608 (533, 479, 462, 387, 376, 359, 
333, 130) 
 P + GSH – 2H   608.1, 609.1, 610.1 
A1 (270) a576 (501, 447, 430, 355, 344, 327, 
301, 130) 
P + GSH – 2H   576.1, 577.1, 578.1 
A2 (284) -     -  - 
A3 (330) -     -  - 
A4 (330) a636 (561, 507, 490, 415, 404, 387, 
361, 130) 
 P + GSH – 2H  636.2, 637.2, 638.2 
A6 (274) a580 (505, 451, 434, 359, 348, 331, 
305, 130) 
 P + GSH – 2H  580.1, 581.1, 582.1 
aThe GSH adducts detected were the peaks detected by NL scan for m/z 129 Da. bProduct ions listed were greater than 
5% relative intensity. The boldface type denotes the product ions from the loss of 129 Da mass units from the parent 
ion. cIsotopic peaks were obtained by ER in positive ion scanning mode. 
 
In summary, the pilot compound PC1 easily oxidized in the presence of mushroom tyrosine 
to reactive quinone. Enhanced resolution MS gave m/z 458.1 Da consistent with addition of one 
glutathione molecule to PC1 (Table 4-4). NDGA and its catechol analogues (A1, A4 and A6) were 
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similarly oxidized to their corresponding quinoid species in the presence of mushroom tyrosinase 
and were stably trapped as glutathione conjugates for analysis (Table 4-4). As expected, we found 
no evidence of GSH conjugates for PC2 and the phenol analogues of NDGA (A2 and A3) in the 
mushroom tyrosinase-catalyzed oxidations indicating that the phenols do not form reactive 
intermediates under these conditions.   
 
4.3.3 Isomerization of NDGA o-Q to p-QM 
In theory, the structure of NDGA suggests possible direct oxidation to either o-Q or p-QM 
(Scheme 4-12). Surprisingly, NDGA does not appear to form the p-QM33 even though its o-Q 
meets the structural requirements for isomerization.77,78 The presence of benzyl protons available 
for abstraction suggests that the NDGA o-Q 5b can tautomerize to a p-QM 5c.79 We investigated a 
possible isomerization of o-Q to p-QM using A1 and A4. This study was expected to provide 
insight into the contribution of NDGA p-QM to its toxicity. Based on our observation that A1 and 
A4 form o-Qs but do not cyclize to dibenzocyclooctadiene derivatives in aqueous phosphate buffer 
(pH 7.4), we selected both compounds for this study. This was based in part on the assumption that 
competition between isomerization and intramolecular cyclization should not occur for A1 or A4 as 
may be the case for NDGA.  We therefore predicted that A1 or A4 will form p-QM.  
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Scheme 4-12: Proposed oxidation of NDGA 1 to p-QM 5c either directly or via isomerization of its 
o-Q 5b. 
A1 or A4 was oxidized with mushroom tyrosinase in the presence and absence of GSH for 
60 min. An aliquot from the experiment conducted in the absence of GSH was stirred in phosphate 
buffer after the 60 min incubation to allow for isomerization. GSH was added at different time 
points and samples were analyzed by HPLC and LC-MS. As shown in Figure 4-24, suspected GSH 
conjugate peaks were observed at 21.7 and 20.6 min respectively for A1 and A4 from the 
experiment conducted in the presence of GSH. However, HPLC analyses of time point samples 
obtained from 60 min incubation without GSH followed by stirring in a phosphate buffer 
experiment gave no evidence of conjugates formation.  
  
Figure 4-24: HPLC chromatograms for A1 (panel A) and A4 (panel B) following mushroom 
tyrosinase-catalyzed incubation for 60 min in the presence of GSH.  
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Following LC-MS analyses, the peaks observed at 21.7 and 20.6 min by HPLC from A1 and 
A4 incubations in the presence of GSH gave m/z 576  and 636 consistent with the [M+H]+ for A1-
GSH and A4-GSH conjugates respectively.  Product ions generated from the extracted ion 
chromatogram (XIC) (Figure 4-25) were consistent with fragmentation patterns oberved for A1 or 
A4 conjugates derived from their respective o-Qs via mushroom-tyrosinase catalyzed oxidations. 
No GSH conjugates were detected in the time point experiments where the initial incubation was 
done in the absence of GSH, suggesting that quinones were not stably present after 60 min 
incubations. The results of this study suggest that isomerization of o-Q to p-QM did not occur for 
A1 or A4. 
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Figure 4-25: LC-MS data for A1 and A4 incubation for 60 min with mushroom tyrosinase in the presence of 
GSH: (A) XIC chromatogram and (B) product ion for A1-GSH conjugate; (C) XIC chromatogram and (D) 
product ion for A4-GSH conjugate.   
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4.4 Chemical Oxidation Studies 
Chemical oxidations were performed using silver oxide and the resultant electrophilic 
entities were trapped as GSH adducts. This is a classical approach utilized to generate p-quinone 
methides from catechols and/or phenols.78, 80 Previous attempts to oxidize NDGA directly to a p-
quinone methide with silver oxide was unsuccessful but resulted in a complex mixture of products 
none of which was glutathione reactive.35 The reported results were based only on HPLC-UV 
analysis and are possibly limited by instrument sensitivity. To further probe this observation, 
eugenol, PC1 and PC2 were used to establish and validate the chemical oxidation protocol. 
Eugenol and PC2 have previously been oxidized to p-quinone methide with Ag2O.
78, 133 The 
experiments were repeated with NDGA and its prepared analogues. The conditions used for HPLC 
and MS analysis were the same as those used for enzyme oxidation studies. However, additional 
MS experiments using PI scan for m/z 272 Da in the negative ESI mode and NL scan for m/z 307 
Da in positive ion mode were done. Table 4-5 shows the sensitivities of various MS scan modes 
used in detecting GSH adducts following Ag2O oxidation experiment 
 
4.4.1 Precursor Ion (PI) ESI-MS Analysis 
Following the non-detection of GSH conjugates for eugenol, PC2 and the phenol NDGA 
analogues by NL 129 Da scanning experiment even though eugenol and PC2 are known to oxidize 
to p-QM in the presence of Ag2O,
78, 133 the potential of PI 272 Da scanning in negative ionization 
mode as an alternative detection method was explored.  The PI scan for 272 Da appears to be more 
sensitive and has broader applicability in detecting GSH conjugates of different classes for 
compounds.116 The results of this study revealed that, PI 272 Da scan was successful in detecting 
GSH adducts of PC1, A1 and NDGA at m/z 456.2, 574.1 and 606.3 Da respectively (Table 4-5). In 
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addition, the observed m/z 306.1 Da was consistent with excess GSH. Surprisingly, we saw no 
evidence of GSH conjugates for eugenol, PC2, A2 and A3 by PI 272 Da scanning in negative ion 
mode.  
 
4.4.2 Neutral Loss (NL) ESI-MS Analysis 
In addition to NL 129 Da scanning in positive ionization mode, NL 307 Da corresponding 
to a loss of GSH moiety has been employed in detection of GSH conjugates, albeit to a lower 
extent.116 To determine the potential utility of NL 307 Da for detecting GSH conjugates, the Ag2O-
catalysed oxidation samples were analyzed. Interestingly, adducts generated from PC1, NDGA and 
its catechol analogues could not be detected by NL 307 scanning in positive ion mode. However, 
GSH adducts of eugenol, PC2 and A2 could easily be detected by NL 307 Da scan (Table 4-5). A 
m/z 470.2, 472.2 and 590.3 Da detected by NL 307 Da is consistent with GSH adducts of eugenol, 
PC2 and A2 respectively.  
Table 4-5: Detection of GSH adducts using different ESI-MS scanning techniques. 
Compound-GSH 
conjugate (M, Da) 
MS Detection Technique 
ESI-MS (+) NL 129 ESI-MS (+) NL 307 ESI-MS (-) PI 272 
Eugenol-GSH (469) ND 470.1 ND 
PC1-GSH (457) 458.1 ND 456.2 
PC2-GSH (471) ND 472.2 ND 
NDGA-GSH (607) 608.3 ND 606.3 
A1-GSH (575) 576.1 ND 574.2 
A2-GSH (598) ND 590.2 ND 
A3-GSH (635) ND ND ND 
A4-GSH (635) 636.2 ND 634.2 
     ND = not detected 
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4.4.3 Tandem ESI-MS-MS Analysis 
Tandem MS/MS experiments were performed on all suspected GSH conjugates to obtain 
further information for structure elucidation. Examples of MS/MS spectral data and summary of 
product ions following Ag2O catalyzed oxidation in the presence of GSH are shown in Figure 4-26 
and Table 4-6 respectively.  
  
  
Figure 4-26: Tandem ESI-MS/MS in positive ion mode for GSH conjugates of A1 (Panel A), A2 
(Panel B), NDGA (Panel C) and A4 (Panel D) following silver oxide oxidation. 
 +MS2 (576.30) CE (35): 77 MCA scans from Sample 1 (IA-3-260-A1 MSMS 2B) of IA-3-260-A1 MSMS ... Max. 1.8e6 cps.
100 150 200 250 300 350 400 450 500 550 600
m/z, Da
0.0
1.0e5
2.0e5
3.0e5
4.0e5
5.0e5
6.0e5
7.0e5
8.0e5
9.0e5
1.0e6
1.1e6
1.2e6
1.3e6
1.4e6
1.5e6
1.6e6
1.7e6
1.8e6
In
te
n
s
it
y
, 
c
p
s
130.09
327.14
301.11 344.23
447.21
501.25
195.09 430.13
155.03
355.15
145.04 167.11
179.14159.20
273.03 576.40111.97 308.01196.91 330.19267.06162.10 438.08 558.08382.10
 +MS2 (608.10) CE (35): 762 MCA scans from Sample 1 (IA-3-260-NDGA MSMS 2) of IA-3-260-NDGA ... Max. 2.6e5 cps.
100 150 200 250 300 350 400 450 500 550 600 650
m/z, Da
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
In
te
n
s
it
y
, 
c
p
s
145.60 479.60
333.50
359.80
462.50376.60130.70 609.20
 +MS2 (636.30) CE (35): 679 MCA scans from Sample 1 (IA-3-260-A4 MSMS) of IA-3-260-A4 MSMS.wif... Max. 5.5e7 cps.
100 150 200 250 300 350 400 450 500 550 600 650 700
m/z, Da
0.0
5.0e6
1.0e7
1.5e7
2.0e7
2.5e7
3.0e7
3.5e7
4.0e7
4.5e7
5.0e7
5.5e7
In
te
n
s
it
y
, 
c
p
s
145.46
147.45
507.85
387.76
415.78 561.88
404.81343.74
269.35 637.01219.58 490.79143.41151.52 327.64 369.80 391.45
(A) (B) 
(C) (D) 
 
 
151 
 
Table 4-6: Summary of Tandem MS/MS data for GSH conjugates following Silver oxide oxidation 
experiment. 
Compound  
    (M) 
MH+ and (Major fragments) of GSH 
adductc 
    Adduct 
composition 
Isotopic peaksf 
Eugenol (164) a470 (308, 233, 179, 163d)  P + GSH – 2H   470.1, 471.1, 472.1 
PC1 (152) b458 (329e, 312, 226, 209, 183, 145, 
130) 
 P + GSH – 2H   458.1, 459.1, 460.1 
PC2 (166) a472 (308, 233, 179, 165d) -   472.2, 473.2, 474.2 
NDGA (302) b608 (479e, 462, 376, 359, 333, 145, 
130) 
 P + GSH – 2H   608.1, 609.1, 610.1 
A1 (270) b576 (501, 447e, 430, 355, 344, 327, 
301, 130) 
P + GSH – 2H   576.1, 577.1, 578.1 
A2 (284) a590 (308, 283d, 159, 179, 137)     -  - 
A3 (330) -     -  - 
A4 (330) b636 (561, 507e, 490, 415, 404, 387, 
343, 327, 145) 
 P + GSH – 2H  636.2, 637.2, 638.2 
aThe GSH adducts were detected by NL scan for m/z 307 Da in positive ion mode only. bThe GSH adducts were 
detected by either NL scan for m/z 129 Da in positive ion mode or PI scan for m/z 272 Da in negative ion mode. cThe 
product ions were obtained in positive ion mode and the major ions listed were greater than 5% relative intensity. dThe 
product ions from the loss of 307 mass unit from the parent ions. eThe product ions from the loss of 129 Da mass unit 
from the parent ion. fIsotopic peaks were obtained by ER in positive ion scanning mode. 
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4.5 Cytochrome P450 Oxidation Studies 
In order to assess the relevance of the observed reactive metabolites in biological systems, 
in-vitro microsomal incubations using rat liver microsomes were performed. The results were 
compared with those obtained from chemical or enzyme-catalyzed oxidation studies. HPLC 
analyses showed significant loss of substrates although product peaks were barely seen. The 
samples were further analyzed by LC-ESI-MS using NL 129 or 307 Da scan in positive ion mode 
or PI 272 in negative ion mode as detection techniques. Suspected GSH adducts were subjected to 
tandem MS/MS analysis to obtain further information for structure elucidation in a second LC-ESI-
MS run.  
Glutathione conjugates of NDGA and its catechol analogues were detected by NL 129 Da 
scan in the LC-ESI-MS experiments. GSH-trapped conjugates of NDGA, A1, A4 and A6 gave 
parent ions (MH+)  at m/z 608.1, 576.1, 636.2 and 580.1 respectively. Tandem MS/MS analyses 
gave product ions (Table 4-7 ) generated from common neutral losses of glycine (75 Da) and 
pyroglutamic acid (129 Da) in addition to other typical losses including 146, 232, 249 and 275 Da 
mass units from the parent ion (MH+) for all GSH-trapped conjugates. Also, cytochrome P450 
mediated oxidation of NDGA-derived dibenzocyclooctadiene lignan 2 gave a parent ion MH+ at 
606.2 Da and product ions consistent with GSH conjugates. Like the parent ion, observed product 
ions (Table 4-7) were two mass units lower than their corresponding product ions obtained for 
NDGA. An example of an ion chromatogram from the LC-ESI-MS analysis is shown in Figure 4-
27 for RLM incubation of A1 in the presence of GSH. Incubations performed in the absence of 
NADPH gave the same results for NDGA and its catechol analogues suggesting that oxidation was 
independent of NADPH and possibly results from autoxidation. There was no evidence of P450 
enzyme mediated oxidation to reactive quinones for the phenolic analogues A2, A3 and A8 by NL 
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129 Da or 307 scanning in positive ion mode. The results were no different when the samples were 
re-analyses using PI 272 Da scan in negative ion mode as detection method.  
 
Table 4-7: Summary of Tandem MS/MS data for GSH conjugates following RLM incubation 
experiments. 
Compound  
    (M) 
MH+ and (Major fragments) of GSH 
adductb 
    Adduct 
composition 
Isotopic peaksf 
NDGA (302) a608 (533, 479, 462, 444, 376, 359, 
341, 333, 315, 191, 130) 
 P + GSH – 2H   608.1, 609.1, 610.1 
A1 (270) a576 (501, 447, 430, 355, 344, 327, 
301, 130) 
P + GSH – 2H   576.1, 577.1, 578.1 
A4 (330) a636 (561, 507, 415, 404, 387, 361, 
343, 327, 315, 233, 219) 
P + GSH – 2H  636.1. 637.1, 638.1 
A6 (274) a580 (505, 451, 442, 331, 305, 287, 
199, 163, 147, 130) 
P + GSH – 2H  580.1, 581.1, 582.1 
cNDGA 2 (300) a606 (531, 477, 460, 374, 357, 331, 
313, 298, 261, 130) 
 P + GSH – 2H  636.2, 637.2, 638.2 
aThe GSH adducts were detected by NL scan for m/z 129 Da in positive ion mode. bThe product ions were obtained in 
positive ion mode and the major ions listed were greater than 5% relative intensity. The boldface type denotes product 
ions from the loss of 129 Da mass units from the parent ion. fIsotopic peaks were obtained by ER in positive ion 
scanning mode. 
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Figure 4-27: NL and LC/MS/MS analysis of NDGA analogue A1-GSH conjugate formed in the 
RLM incubation. (A) NL scanning of 129 Da; (B) TIC of MSMS for 576.1 Da; (C) Product ion 
spectrum of MH+ (576.1) for A1-GSH conjugate. 
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4.5.1 MRM-EPI MS Analysis of Microsomal Incubations 
Rat liver microsomal incubations were analyzed further using the quadrupole-linear ion trap 
mass spectrometry (Q-trap) which combines MS/MS scan functions of both the triple quadrupole 
and the ion trap.128 Multiple reactions monitoring (MRM) was used as a survey scan to trigger 
acquisition of enhance product ion (EPI) data. As exemplified by A1 (Figure 4-28) and A4 (Figure 
4-29), the results of this study was consistent with data obtained by using the NL 129 Da detection 
method. Again, no evidence of reactive metabolites formation was seen for the phenol analogues of 
NDGA by the MRM-EPI technique. 
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Figure 4-28: MRM-EPI analysis of GSH conjugate formed in the RLM incubation for A1-GSH 
conjugate: XIC (panel A); MRM (panel B) and EPI  (panel C).  
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Figure 4-29: MRM-EPI analysis of GSH conjugate formed in the RLM incubation for A4-GSH 
conjugate: XIC (panel A); MRM (panel B) and EPI  (panel C).  
 
 
4.6 Preliminary Cytotoxicity Evaluation 
NDGA 1, cNDGA 2 and analogues synthesized for this study were evaluated for 
cytotoxicity against four human breast cancer cell lines T47D, MDA-MB-231 (M231), MDA-MB-
468 (M468), MCF7, and a lung cancer cell line A549 by our collaborator (J. Tuszynski) at the 
Cross Cancer Institute (Edmonton, AB). The cell lines were selected based on availability and 
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establilshed cell lines used in the Tuszynski. The MTS tetrazolium dye assay40 was used to measure 
changes in metabolism based on which the cytotoxicity of treatments were inferred (Table 4-8). 
Thiocolchicine and linoleic acid were used as positive and negative controls respectively. NDGA, 
the parent compound was tested for comparison. 
 
Table 4-8: Cytotoxicity of NDGA and its prepared analogues in the human lung cancer cell line 
A549 and four different human breast cancer cell lines. 
Compound Cell lines, IC50 (µM) 
A549 MCF7 MDA-MB-231 MDA-MB-468 T47D 
Thiocolchicine 0.035 0.078 0.002 0.021 0.004 
Linoleic acid 229.08 371.53 870.96 199.53 239.88 
NDGA 1 676.08 190.54 - - - 
A1 125.48 199.53 - ? - 
A2 257.04 281.84 218.78 ? 190.55 
A3b 295.12 190.55 95.45 83.18 75.86 
A6 891.25 1288.25 - - - 
cNDGA 2 1258.92 - - - - 
cA6 84 724.43 2041.74 - - - 
M4N 14 234.42 100.00 389.05 758.58 588.84 
Note: dash (-) indicates no growth inhibition effect, and “?” indicates results discarded due to problems with the plate 
 
As shown in Table 4-8, NDGA and its analogues had no significant growth inhibition effect 
against all the cell lines tested in comparison with the positive control thiocolchicine although the 
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phenol analogues A3b and A2 were generally better than the parent compound NDGA against the 
cell line used. Given that the phenol analogues are oxidatively more stable than the catechol 
analogues and NDGA, further biological assays in appropriate cell lines where NDGA shows 
cytotoxic effects are required for better comparison. Contrary to our expectation, cNDGA had no 
inhibitory activity or was less active in comparison to NDGA at inhibiting the growth the cancer 
cell lines tested 
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5 DISCUSSION 
 
5.1 Synthesis and Characterization of NGDA Analogues 
A number of approaches have been reported in the literature for synthesis of dibenzylbutane 
type lignans.48, 97, 100, 100-102, 102, 106, 107 Two of these approaches were exploited for constructing the 
basic lignan skeleton  in this project. We were initially interested in preparing analogues with 
defined relative and absolute configuration. An approach utilizing Stobbe condensation-alkylation 
and resolution of intermediate (±)-diacid via diastereomeric quinine salts is reported to yield 
enantiomerically enriched lignans.102 However, we could not successfully resolve our intermediate 
(±)-diacids as the expected fractional crystallization of the diastereomeric quinine salts did not 
occur. Whether this resulted from the different substituents on the aromatic rings was not 
investigated. The second approach involved consecutive Stobbe condensation reactions as an 
alternative pathway to the basic 18-carbon lignan skeleton.  Although relative configuration about 
the two stereogenic centers could not be controlled, the double Stobbe condensation pathway was 
versatile in providing access to all the desired compounds for this study. In addition, we could 
obtain separation into two pairs of enantiomers or a meso-compound and racemic product 
following flash chromatography of intermediate diols for A3 and A8. In the case of A3, the NMR 
of separated intermediate diols was compared with that of SECO 9 to obtain some information 
about which fraction is the meso-compound. We have also seen similar separation following a flash 
column on intermediate tosylates of A3 and A8. Thus, the target analogues were successfully 
synthesized in yields ranging from 8-45% by literature methods with modifications where 
appropriate. The prepared analogues were characterized by HPLC-UV-PDA, ESI-MS and NMR 
methods as reported in Chapter 3. The UV absorptions were consistent with that observed for 
NDGA.  
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Molecular mass of each of the prepared analogues was confirmed by ER-ESI-MS analysis. 
The parent ions [M-H]- and isotopic masses observed by ER-ESI-MS in negative ionization mode 
were in agreement with calculated masses. The fragmentation patterns observed by tandem MS/MS 
analysis were consistent with those obtained for NDGA with a base peak at m/z 122 Da as 
illustrated in Scheme 5-1 for NDGA. The product ions obtained for each analogue are tabulated in 
Table 3-1 and were in agreement with those obtained for standard NDGA. 
 
 
 
Scheme 5-1: Proposed Fragmentation of the [M-H]- ion of NDGA (m/z 301) following CID. 
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5.2 Autoxidation of NDGA 
The objective of this phase of the study was to investigate the mechanisms of intramolecular 
cyclization of NDGA and its analogues in phosphate buffer (pH 7.4) at 37ºC to 
dibenzocyclooctadiene lignans.  The dibenzocyclooctadiene family of lignans exhibits numerous 
pharmacological activities38, 39, 55 including antiviral,40-42 anticancer,41 anti-inflammatory42 and 
hepatoprotective effects.43 Billinsky et al.,35 reported a unique schisandrin-like 
dibenzocyclooctadiene lignan derived from NDGA via autoxidation under physiologically relevant 
conditions. Given the important biological activities of dibenzocyclooctadiene lignans,38, 49 and the 
fact that conditions of biological evaluations involving NDGA5, 36 as well as methods of Chaparral 
tea preparation24, 35 favour autoxidation, we speculated that the intramolecular cyclization product 
probably contributes to the broad spectrum of beneficial properties reported for NDGA. Wagner et 
al., suggested that any biological action by NDGA treatment could result from either NDGA itself 
or its oxidation products37 since many antimicrobial and antineoplastic agents are known to 
function by interacting with DNA and subsequently affecting nucleic acid metabolism.53, 54 The 
authors37 report that NDGA converts to “activated” NDGA in the presence of molecular oxygen 
which formed a stable complex with duplex DNA although the structure of the oxidation product 
was not elucidated. This “activated” NDGA was later confirmed as the dibenzocyclooctadiene 
derivative.35  
There is growing evidence in the literature that chemical modification of NDGA reduces 
toxicity, combined with enhanced therapeutic effects, indicating that derivatives of NDGA may 
become important drugs in the future.6 Therefore, investigating the mechanism of autoxidation to 
dibenzocyclooctadiene derivatives of NDGA and its analogues will aid in understanding the 
structural features which influence the previously reported intramolecular cyclization process. We 
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hypothesized that intramolecular cyclization of NDGA to the dibenzocyclooctadiene lignan follows 
a radical-mediated pathway rather than an electrophilic substitution mechanism. A radical-mediated 
mechanism has been proposed by Galano et al.,22 using a combination of theoretical and 
electrochemical techniques. In these studies, we designed and synthesized a series of NDGA 
analogues and evaluated their autoxidative potential in a phosphate buffer under aerobic condition 
at physiological pH and 37 ºC35 in our effort to unravel the exact mechanism of NDGA cyclization.  
Like NDGA, compound A6 underwent autoxidation to the corresponding 
dibenzocyclooctadiene lignan, although at a faster rate than NDGA. The rate enhancement seems to 
correlate with conformational flexibility as the absence of substitution on the butane bridge in the 
case of A6 could be expected to confer a less restrictive intramolecular interaction between the two 
aromatic rings allowing for a faster cyclization than NDGA. Although a Thorpe-Ingold effect is 
typically experienced by geminal substituents,134 the vicinal methyl groups attached to the butane-
bridge of NDGA likely generate  CH3-CH3 as well as CH3-CH2-Ar steric interactions as shown in 
Figure 5-1. It is unlikely that the most stable conformations I and IV for NDGA and A6 
respectively favour cyclization and that the required conformations for cyclization are II or III and 
V or VI. The presence of additional CH3-CH3 and CH3-CH2-Ar steric interactions suggests  
conformations II or III are more difficult to attain in comparison with V or VI.  This conformational 
flexibility probably explain the faster rate of cyclization observed for A6.  
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Figure 5-1: Conformational representations for NDGA (I, II, III) and A6 (IV, V, VI). I and IV 
represent the most stable conformations for NDGA and A6 respectively; II or III and V or VI 
conformers are the required formations for cyclization. 
 
Compounds A1 and A4 oxidized to yield o-Q although subsequent nucleophilic attack by 
the unoxidized ring did not occur. Given that intramolecular reactions are generally kinetically 
favoured over intermolecular reactions and that the dimethoxy substituted ring of A4 is comparable 
to the unoxidized ring of NDGA in nucleophilicity, A4 was expected to form a 
dibenzocyclooctadiene derivative if the mechanism involves electrophilic substitution. Compound 
A1 was also expected to autoxidize although we predicted it to occur at a slower rate than NDGA. 
Oxidation of polyphenols by molecular oxygen have resulted in intermolecular reaction products66, 
67 and oxidation of polyphenols present in tea have resulted in dimers and other oligomers via 
intermolecular nucleophilic attack of an unoxidized ring on an o-Q.66, 67 The absence of 
intramolecular cyclization in A1 or A4 could imply that a radical-mediated process more accurately 
describes NDGA oxidative cyclization. This is supported by the biosynthesis of 
dibenzocyclooctadiene series of lignans in plants, which is known to involve enzymatic 
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intramolecular oxidative coupling of phenolic precursors via a radical cation intermediate.60 The 
biosynthetic approach has been exploited in many synthetic strategies to construct the biaryl 
linkage of the dibenzocyclooctadiene lignan core structure.38, 59, 60 In this vein, lignans belonging to 
the dibenzylbutane class have served as precursors to dibenzocyclooctadiene derivatives via 
intramolecular coupling reactions using coupling reagents such as ruthenium dioxide (RuO2) for 
phenols60 or 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) for non-phenols.38 No such similar 
report exists in the literature involving a catechol-containing substrate such as NDGA. The role of 
conformational rigidity in preventing intramolecular cyclization has not been clarified. However, 
this hypothesis may not explain the situation for A1 or A4 given that both compounds are 
conformationally equivalent to NDGA.  
Attempts to confirm a radical-mediated pathway for cyclization using compound A7 was 
unsuccessful, although our observation was similar to a result reported by Robin et al., using RuO2 
for cyclization of an ortho-phenol substituted lignan.60 Robin found however that additional 
methoxy substituents on the aromatic ring facilitated cyclization, suggesting that the electron-
donating methoxy substituents may be critical to cyclization, possibly due to enhanced stability of a 
radical intermediate. We investigated this hypothesis with compound A8 where the methoxy 
substituents were expected to stabilize the intermediate radical to allow for cyclization. In spite of 
the presence of methoxy groups on both aromatic rings, incubation of A8 at pH 7.4 gave no 
intramolecular cyclization product. The intermediate radical of A8 may be too stable to react or the 
intramolecular cyclization mechanism is not a simple di-radical coupling as proposed by us35 and 
Galano et al.22 An intriguing possibility, outlined in Scheme 5-2, involves attack of an ortho-
quinone by an ionized ring.  A sequential 2 proton 2 electron loss is expected to yield 5a or 5b with 
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a deprotonation step expected to be pH dependent. This hypothesis would require an analogue 
consisting of one catechol substituted ring and one 3-hydroxy-4-methoxy substituted ring.  
 
Scheme 5-2: Modification to the proposed mechanism of intramolecular cyclization of 
dibenzylbutane lignans to dibenzocyclooctadiene derivatives. 
 
Another interesting finding of this study is the inhibition of autoxidation by glutathione, a 
nucleophilic trapping agent used in this study. As shown in Figure 4-19 and Table 4-2, the rate of 
intramolecular cyclization and the amount of dibenzocyclooctadiene derivative produced decreased 
significantly in the presence of GSH. An o-Q will be expected to decrease the concentration of 
NDGA or A6 as a result of irreversible conversion to GSH conjugates whilst a semiquinone radical 
or a di-radical intermediate could regenerate the starting material in the presence of GSH via one 
electron reduction135, 136 as shown in Scheme 5-3. In addition, thiol compounds can regenerate the 
catechol moiety in situ during the oxidation reaction of polyphenols and are reported to exhibit 
potent synergistic effects on the antioxidant activity of polyphenols.137 Superoxide dismutase 
(SOD) suppresses oxidation of polyphenols by purging the system of superoxide ions.67 GSH is 
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also known to react with superoxide ion to generate oxidized GSH (GSSG)135 which will be 
expected to decrease the rate of superoxide-dependent chain oxidation. The proposed radical-
mediated or electrophilic substitution mechanisms can both generate superoxide ions, suggesting 
that incubation in the presence of SOD might not clarify the intramolecular oxidation process. The 
inhibition of intramolecular cyclization suggests that GSH acts as radical scavenger as illustrated in 
Scheme 5.3 and that the dibenzocyclooctadiene product only formed atfter GSH was depleted. This  
supports the involvement of free radicals as opposed to o-Q in the intramolecular cyclization 
process. 
 
Scheme 5-3: Proposed mechanism of regeneration of NDGA following incubation with excess 
GSH.  
 
Another important factor in polyphenol oxidation is the catalytic effect of transition metals. 
Chelating agents such as EDTA and Desferal have been employed to suppress or eliminate this 
catalytic effect.67 We did not determine whether any metals were present in our incubation system 
as our intent was to examine the analogues in our previously established conditions where NDGA 
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was observed to form a dibenzocyclooctadiene lignan. It is possible that the use of metal-ions-free 
buffer will inhibit or slow down the intramolecular oxidation reactions and also improve the 
stability of the NDGA and its analogues although this seems impractical for the purpose of 
biological evaluation studies. Also, the instability of NDGA in the extraction process is well known 
and likely oxidizes during traditional preparation of creosote bush. Our results suggest that 
electrophilic substitution makes no contribution to the intramolecular cyclization process and that 
NDGA autoxidative cyclization is a radical mediated process. This notwithstanding the inability of 
compound A8 to undergo intramolecular cyclization is intriguing and raises the question of whether 
a radical-mediated mechanism as a standalone is sufficient to explicitly describe autoxidation of 
dibenzylbutane lignans to dibenzocyclooctadiene derivatives especially for the non-dicatechol 
lignans.  
 
5.3 Assessment of Reactive Metabolites Formation of NDGA Analogues 
In order to minimize bioactivation of new chemotypes during the drug discovery process, a 
variety of experimental approaches have been developed and incorporated into early optimization 
of lead compounds including routine in vitro evaluation for reactive metabolite (RM) formation.129, 
138  RMs have been implicated in many drug-induced toxicities including hepatotoxicity.139 Despite 
the numerous known pharmacological properties of NDGA, its use is also associated with toxic 
outcomes including hepatic injury possibly mediated by RMs.32 Therefore, this phase of the project 
evaluated the metabolic activation potential of NDGA and its analogues with the overall goal of 
eliminating RMs liability through rational structural modification. This study was also expected to 
provide better appreciation of  the nature of RMs such as why NDGA does not appear to form p-
QM and how ring substitutions affect RMs formation. The potential of the dibenzocyclooctadiene 
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lignan 2 derived from NDGA under physiological conditions to contribute to its toxicological 
properties via reactive metabolite formation was also evaluated. This compound has been 
postulated to contribute to pharmacological properties attributed to NDGA and therefore 
assessment of its potential reactive metabolite liability is critical to its safety profile. We incubated 
NDGA and its analogues in rat liver microsomes (RLM) in the presence of glutathione as a 
nucleophilic trapping agent. Standards for comparison were generated by performing glutathione 
trapping experiments with chemical and enzyme oxidation systems. 
The results of this study demonstrate that NDGA and its catechol-type analogues were 
oxidized to their corresponding quinoid reactive intermediates by cytochrome P450s. We saw no 
evidence of RMs when the phenol-type analogues were incubated with microsomes. GSH 
conjugates were detected by ESI-MS scanning for neutral loss NL 129 Da or 307 Da in positive 
ionization mode or PI 272 Da scanning in negative ionization mode. These methods have been 
described in the literature for detecting different classes of GSH adducts116, 127 although none of 
them has general applicability. To obtain further information for structure determination, GSH 
conjugates were subjected to tandem MS/MS analysis or MRM-EPI analysis. Product ions obtained 
from these studies were consistent with previous reports.116, 127 As reported in Chapter 4, common 
neutral losses of glycine (75 Da) and pyroglutamic acid (129 Da) as well as other typical losses 
from the parent ion MH+ of GSH conjugates including 146, 232, 249 and 275 Da mass units were 
observed indicating that NDGA, A1, A4, A6, and cNDGA 2 were oxidized by P450 enzymes to 
their respective reactive metabolites. The typical fragmentation patterns observed for the GSH 
conjugates of NDGA and its analogues are summarized in Figure 5-2. The product ions are 
indicated by a- to k- in accordance with the literature117, 132, 140  
  
 
 
170 
 
 
 
 
Figure 5-2: Typical fragmentation pathways for GSH conjugates following CID for dibenzylbutane 
type lignans. P represents the parent ion (MH+). 
 
Fragmentation-based methods have been used to differentiate glutathione conjugates 
belonging to different structural classes.132 In particular, the cleavage of the cysteinyl C-S bond 
leading to formation of d/k-type ions is diagnostic for aromatic conjugates whereas benzylic 
conjugates primarily yield i/j-type ions upon cleavage of the C-S bond between the drug molecule 
and GSH.132 As speculated by the authors, the strong π–backbonding interaction between the lone-
pair electron of the glutathionyl sulfur atom and the aromatic ring may increase the resistance of the 
C-S bond between the drug and GSH to CID. The product ions obtained for NDGA and its 
catechol-type analogues following P450-mediated bioactivation are consistent with aromatic 
Fragment type Positive m/z 
a P-75 
b 145 
c P-146 
d P-275 
e P-129 
f 130 
g P-232 
h P-249 
i 308 
j P-307 
  
k 274 
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conjugates indicating that the conjugates were derived from o-Qs. The product ions (Table 4-7 ) 
were mainly derived from cleavage of bonds within the glutathionyl moiety as observed in the 
enzyme oxidation system (Table 4-4) and included the a-, b-, c-, d-, e-, f-, g- and h-type ions  for 
NDGA and its catechol-type analogues except A6 where b-, c- and g-type ions were not detected in 
the P450 oxidation system. It is worth noting that the d-type ion formed by the cleavage of the 
cysteinyl C-S bond and characteristic of ring adducts132 was observed for NDGA and all its 
catechol-type analogues. The only evidence of benzylic conjugates which primarily yield i/j-type 
ions upon cleavage of the C-S bond between the drug molecule and GSH132 was seen for the 
phenolic analogue A2 following Ag2O catalyzed oxidation. A similar observation was made for the 
phenolic compounds eugenol and PC2 (Table 4-6).  
Another noteworthy observation from this study is the potential diagnostic utility of the MS 
detection methods NL 129 and NL 307 in distinguishing aromatic and benzylic conjugates 
respectively. GSH conjugates of NDGA and its catechol analogues were consistently detected by 
NL 129 but not NL 307 scanning in positive ionization mode whilst conjugates of the phenol 
analogue A2, eugenol and PC2 formed in Ag2O catalyzed oxidation system were only detectable by 
NL 307 Da scanning. This is in agreement with the findings of Xie et al.,132 who reported that 
cleavage of the C-S bond between the test compound and GSH is a less favourable pathway when 
addition occurs on the ring than when is exocyclic. Tandem MS/MS analysis provided further 
support for this potential utility when GSH conjugates of NDGA and its catechol analogues all gave 
a product ion at m/z 130 Da consistent with the loss of pyroglutamic acid whilst conjugates of A2, 
eugenol and PC1 gave m/z 308 Da resulting from the loss of glutathione moiety (Tables 4-4, 4-6 
and 4-7).  
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Although the method of scanning for NL 129 Da is a widely used approach for detecting 
GSH adducts, especially when protonated molecules of GSH conjugates cannot be predicted, it 
suffers low LC/MS sensitivity and limited selectivity resulting from the interference of endogenous 
compounds and background noise.127 Also, neutral loss fragmentation patterns are compound-
dependent making the effectiveness of NL experiments vary among different classes of GSH 
adducts. To improve the selectivity of NL scanning for GSH adducts, the following MS techniques 
have been explored in the literature: (a) methods using a mixture of GSH and stable-isotope 
labelled GSH (1:1 ratio) as trapping agent;124, 141 (b) high-resolution LC/MS;118 (c) multiple 
reaction monitoring (MRM) method to monitor typical transitions of protonated (MH+) potential 
reactive metabolite trapped as GSH adduct;142 and (d) precursor ion (PI) scanning in negative 
electrospray ionization mode.116 Although an MRM-based approach seems to provide superior 
sensitivity and selectivity for GSH adducts, especially where isotope labelled GSH is not available, 
it only detects the GSH adducts pre-set on an MRM transition protocol.127 Therefore the MRM 
approach has been used in conjunction with PI or NL when comprehensive analysis of predicted 
and unpredicted GSH conjugates is desired.127 In order to further confirm the RMs formed in P450s 
mediated oxidation system, MRM was used as a survey scan to trigger acquisition of EPI. As 
shown in Figures 4-28 and 4-29, the results of this study were consistent with those of NL 129 
scanning and tandem MS/MS studies.  The P450-mediated bioactivation study also revealed that 
the NDGA-derived dibenzocyclooctadiene lignan 2 potentially makes contribution to NDGA 
toxicity via oxidation to reactive quinones. Results of ESI-MS/MS experiments (Table 4-7) clearly 
demonstrate evidence of P450-mediated oxidation to a reactive quinone. Notably, the 2 mass unit 
difference between NDGA (302 Da) and the cNDGA (300 Da) was maintained in the 
corresponding MH+ for GSH monoconjugates at m/z 608 and 606 Da respectively. Additionally, 
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major product ions obtained for NDGA-GSH and cNDGA-GSH conjugates differed by 2 mass 
units. This observation is in agreement with findings by Galano et al.22 who recently reported that 
NDGA forms a cyclic compound which can be further oxidized, although at a higher potential than 
NDGA.  
 
5.3.1 Isomerization of NDGA o-Q to p-QM 
The results of this study revealed that isomerization of NDGA o-Q 5b to p-QM 5c does not 
occur for either A1 or A4, suggesting that NDGA o-Q is the major toxicophore and likely 
responsible for  RMs-mediated toxicities. Steric hindrance at the benzyl carbon has been previously 
invoked to explain why NDGA does not form a p-QM. Compound A2 has the same steric bulk at 
the benzyl carbon and yet formed a GSH conjugate derived from p-QM in the chemical oxidation 
system. Also conversion of SECO to lariciresinol has been proposed to occur via p-QM 
intermediate, although the benzyl carbon has the same chemical environment. It is likely that p-QM 
formation from the dibenzylbutane-type lignans is a direct oxidation process and that isomerization 
contributes negligibly to its formation, as may be the case for NDGA. Like A2 and SECO, 
compound A3 lacks the potential to form an o-Q and was expected to oxidize directly to a p-QM. 
Surprisingly, A3 did not form a GSH reactive product in the P450 oxidation system nor in the Ag2O 
catalyzed oxidation system. No direct evidence of RMs formation has been reported for the 
standard compounds meso-dihydroguaiaretic acid (DGA) as well as SECO in the literature.  
Taken together, the results demonstrate that RMs formation is dependent on substituents 
and/or substitution pattern on the two aromatic rings of NDGA. It was observed that P450-mediated 
oxidation of the dibenzylbutane family of lignans do not form p-QM and that the o-Q is the major 
reactive toxicophore which likely leads to some of the toxic effects associated with NDGA use. It is 
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concluded that structural modification efforts should focus on phenol-type analogues to potentially 
enhance safety profile of NDGA. Notably, phenols such as A3 and A8 require further investigation 
as these phenols demonstrated improved stability at pH 7.4 and meta-OH substituted lignans, such 
as enterolactone, display pharmacological activity.69, 143  
 
5.4 Preliminary Cytotoxicity Evaluation 
NDGA derived-dibenzocyclooctadiene lignan (cNDGA 2) was evaluated for the first time 
for biological activity. We have speculated based on the conditions of its formation and the known 
pharmacological properties of the dibenzocyclooctadiene family of lignans that cNDGA possibly 
makes contribution to biological activities reported for NDGA. Thus, NDGA, cNDGA and the 
analogues synthesized for this project were evaluated for cytotoxicity against four human breast 
cancer cell lines T47D, MDA-MB-231 (M231), MDA-MB-468 (M468), MCF7, and a lung cancer 
cell line A549 by our collaborator (J. Tuszynski) at the Cross Cancer Institute (Edmonton, AB).  As 
shown in Table 4-8, NDGA and its analogues had no significant growth inhibition effect against all 
the cell line tested in comparison with the positive control thiocolchicine although the phenol 
analogues A3b and A2 were generally better than the parent compound NDGA against the cell line 
used. Given that the phenol analogues are oxidatively more stable than the catechol analogues and 
NDGA, further biological assays in appropriate cell lines where NDGA shows cytotoxic effects are 
required for better comparison.  
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6 SUMMARY AND CONCLUSIONS 
 
In summary, a series of NDGA analogues were designed, synthesized and characterized for 
the purpose of investigating the structural features that influence pharmacological and toxicological 
properties of NDGA. The potentials of the prepared analogues to undergo intramolecular 
cyclization under our previously established physiologically relevant conditions35 where NDGA 
was observed to form a dibenzocyclooctadiene lignan were evaluated. This study was intended to 
help explain the mechanisms of NDGA intramolecular cyclization to a dibenzocyclooctadiene 
derivative and provide information about structural features that influence pharmacological 
properties of NDGA. The results demonstrate that electrophilic substitution makes no contribution 
to the intramolecular cyclization process and that NDGA autoxidative intramolecular cyclization is 
a radical-mediated process. NDGA and A6 (both containing a di-catechol) autoxidized to their 
corresponding dibenzocyclooctadiene derivatives 2 and 84 respectively which were fully 
characterized by MS and NMR techniques. However, the mono-catechol analogues A1 and A4 
underwent oxidation to o-Q but no evidence of cyclization was found implying that electrophilic 
substitution cannot account for NDGA cyclization. Attempts to confirm the radical-mediated 
pathway with A7 were unsuccessful although our observation was similar to a result reported by 
Robin et al., using RuO2 for cyclization of an ortho-phenol substituted lignan.
60 The pronounced 
suppression of cyclization for NDGA and A6 observed in the presence of 20 fold excess GSH 
supports the involvement of free radicals as opposed to o-Q in the intramolecular cyclization 
process. We also evaluated the stability of the analogues under the conditions used for this study. It 
was observed that stability of the analogues is dependent on the degree of substitution of the 
aromatic rings. At pH 7.4, the catechol-type analogues were generally less stable in comparison to 
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the phenol-type analogues. Compound A6 which lacks substitution on the butane-bridge degraded 
faster than NDGA possibly as a result of its conformational flexibility.  
Oxidative metabolism and bioactivation studies on NDGA and its analogues revealed that 
reactive metabolites formation is dependent on substitution and/or substitution pattern of the 
aromatic rings. Cytochrome P450-mediated oxidation of NDGA and its catechol-type analogues 
yielded electrophilic intermediates which reacted with GSH. LC-ESI-MS analysis in positive 
ionization mode gave parent ions at m/z 608, 576, 636 and 580 Da, consistent with addition of GSH 
to NDGA, A1, A4 and A6 respectively. A further tandem MS/MS studies gave products ions 
consistent with typical fragmentation patterns reported for GSH conjugates.116, 127, 129 The 
fragmentation patterns were used to identify the GSH conjugates as ring adducts derived from o-
Q132 although the position of attachment on the aromatic ring could not be determined. We also 
found that NL 129 or 307 scanning in positive ionization mode has potential diagnostic utility in 
distinguishing between aromatic and benzylic GSH conjugates. GSH conjugates of NDGA and its 
catechol-type analogues were consistently detected by NL 129 but not NL 307 scanning whilst 
conjugates of the phenol analogue A2, eugenol and PC2 formed in a Ag2O catalyzed oxidation 
system were only detectable by NL 307 Da scanning. This is in agreement with the findings of Xie 
et al.132 We found no evidence of p-QM formation either directly or via isomerization of o-Q 
intermediates suggesting that o-Q is the major reactive toxicophore responsible for reactive 
metabolite generated toxicities associated with NDGA use. In addition, we demonstrated that the 
NDGA-derived dibenzycyclooctadiene lignan (cNDGA 2) undergoes P450-mediated oxidation to a 
reactive metabolite which might contribute to the toxicological properties of NDGA. There was no 
evidence of P450-mediated oxidation to reactive metabolites for the phenol-type NDGA analogues. 
It is concluded that structural modification efforts should focus on phenol-type analogues.  
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Cytotoxicity of the NDGA analogues and the possible involvement of cNDGA in 
pharmacological properties attributed to NDGA were examined against human breast cancer cell 
lines T47D, MDA-MB-231 (M231), MDA-MB-468 (M468), MCF7, and a lung cancer cell line 
A549. This preliminary study gave growth inhibition (GI50) at micro molar concentration levels or 
showed no growth inhibitory effect. The results indicate that the analogues are several folds less 
potent in comparison to a known cytotoxic compound thiocolchicine against the cell lines used. The 
cNDGA showed no growth inhibition against human breast cancer cells and about two fold less 
potent than NDGA against the lung cancer cell line A549.  
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7 FUTURE RESEARCH 
On the basis of the findings made in these studies, the following are intended to direct future 
efforts at advancing this research project. 
Given the interesting observation that absence of substituents on the butane-bridge of the 
two aromatic rings enhances intramolecular cyclization to dibenzocyclooctadiene derivatives, a 
successful synthesis of A5 and evaluation of its autoxidation potential under similar conditions used 
for NDGA and A6 will provide further information about structural features which influence the 
oxidative cyclization rate. From our observation with A6, compound A5 will be expected to cyclize 
at a reduced rate in comparison to NDGA. The synthetic challenge that remained was introduction 
of the additional methyl substituents at positions C2 and C3 of the butane-bridge. One potential 
approach to forming the required basic lignan skeleton is shown in Scheme 7-1. Step 1 of this 
scheme involves esterification of 2,3-dimethylsuccinic acid. The use of MeI in DMSO/K2CO3 gave 
access to esters in good yield in this project and may be applicable. It is anticipated that the basic 
lignan skeleton may be obtainable via alkylation although step 2 is yet unstudied. Following a 
successful LDA alkylation, a couple of reductive steps and demethylation using BBr3 as reported in 
this project should allow access to compound A5. 
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Scheme 7-1: Potential synthetic approach to basic lignan skeleton for compound A5. 
Also, the inability of compound A8 to undergo intramolecular cyclization raises the 
question of whether radical-mediated mechanism as a standalone is sufficient to explicitly describe 
autoxidation of dibenzylbutane lignans to dibenzocyclooctadiene derivatives especially for non-
dicatechol lignans. Access to NDGA analogues shown in Figure 7-1 will be useful in verifying an 
intriguing possibility outlined in Scheme 5-2 of this project. This modified mechanism involves 
attack of an ortho-quinone by an ionized ring suggesting that compound 7-1 but not 7-2 should 
cyclize. The proposed compounds are obtainable by consecutive Stobbe condensation approach 
used in this project. 
 
Figure 7-1: Proposed compounds for verifying the modified mechanism of intramolecular 
cyclization of NDGA. 
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Another potential direction for this research is isolation of the GSH conjugates formed via 
P450 mediated oxidations of A1, A4, and A6 for NMR studies. The conjugates were identified as 
ring adducts derived from o-Qs by MS.132 However, NMR studies will be useful to define the 
position at which the GSH binds to these analogues and provide further support for the nature of the 
electrophilic entities. Following successful NMR determination of positions of GSH attachment, 
the pure isolates could be used in MS studies for validation of the diagnostic utility of NL 129 and 
NL 307 scanning modes for aromatic and benzylic adducts respectively. This will be extremely 
useful in the early drug discovery and optimization process for providing insight into the nature of 
reactive metabolites in real-time without the need for reference standards or the tedious and time-
consuming isolations for nuclear magnetic resonance (NMR) identification.  
Analogues of NDGA have been assessed for their growth inhibitory activity against human 
breast cancer, human colon cancer and human melanoma cell lines. The lignans had IC50 values of 
5–60 µM.5 M4N 14 inhibits the growth of a number of tumor cell lines in vitro and also the growth 
of both murine and human melanomas and human colon cancer in vivo without apparent hepatic 
and renal toxicity.92 Given that our preliminary cytotoxicity evaluation results varied widely from 
previous reports, it is recommended that biological activity screening of the analogues prepared for 
this project be repeated. Anti-viral activity has also been reported for NDGA and its derivatives.21 It 
may be interesting to evaluate the analogues prepared for this project in a similar model. M4N 14, 
which is being developed as an anticancer and antiviral drug, was also synthesized in addition to 
the analogues studied in this project. This presents a great opportunity to compare the biological 
activities of the analogues with two standards, NDGA and M4N to establish whether the findings 
support the idea that the “free” phenolic hydroxyl groups facilitate intolerable in vivo toxicity. 
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